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Hepatitis B virus (HBV) infection is the most common cause of chronic viral liver 
disease in Singapore.  Therefore, the application of pharmacoeconomic and outcomes 
principles in evaluating the management of HBV infection would be a logical approach 
to quantify the impact of the disease.  Hence, the purpose of this thesis is to conduct cost-
effectiveness and health status assessment studies for HBV infection in Singapore to 
provide healthcare professionals and decision makers with information that will enable a 
more holistic management of the disease. 
 
Particularly, health-related quality of life (HRQoL) outcomes may provide useful 
information concerning patients’ perceived health status in terms of physical, 
psychological and social functioning.  Therefore, we first studied the HRQoL of HBV 
infected patients compared with the patients with diabetes mellitus, hypertension and 
normal controls using generic HRQoL instruments such as the Short form 36 Health 
Survey (SF-36) and the EQ-5D self-report questionnaire (EQ-5D).  Subsequently, we 
culturally adapted and validated the Hepatitis Quality of Life Questionnaire (HQLQ), a 
disease-specific instrument for HBV infected patients in Singapore.  After this, a cost 
analysis study was performed for the management of HBV infection in Singapore 
compared with the data from Hong Kong.  This was then followed by a detailed cost-of-
illness (COI) study, measuring both direct and indirect cost of HBV infection in 
Singapore.  Finally, HRQoL (utility scores) and cost data generated from the above-
mentioned studies were used to conduct the hypothetical cost-effectiveness and cost-
  vi
utility analyses to compare the present alternatives treatment of antivirals for HBV 
infection for the initial phase of infection.    
 
From these studies, we identified several useful findings. First, we found that HBV 
patients with early stage disease including those with compensated cirrhosis had scores 
comparable to that of healthy controls and hypertensive patients, and their health status 
deteriorated only with disease progression.  Secondly, the disease affected the mental 
domain more adversely than the physical domain in HBV patients.  Third, we found the 
culturally adapted HQLQ to be a valid and reliable instrument for assessing HRQoL in 
HBV infected patients in Singapore.  Fourth, our cost analysis and COI study confirmed 
that HBV and its complications acted as a significant burden to the healthcare budgets of 
Hong Kong and Singapore.  Fifth, we found that lamivudine therapy was the most cost-
effective treatment option available currently for HBV patients in comparison to the other 
treatment option such as adefovir in term of response rate, total QALY gained and 
percentage of cirrhosis prevented at the initial phase of HBV infection.   
 
In conclusion, these findings highlighted the potential areas for educational and clinical 
interventions in the management of HBV infection.  Specifically, HQLQ was found to be 
a useful tool for healthcare professionals or researchers to evaluate the HRQoL of HBV 
patients.  Besides, cost data generated from the studies may provide valuable information 
for healthcare planners and providers, especially in the area of resource allocation.  
Therefore, this thesis has laid the groundwork for better management of HBV infection in 
Singapore and demonstrated that the feasibility of studying other disease entities by using 
pharmacoeconomics and health outcomes researches. 
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Chapter 1. Introduction  Siew Chin, Ong 
 
1.1 Hepatitis B viral infection - An Important Public Health Issue 
Hepatitis is a general term meaning inflammation of the liver and can be caused by a 
variety of different viruses such as hepatitis A, B, C, D and E (Roger, 2002).  Of the 
many viral causes of human hepatitis, few are of greater global importance than hepatitis 
B virus (HBV).  HBV infection is a major public health concern globally for several 
important reasons.  First, HBV infection is one of the most common and serious 
infectious diseases, with an estimated 400 million people infected worldwide and causing 
one million deaths annually (Lavanchy, 2004).  Specifically, more than 75% of those 
infected are from South-East Asia and the Western Pacific region.  Singapore being part 
of South-East Asia is one of the endemic areas and HBV infection is the most common 
cause of chronic viral liver disease in this country (Guan, 1996; James et al, 2001).  
  
Secondly, the disease burden associated with HBV infection is enormous as the people 
infected with HBV have a greatly increased risk of morbidity and mortality.  HBV may 
be considered as the cause of up to 80% of all cases of hepatocellular carcinoma (HCC) 
worldwide, second only to tobacco among known human carcinogens.  HCC is one of the 
most rapidly growing of all tumors, and most untreated patients die within 12 months of 
the onset of symptoms (Johnson, 2000).  In Singapore, HCC is the fourth commonest 
cancer for males with about three quarters of HCC patients being HBV infected (Chia et 
al, 2002; Guan et al, 1989; Oon, 1987).   In addition, cirrhosis is seen in about 20% of 
HBV carriers locally (James, 2001).  In fact, excluding deaths due to HCC, chronic liver 
disease and cirrhosis accounted for 0.7% of total annual deaths in Singapore (State of 
Health Editorial Committee, 2002).  Furthermore, the most important mode of HBV 
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transmission globally is perinatal (from the mother to her newborn baby) on top of 
transmission through percutaneous or parenteral contact with infected blood, body fluids, 
and by sexual intercourse (Ganem et al, 2001; Gitlin et al, 1997; Hollinger et al, 2001; 
Mahoney et al, 1999).  If a pregnant woman is an HBV carrier and is also HBeAg-
positive, her newborn baby has 90% likelihood to be infected and become a carrier.  Of 
these children, 25% will die subsequently from chronic liver disease or liver cancer 
(Hollinger et al, 2001). 
 
Treatment cost for HBV infection is increasing relatively sharply, mainly due to the 
increased cost for newer class of antiviral drugs and laboratory tests or procedures for the 
management of HBV infection.  For example, the cost per tablet for newer antiviral 
adefovir dipivoxil is SGD10.37 compared to SGD6.65 for the older antiviral, lamivudine.  
It means a patient needs to pay an extra SGD1357.80 per year for using adefovir, which 
has been claimed to be more effective than lamivudine in treating HBV infected patient 
by the pharmaceutical company.   
 
Therefore, the cost of managing HBV infection has become an important issue to 
patients, third-party payers, and governments alike.  Today, and in the future, it is 
necessary to scientifically and systematically value the costs and consequences of 
management for HBV infection.  In view of this, the application of pharmacoeconomic 
and outcomes principles in evaluating the management of HBV infection would be a 
logical approach.  
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1.2 Overview of Pharmacoeconomics and Outcomes Research  
Healthcare reform and technological advances are creating changes in how health care 
interventions are evaluated.  Increasingly, patients and other healthcare providers and 
decision-makers are presented with new technologies that are much more expensive than 
those conventionally available.  Specifically, efficacy of the interventions may have been 
clearly demonstrated, but the major question is how one can determine whether there is 
good value in the investment in the new pharmaceutical products or pharmaceutical 
services relative to other treatment options.  To make such a decision, there is a need to 
rationally evaluate the costs and consequences of these interventions.   
Nevertheless, it is not appropriate to make a decision primarily based on cost alone, as 
cost containment has at times negative impact on clinical outcomes.  Likewise, clinical 
endpoints solely are also no longer sufficient to make fully informed patient care 
decisions.  Pharmacoeconomics and outcomes research is therefore increasingly being 
used by policy makers and healthcare professionals to quantify the impact and provide a 
more holistic management of chronic diseases as it provides the means to incorporate 
both clinical endpoints and economic data (i.e., the cost and consequences) to fully and 
more properly evaluate pharmaceutical products and services (Osterhaus et al., 2003).   
Briefly, pharmacoeconomics has been defined as “the description and analysis of the 
costs of drug therapy to health care systems and society.”(Townsend, 1987).  Typically, 
pharmacoeconomics is defined as the description and analysis of the costs and 
consequences of pharmaceuticals and pharmaceuticals services, and its impact on 
individuals, health care systems, and society.  On the other hand, outcomes research is 
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more broadly defined as studies that attempt to identify, measure, and evaluate the end 
results of health care services in general; includes not only clinical effects, but also 
economic and humanistic outcomes. Hence, pharmacoeonomics is a division of outcomes 
research; however, not all outcomes research is pharmacoeconomic research (Bungay et 
al., 2003).   
The outcomes of pharmaceutical interventions should not be unidimensional as these will 
give comprehensive and complete information on the impact of new treatments on 
patients’ functioning and well-being.  Hence, outcome measurement must take into 
account economic considerations while recognizing that acceptable clinical and 
humanistic outcomes are also important objectives.  It has been proposed that the 
evaluation of drug therapy and related services should include an assessment of 
economic, clinical, and humanistic outcomes (ECHO) model.  Clinical outcomes are 
defined as medical events that occur as a result of disease or treatment.  Economic 
outcomes are defined as direct, indirect, and intangible costs, compared with the 
consequences of medical treatment alternatives.  Humanistic outcomes are defined as the 
consequences of disease or treatment on patient functional status, or quality of life 
(Bungay et al., 2003).  The true value of healthcare interventions, programs, and policy 
can be assessed only if all three dimensions of outcomes are measured and considered 
(Bootman et al., 1999; Cramer et al, 1998).  
In detail, pharmacoeconomic research identifies, measures, and compares the costs (i.e., 
resources consumed) and consequences (clinical, economic, and humanistic) of 
pharmaceutical products and services.  Within this framework are included the research 
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methods related to cost-minimization, cost-effectiveness, cost-benefit, cost-of-illness, 
cost-utility, and decision analysis, as well as quality-of-life and other humanistic 
assessments. Table 1.1 outlines different types of pharmacoecoeonomic methodologies, 
as well as their cost and outcomes measured (adapted from Bootman et al., 1999 and Lara 
et al., 2004).  In essence, pharmacoeconomic analysis uses tools for examining the impact 
(desirable and undesirable) of alternative drug therapies and other medical interventions 
(Bootman et al., 1999).  Furthermore, pharmacoeconomics is not about determining the 
cheapest health care alternatives, but is about determining those alternatives that provide 
the best health care outcome per dollar spent. 
The next few sections are devoted to introducing some background knowledge and the 
rationale for performing health-related quality of life (HRQoL) assessment, cost-of-
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Table 1.1 Pharmacoecoeonomic methodologies 
Methodology Measurement of outcome (health benefits) 








Assumed to be equivalent in 
comparative groups and can take 
any form (e.g. number of cases 
detected, reductions in cholesterol 
levels, years of life saved) 
 
Additional costs of 










Health benefits across therapies are 
measured in similar natural units (e.g. 
life-years gained, mm Hg blood 
pressure, mmol/L blood glucose) 
 
Cost per life year 
gained, cost per life 
saved, cost per 







Health benefits across therapies are 















Measured in similar or different units 
and are always valued in monetary units 
(e.g. amount willing to pay to prevent a 
death, amount willing to pay to reduce 
exposure to a hazard) 
 
Net benefits = 
Benefits minus costs, 





1.2.1 Health-related Quality of Life Study 
In healthcare research and practice, quality of life has become ever more important since 
the World Health Organization
 
defined health as being not only the absence of disease 
and infirmity but also the presence of physical, mental and social well-being (WHO, 
1948).  However, despite widespread interest in “quality of life” and more specifically 
“health-related quality of life” (HRQOL) in clinical medicine, there is a lack of consensus 
on the definition of the term.  For example, the definition by Testa et al of HRQoL 
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referred to the physical, psychological, and social domains of health, seen as distinct 
areas that are influenced by a person’s experiences, beliefs, expectations, and perceptions 
(Testa et al., 1996).  On the other hand, the International Society for Pharmacoeconomics 
and Outcomes Research defined HRQoL as “a broad theoretical construct developed to 
explain and organize measures concerned with the evaluation of health status, attitudes, 
values, and perceived levels of satisfaction and general well-being with respect to either 
specific health conditions or life as a whole from the individual’s perspective” (Berger et 
al., 2003).  Nevertheless, though these definitions are slightly different from each other, 
most researchers agreed that it should encompass three broad domains of health, namely 
physical, mental and social functioning (Schipper et al., 1996). 
 
A comprehensive definition of disease management provides an opportunity to track a 
population of patients across an entire continuum of a condition, from wellness through 
disease and disability, so that improvements in health status and quality of life and 
efficiencies in the application of health care resources can be demonstrated (Solz et al, 
2001).  However, traditionally physicians have concerned themselves mainly with 
conventional clinical outcomes such as changes in laboratory indices and the impact of a 
disease on life expectancy, leading in some circumstances, closer attention being paid to 
normalizing the patients’ biochemistry readings rather than the patients’ overall well-
being.   In other words, the traditional “biomedical model” of health based on clinical 
sciences (molecular biology, genetics, physiology, biochemistry, etc) tend to be one-
dimensional.   This often leads to the criticism that the biomedical model of healthcare 
delivery is overlooking the fact that healthcare delivery is fundamentally a humanistic 
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exchange and therefore, patient’s perspective needs to be taken into consideration in the 
assessment process. 
 
Generally from patients’ perspective, the impact of any treatment on their quality of life 
is what they care about most rather than clinical outcomes.  McNeil et al. reported this 
finding about 24 years ago in a study in which they found that a significant proportion of 
cancer patients were more concerned about quality of life than longevity (McNeil et al., 
1981).  In a more recent study, Gage et al also found that almost 50% of patients who had 
atrial fibrillation considered disability associated with severe stroke to be a health state 
that was worse than death.(Gage et al., 1996).  
   
So, assessing interventions only in terms of length of life, survival, or mortality is 
insufficient to characterize the health outcomes about which patients care.  As a result, 
there exists strong rationale for measuring HRQoL as one of the outcomes especially in 
the management of chronic diseases such as HBV infection to provide a more holistic 
approach in the management of the disease.  However, HRQoL has only recently been 
investigated in patients with chronic viral hepatitis,  with more attention  being given to 
patients with chronic hepatitis C (Davis et al., 1994; Carithers et al.,1996; Hunt., et al., 
1997; Bayliss et al., 1998; Foster et al., 1998; Bonkovsky et al., 1999; Ware JE et al 
1999; Rodger et al., 1999; Hussain et al., 2001; Fontana et al., 2001; McHutchison et al.,  
2001; Schwarzinger et al., 2004).  Furthermore, to date most of such research is 
conducted in western countries.  There exists very limited data on psychological 
consequences and changes in quality of life of HBV patients, especially in South-East 
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Asian countries, even though the disease is endemic in this part of the world.  Therefore, 
one of the objectives of this thesis is to attempt to fill this gap and hopefully contribute to 
the management of HBV infected patients.  We will show later in the following chapters 
that utilities scores generated by our HRQoL studies may be useful in calculating quality-
adjusted life-year (QALY), a useful outcome indicator for cost-utility analysis (Cramer et 
al., 1998), hence demonstrating that the current thesis contributes to the current 
knowledge gap in the  assessment  of the cost-effectiveness of new treatment modalities 
for the management of chronic hepatitis B infection (CHB) in Singapore and possibly 
other Asian countries. 
 
Generally speaking, HRQoL instruments may be classified as profile-based or 
preference-based (Coons et al., 2000).  Profile-based instruments typically comprise two 
or more domains of HRQoL with each domain yielding a domain score, thus generating a 
profile of scores. For example, the Short Form 36 Health Survey (SF-36) is a popular 
profile-based instrument comprising 8 domains (or scales), thus generating 8 domains (or 
scale) scores (Ware et al, 1994).  Unlike profile-based instruments, preference-based 
instruments generate a single utility score (or index) that reflects the HRQoL of an 
individual at a particular point in time.  For example, the EQ-5D self-report questionnaire 
(EQ-5D), is a widely used preference-based instrument (Brooks, 1996).   
 
Furthermore, HRQoL instruments may be classified as generic or disease-specific as well 
based on the generalizability of the results from the HRQoL assessment (Patrick and 
Deyo, 1989). Generic HRQoL instruments may be used in healthy or sick population; and 
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in sick population, across a variety of diseases (Fayers and Machin, 2000).  Hence, they 
allow the assessment of HRQoL across diverse population groups using a set of items 
that are applicable to all patients regardless of their disease types or to the general 
population.  On the other hand, disease-specific HRQoL instruments comprise items that 
aim to measure areas of life specifically affected by the disease of interest (Fayers and 
Machin, 2000).  
 
1.2.2 Cost-of-illness study  
Economically, the HBV infection imposes a significant personal and social burden on 
those infected, as well as to the health care system.  The actual and potential costs of 
CHB treatment and care are substantial (Yang et al., 2001).  For example, the estimated 
total annual cost (direct plus indirect) associated with HBV-related diseases in South 
Korea in 1997 was US$833.1 million, of which the direct costs amounting to US$696.2 
million, which is equivalent to 3.2% of the national healthcare expenditure for 1997 
(Yang et al., 2001).  Another cost study carried out in Hong Kong estimated the total 
direct cost of managing HBV infection to be approximately US$3.3 billion per annum (Li 
et al, 2004).  Nevertheless, there again exists very little data on the financial burden of 
hepatitis B to the Singapore society as a whole.  Therefore, there is a rationale for 
quantifying the cost-of-illness (COI) caused by CHB for clinical and health care planning 
purposes.  A COI evaluation identifies and estimates the overall cost of a particular 
disease in a defined population (Bungay et al., 2003).  In other words, a COI model 
would help to quantify the burden of HBV to Singapore society.   
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COI is also an important input in cost-effectiveness analysis.  COI studies estimate 
expenditures (direct costs) and the value of output lost (indirect costs) due to illness and 
disease.  Typically included are expenditures for healthcare and the value of output lost 
due to cessation or reduction of productivity activity from a sick or deceased individual 
(Hodgson, 1994).   
Even though a cost-of-illness study is not a complete economic evaluation, the 
information generated can be used to assist healthcare providers in several important 
areas in the management of hepatitis B, specifically in   (1) facilitating informed choices 
in allocating resources, (2) heightening awareness of the problem, in both medical and 
non-medical professions, (3) defining and prioritising the burden of CHB compared with 
other illness, (4) establishing the need for effective medicines, and (5) designing 
prevention and vaccination policies (Szucs, 1999).   
 
1.2.3 Cost-effectiveness/ utility study 
As CHB and its treatment with anti-viral agents induce substantial costs, optimal and 
appropriate use of this class of drug is important in resource allocation.  A 
pharmacoeconomic study by way of cost-effectiveness and cost-utility analysis would be 
greatly useful in the management of HBV infection in Singapore.   
Particularly, cost-effectiveness analysis (CEA) is an approach used for identifying, 
measuring, and comparing the significant costs and consequences of alternative 
interventions (Chrischilles, 1999).  Generally, it is defined as a series of analytical and 
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mathematical procedures that aid in the selection of a course of action from various 
alternative approaches.  CEA has been applied to health matters where the program’s 
inputs can be readily measured in dollars, but the program’s output are more 
appropriately stated in terms of health improvement created (e.g., life-years extended, 
clinical cures) (Bootman et al., 1999).  In other words, CEA measure effects in non-
monetary terms. 
Cost-utility analysis (CUA), on the other hand, is an economic tool in which the 
intervention consequence is measured in terms of quantity and quality of life (Bootman et 
al., 1999).  It is the most common approach to combining quantity and quality-of-life 
outcomes in economic evaluations, using quality-adjusted life-years (QALY) gained as 
the outcome measure (Drummond, 1992).  It is much the same as CEA with the added 
dimension of a particular point of view, most often that of the patient.  The measurement 
of utility is necessary for the calculation of the outcome measure in this type of analysis: 
QALY gained.  Utility is the value or worth placed on a level of health status, or 
improvement in health status, as measured by the preferences of individuals or society 
(Drummond et al., 1987).   
So in summary, the current thesis is organized in the following sequence to address the 
aforementioned research questions. 
1.  Impact of HBV on HRQoL - We would first discuss how HBV infection affects a 
patient’s HRQoL, compared with patients with diabetes mellitus, hypertension and 
healthy subject using generic HRQoL instruments in Chapter 2.   This would then be 
followed by cultural adaptation and validation of Hepatitis Quality of Life Questionnaire 
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(HQLQ), a disease-specific instrument for HBV infected patients in Singapore in Chapter 
3.  
2.  Financial Impact of HBV infection – In order to quantify the financial impact of 
HBV infection in Singapore, a cost analysis study was performed for the management of 
HBV infection and its associated complications in Singapore compared with the data 
from Hong Kong as a preliminary study for the COI study.  Details of the cost analysis 
study would be presented in Chapter 4.   This would then be followed by a detailed COI 
study, measuring both direct and indirect cost of HBV infection to quantify the burden of 
illness to Singapore society in Chapter 5.     
3.  Economic Evaluation of HBV infection - Chapter 6 of the thesis was therefore an 
endeavour to discuss in detail the CEA and CUA designed to assist decision-makers in 
identifying a preferred choice among possible alternatives.  
The last chapter of the thesis has concluded all the major findings of the above defined 


















Chapter 2.  
How does Hepatitis B Virus Infection affect a Patient’s 
Health-Related Quality of Life:   
A Comparison with patients with diabetes, hypertension 
and healthy subjects 
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2.1 INTRODUCTION 
Hepatitis B remains one of the most common viral infections affecting humans, with an 
estimated 400 million people infected worldwide and causing one million deaths annually 
(Lavanchy, 2004).  Clinically, people with chronic hepatitis infection are at high risks of 
liver damage; with approximately 15-40% of infected patients eventually developing 
cirrhosis, liver failure, or hepatocellular carcinoma during the course of hepatitis B virus 
(HBV) infection (McMahon, 1997; Lok, 2002).  Symptoms of acute HBV infection are 
well documented but those of chronic HBV infection are less clear. Little is known 
otherwise about symptoms in patients with chronic hepatitis B and even less about its 
impact on health-related quality of life of such patients. It is a field that is poorly studied 
despite it being the most prevalent form of chronic viral hepatitis worldwide.  In contrast, 
HRQoL has been well studied in patients with chronic hepatitis C (Davis et al., 1994; 
Carithers et al., 1996; Hunt., et al., 1997; Bayliss et al., 1998; Foster et al., 1998; 
Bonkovsky et al., 1999; Ware JE et al 1999; Rodger et al., 1999; Hussain et al., 2001; 
Fontana et al., 2001; McHutchison et al., 2001; Schwarzinger et al., 2004).  These studies 
had reported a consistent and marked reduction in HRQoL among patients with chronic 
hepatitis C as compared with the general population. 
Health-related quality of life (HRQoL) is a multifactorial construct that describes 
individuals’ perceptions of their physical, psychological and social functioning (Schipper 
et al, 1996).  Thus, HRQoL is a more important indicator in assessing patient’s functional 
health and well-being more holistically than to rely solely on clinical parameters in 
chronic diseases where mortality is not an immediate concern.  
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.  
The evaluation of HRQoL in patients with chronic hepatitis B is particularly important 
since it is the leading worldwide cause of liver disease, liver death and liver morbidity 
(Lavanchy, 2005; Merican et al., 2000; Lok et al., 2001; Lee, 1997).  The natural history 
of HBV infection is complex and comprises a number of phases, and infected patients 
who develop progressive liver disease would eventually suffer from liver cirrhosis and 
its complications as well as possible hepatocellular carcinoma.  However, many patients 
only seek medical care when they develop symptoms, and when the liver disease is well 
advanced.  Misconceptions amongst such patients have been found, particularly with 
regards to the link between symptoms and complications of chronic hepatitis B (Wai et 
al., 2005; Tan et al., 2005), and these may contribute towards compliance to follow-up, 
and the desire to seek medical attention only when symptomatic.  With the advent of new 
therapeutic agents, there is a greater possibility of preventing complications and 
consequently establishing the relationship between stages of chronic hepatitis B liver 
disease and HRQoL becomes an important issue in the overall management of HBV 
infections.   It is thus our objective in this chapter to determine the relationship between 
HRQoL and the stages of chronic hepatitis B infection compared to normal controls and 
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2.2 METHODS 
Subjects and Study Design 
Patients with chronic HBV defined as having HBsAg positive for >6months were 
enrolled from August 2003 to November 2006, by convenience sampling from the 
specialist Gastroenterology and Liver Clinic  at the National University Hospital (NUH), 
a major tertiary referral hospital in Singapore.  HBV patients were identified from the 
database kept by the department and were stratified by the following clinical groups: 
 
Asymptomatic carrier (AS)  HBsAg +ve, HBeAg -ve with normal liver 
function tests (LFTs) 
 
Chronic hepatitis B (CHB) HBsAg +ve with abnormal LFTs and 
increased HBV DNA. 
 
Compensated cirrhosis (CC) Cirrhosis based on liver biopsy or obvious 
findings on ultrasound imaging. 
 
Decompensated cirrhosis (DC) Cirrhosis with a history of either ascites, 
variceal bleeding, spontaneous bacterial 
peritonitis, hepatorenal syndrome. 
 
Hepatocellular carcinoma (HCC) Confirmed radiologically with or without 
raised alphafetoprotein. 
  
Post-liver transplants (PLT) Transplanted due to complications of 
chronic hepatitis B. 
 
Patients with hypertension were chosen as one of the comparison groups due to the 
asymptomatic nature of the disease initially (Lawrence et al, 1996; Hope et al., 1994), 
which resembled the initial phase of chronic hepatitis B.  On the other hand, DM patients 
served as another chronic disease control which represented a group who reported poorer 
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overall HRQoL compared with the general population (Wee et al., 2005; Holmes et al., 
2000; Rubin and Peyrot, 1999).  
 
Hypertensive patients were recruited from the Hypertension Clinic at NUH from May 
2004 to December 2004, and were mainly referred by the physicians while they attended 
the clinic, by convenience sampling.  Before the study, the physician was briefed 
regarding the nature of the study and the characteristics of patients we intended to recruit, 
i.e. asymptomatic essential hypertensive without any complication (inclusion criteria).   
 
Besides a clinical diagnosis of the disease, other inclusion criteria for HBV and 
hypertensive patients were age above 16, and the ability to self-complete the 
questionnaires in English or Chinese.  The exclusion criteria for HBV patients were those 
illiterate (exceptions were applied if the family members or care-givers offered to read 
out the questions to patients and obtained the answers directly from them).  After 
informed consent, HBV and hypertensive patients filled in the SF-36 and EQ-5D 
questionnaires prior to or after their clinic appointments.  
The DM patients were recruited from July to October 2003 at the Diabetes Centre from 
the Singapore General Hospital, a tertiary acute-care referral hospital by convenience 
sampling.  The inclusion criteria were age above 18, and presence of Type 1 or 2 DM.  
Subjects with gestational DM were excluded.  Subjects were requested to fill in the EQ-
5D and Audit of Diabetes-Dependent Quality of Life Questionnaire [results of which was 
reported elsewhere (Wee et al, 2006)].  Only the EQ-5D data for DM patients were used 
in this study for comparison.  
 19
 
Chapter 2. Health related quality of life in chronic hepatitis B patients       Siew Chin, Ong 
 
Healthy subjects to serve as the control group in the study were randomly selected from 
hospital staff members, their friends and family members.   Family members, relatives or 
friends who accompanying HBV infected patients attending the clinic for follow-up 
consultation were also encouraged to participate in the study during the same period of 
time when we recruited HBV infected patients.  Potential healthy participants were asked 
to indicated “Yes” or “No” in a list of chronic medical conditions including diabetes 
mellitus, hypertension, asthma or other lung diseases, heart diseases, psychological 
problems (eg: anxiety, depression etc), renal diseases etc in the questionnaire to enable us 
to include only those without any significant illnesses.  Participants aged below 16 were 
also excluded from the study. Normal healthy controls filled in the same set of 
questionnaire as HBV and hypertensive patients. Information assessing 
sociodemographic information, such as gender, age, ethnicity, education level, income 
etc., was also collected for all participating subjects.  




The SF-36 is a commonly used profile-based HRQoL instrument with abundant evidence 
of its reliability and validity in determining the HRQoL in various disease populations 
(Brazier et al., 1992; Katz et al., 1992; Kurtin et al., 1992; Phillips et al., 1992; Garratt et 
al., 1993; McHorney et al., 1993; McHorney et al., 1994; Ware 1992).  It consists of 8 
multi-item domains that evaluate various aspects of physical and psychological 
functioning and well-being.  Each domain score has a possible range from 0 to 100, with 
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higher scores indicating better health.  In addition, the eight domains of SF-36 may be 
further aggregated into two summary measures: Physical Component Summary (PCS) 
and Mental Component Summary (MCS) scales (Ware, 1993 and 1994).  The formula for 
calculation of PCS and MCS scale scores for Singapore used in this study were obtained 
from a local study (Thumboo et al., 2003) using the method recommended by the 
developers of the SF-36 (Ware et al., 1994).  The Singapore English and Chinese version 
of SF-36 questionnaire were provided by the developer, and have been validated in 




The EQ-5D self-reported questionnaire (EQ-5D) is a generic preference-based HRQoL 
instrument which has been translated into 27 languages and has been used as an outcome 
measure in many international clinical trials (Rabin et al., 2001).  The questionnaire gives 
both a utility value which  ranges from -0.59 to 1.00, with 0 (corresponding with state of 
death) and 1 (corresponding with full health) based on a five-dimensional health state 
classification, and a score between 0 and 100 (denoting the worst and best imaginable 
health states respectively) on a 20-cm visual analogue scale (VAS).  The five dimensions 
of the self-classifier are mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression with three levels of severity.  The Singapore English and Chinese 
version of EQ-5D questionnaire used in this study were provided by the developer, and 
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Two generic HRQoL instruments were used in the study because we would like to 
evaluate which of these two commonly used instruments would be more suitable for 
measuring HRQoL in HBV patients.  In addition, each of the two instruments has its 
advantages and the information collected may complement each other.  For example, 
utilities scores generated by EQ-5D may be used directly to calculate quality-adjusted 
life-year (QALY), a useful outcome indicator for cost-utility analysis (Cramer et al., 
1998).  On the other hand, SF-36 would provide more comprehensive and 
multidimensional assessment of HRQoL.  Hence, SF-36 and EQ-5D provide different 
information from each other which will enable our HRQoL evaluation of HBV patients to 
be more wide-ranging and informative.   
 
Data Analysis 
Data from participants who have completed the English and Chinese SF-36 versions and 
EQ-5D were pooled to increase power and representativeness of the study.  The validity 
of this approach was supported by previous work demonstrating equivalence of the 
Chinese and English versions of SF-36 (Thumboo et al., 2002c) and EQ-5D (Luo et al., 
2003c) in Singapore. 
One-way analysis of variance (ANOVA) and post-hoc tests were performed to test for 
statistical significance in all scale scores among different categories of hepatitis B 
patients and the other comparison groups.  All comparisons in this study used normal 
control as the comparator group, unless otherwise specified.   
Multiple linear regression analysis (MLR) was performed to assess the effect of various 
stages of HBV infection, hypertension and DM on HRQoL compared to normal controls 
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while adjusting for the influences of sociodemographic factors such as age, gender, 
ethnicity and education level.   
As age, gender, ethnicity and education levels can influence HRQoL scores, magnitude 
of mean score differences in SF-36 summary scales and EQ5D dimensions for HBV 
patients and disease controls were calculated with adjustment for these variables using 
multiple linear regression (MLR) analysis.  Each scale was used as the dependent 
variable in a separate linear regression model (i.e. total of 4 models). Independent 
variables included in each model were different stages of HBV infection and other 
disease controls (normal controls as the referent group), age, gender, ethnicity and 
education level.  
 
All statistical analyses were performed with Statistical Package for the Social Sciences 
(SPSS Inc., Chicago, Illinois) 13.0 for Windows.  Statistical significance for all tests was 
set at 5%.   
 
2.3 RESULTS  
Subject characteristics  
A total of 432 HBV patients, 93 hypertensive patients, 152 DM patients and 108 normal 
controls participated in the study.  Among the HBV patients, there were 156 AS, 142 
with CHB, 66 with CC, 24 with DC, 22 with HCC and 22 with PLT.  The characteristics 
of the subjects are shown in Table 2.1.  The majority from each group of patients was 
Chinese and male except for the normal control group. 
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There are significant differences in ages among different groups of patients, where 
hepatitis B patients and normal controls are generally younger in age compared to 
hypertension and DM groups (ANOVA test).   There are also significant differences in 
gender, race and education level among different groups of patients.  However, these 
actually mirror the expected characteristics of these patient groups in Singapore where 
hepatitis B infection is found predominantly in Chinese males from all age groups, while 
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Table 2.1: Sample characteristics for each group of participants 












Male, number (%) 285 (70.2) 55 (59.1) 78 (51.3) 29 (26.9) 
Age years, mean (SD) 46.2 (12.9) 50.3 (14.4) 52.0 (12.9) 
32.4 
(12.6) 
Race, number (%) 
 Chinese 415 (96.1) 82 (88.2) 74 (48.7) 87 (80.6) 
 Malay  13 (3.2) 1 (1.1) 19 (12.5) 13 (12.0) 
 Indian 1 (0.2) 2 (2.2) 51 (33.6) 5 (4.6) 
 Other 3 (0.6) 8 (8.6) 7 (4.6) 3 (2.8) 
 Not specified 0 (0.0) 0 (0.0) 1 (0.7) 0 (0.0) 
 
Marital status, number (%) 
 Single 81 (20.0) 16 (17.2) N.A 56 (51.9) 
 Married 331 (76.6) 68 (73.1) N.A 50 (46.3) 
 Divorced or separated 7 (1.7) 5 (5.4) N.A 1 (0.9) 
 Widowed  9 (2.1) 4 (4.3) N.A 1 (0.9) 
 Not specified 4 (0.9) 0 (0.0) N.A 0 (0.0) 
 
Education level, number (%) 
 No schooling 9 (2.1) 0 (0) 0 (0) 0 (0) 
 Primary 43 (10.0) 6 (6.5) 6 (3.9) 2 (1.9) 
 Secondary 162 (37.5) 42 (45.2) 90 (59.2) 49 (45.4) 
 Tertiary and above 209 (48.4) 29 (31.2) 34 (22.4) 55 (50.9) 
 Not specified 4 (0.9) 0 (0) 22 (14.5) 2 (1.9) 
 
Employment status, number (%) 
 Working 291 (67.4) 51 (54.8) N.A 71 (67.0) 
 Unemployed 21 (4.9) 4 (4.3) N.A 0 (0.0) 
 Retired 58 (13.4) 23 (24.7) N.A 3 (2.8) 
 Full time student 11 (2.7) 2 (2.2) N.A 24 (22.2) 
 Homemaker or housewife 35 (8.1) 8 (8.6) N.A 6 (5.6) 
 National service personnel 11 (2.7) 5 (5.4) N.A 4 (3.7) 
 Not specified 6 (1.4) 0 (0.0) N.A 0 (0.0) 
 
Personal monthly income, number (%) 
 SGD 0-1999 (USD 0-1211) 203 (47.0) 49 (52.7) 69 (45.4) 64 (60.4) 
 SGD 2000-3999 (USD 1212-2423) 117 (27.1) 23 (24.7) 32 (21.1) 43(39.8) 
 > SGD 4000 (> USD 2424) 89 (20.6) 29 (31.2) 28 (18.4) 6 (5.7) 
 Not specified 23 (5.3) 2 (2.2) 23 (15.1) 3 (2.8) 
Footnote: USD 1 equivalent to SGD 1.65 as of 13 May 05. 
      N.A – Not available 
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There were 20 subjects (3 from normal controls, 2 from hypertensive and 15 from HBV 
patients) who did not complete the physical functioning scale, 1 hypertensive patient did 
not complete the bodily pain scale, 4 subjects (3 from HBV patients and 1 from 
hypertensive group) missed the vitality scale, 1 HBV patient missed the mental health 
scales and 4 subjects (2 hypertensive and 2 HBV patients) did not complete the general 
health scale.  These subjects were removed as respondents must have complete data on 
all eight SF-36 multi-item scales.  
 
The SF-36 scores and standard deviation for different patient groups and normal control 
are shown in Table 2.2.  All of the SF-36 scores were markedly reduced in hepatitis B 
patients with more advanced liver disease (DC and HCC) and PLT, indicating that these 
patients perceive themselves to be unwell and report significant reductions in their quality 
of life (Figures 2.1).  Among these groups, PLT patients generally reported better 
HRQoL in most scales scores than patients with DC and HCC patients. This is congruent 
with the supposition that they have recovered from decompensated liver disease. DC 
patients consistently scored the lowest in all SF-36 scale scores except vitality (VT), role 
emotional (RE) and mental health (MH)  where HCC patients demonstrated the lowest 
scores [mean VT scores: DC= 57.08 (p= 1.00), HCC= 55.91 (p=1.00); mean RE scores: 
DC=70.83 (p=0.277), HCC=66.29 (p=0.035); and mean MH scores: DC= 70.67 (p=1.00), 
HCC= 64.91 (p=0.503)].  In comparison to DC and HCC patients, PLT patients returned 
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a lower role physical (RP) score [mean RP scores: PLT= 57.27 (p<0.001), DC= 69.17 
(p<0.001) and HCC= 59.09 (p<0.001)].  
 
On the other hand, AS and normal control groups showed the best HRQoL scores on all 
SF-36 scales (Figure 2.2) [mean scores for AS: PF= 89.54 (p=1.00), RP= 93.59 (p=1.00), 
BP= 87.36 (p=0.396), GH= 67.51 (p=0.383), VT= 64.52 (p=1.00), SF= 68.42 (p=1.00), 
RE= 92.90 (0.710), and MH= 75.00 (p=1.00);  mean scores for normal controls: PF= 
91.72, RP= 95.19, BP= 81.26, GH= 73.59, VT= 62.84, SF= 67.79, RE= 86.11, and MH= 
73.43].  Not surprisingly, in the scale of general health, normal controls (mean score 
=73.59] showed significantly better self-perceived HRQoL than all other groups [mean 
GH scores: AS= 67.51 (p=0.383), CHB= 60.64 (p<0.001), CC= 58.82 (p<0.001), 
DC=51.45 (p<0.001), HCC=53.27 (p<0.001), and PLT=55.36 (p=0.002)], but otherwise 
there was no significant difference between normal controls, AS, CHB, CC and 
hypertensive patients in all other scales.   
 
For the physical component summary (PCS) scale, the mean scores for AS (mean= 
55.03), CHB (mean= 54.29), CC (mean= 53.05), hypertensive (mean= 52.29) and normal 
controls (mean= 54.19) were higher than the general Singapore population (mean scores 
of 50 and standard deviation of 10) (Table 2.1 and Figure 2.3). There was no significant 
difference between well compensated HBV group [mean AS score=55.03 (p=1.00), mean 
CHB score= 54.29 (p=1.00), and mean CC score= 53.05 (p=1.00)] and normal controls, 
nor were there any differences between hypertensive [mean= 52.29 (p=0.796)] and 
normal controls (mean=54.19)]. However, the HRQoL scores for DC, HCC and PLT 
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infected patients were significantly lower than the normal controls, with HCC patients 
demonstrating the lowest scores (mean= 44.96; reference group). Significant differences 
were observed when mean HCC score was compared with scores from AS, CHB and CC 
[mean AS score=55.03 (p<0.001), mean CHB score=54.29 (p<0.001), mean CC 
score=53.05 (p<0.001)]. Similar result was obtained when comparing HCC score with 
those from hypertensive patients [mean= 52.29 (p=0.001)].   
 
On the other hand, the mental component summary (MCS) scale scores for all groups of 
patients and normal controls in our study showed generally lower scores compared to 
PCS scores and fell below the normative value of the Singapore general population 
(mean scores of 50 and standard deviation of 10), with HCC patients showing the lowest 
score (mean= 40.55).  In comparison, significant differences were observed between 
HCC patients, AS patients [mean AS score= 48.42 (p=0.017)], and normal controls 
[mean= 48.25 (p=0.030)].  But no difference was observed with the other groups [mean 
CHB score= 44.00 (p= 1.00), mean CC score= 46.70 (p= 0.378), mean DC score= 42.28 
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Table 2.2: Mean scores (standard deviation) for SF-36 for each group of patients and 
control 
 




















































































































































































































*P < 0.05 compared with normal healthy control. 
 
Footnote: 
AS  - Asymptomatic carrier  
CHB   - Chronic hepatitis B  
CC  - Compensated cirrhosis 
DC  - Decompensated cirrhosis 
HCC  - Hepatocellular carcinoma 
PLT  - Post-liver transplants  
Hpt  - Hypertensive  
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Figure 2.1: SF-36 scale score for advanced stage of HBV patients, hypertensive 
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Figure 2.2: SF-36 scale score for early stage of HBV patients, hypertensive patients 
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Figure 2.3: Physical and mental components summary scales scores for different 





















Asymptomatic carrier Chronic hepatitis B Compensated cirrhosis Decompensated cirrhosis
Hepatocellular carcinoma Post-liver transplants Hypertensive normal control
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A total of 16 participants consisting of 9 HBV respondents (2.2%), 2 hypertensive 
patients (2.2%), 4 DM patients (2.6%) and 1 normal control (0.9%) did not provide data 
on all five dimensions of the EQ-5D self-classifier and 51 subjects did not answer the 
EQ-5D VAS.  All these participants were excluded from the analysis.  Descriptive data 
such as mean scores (standard deviation), medians and ranges for EQ-5D self-classifier 
and VAS, as well as percentage of respondents to the EQ-5D health descriptive system 
are summarized in Table 2.3.   
 
As expected, participants with better health status had higher mean EQ-5D scores than 
subjects with worse health status (Figures 2.4 and 2.5).  Normal healthy controls 
consistently demonstrated the highest HRQoL in both utility scale and VAS in EQ-5D, 
although there was no significant difference demonstrated compared with the well 
compensated HBV (i.e., AS, CHB and CC) and hypertensive patients.  Among the 
patient groups, HCC patients [mean=0.79 (p<0.001)] scored the lowest, followed by DM 
patients [mean=0.81 (p<0.001)] in EQ-5D utility scale.  In EQ-5D VAS, DM patients 
[mean=64.82 (p<0.001)] had the most impaired HRQoL followed by HCC patients 
[mean=68.50 (p=0.021)].  
 
The domain that was perceived to be most symptomatic by patients was the 
anxiety/depression dimension.  Among HBV infected patients, a similar trend was 
observed as in MCS scale of SF-36 with all groups of HBV patients demonstrating more 
impairment in mental than physical domains [AS: mean MCS= 48.42 (p=1.000), mean 
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After adjusting against normal controls, HCC patients consistently demonstrated 
significant worse HRQoL in both SF-36 summary scales and EQ-5D dimensions than the 
other groups of patients, except in EQ-5D VAS scores where DM patients scored the 
lowest (Table 4) [DM: adjusted mean difference= -17.67 (p<0.001); HCC: adjusted mean 
difference = -14.79(p<0.001)]. 
 
After adjusting for sociodemographic factors (including age, gender, ethnicity and 
education level) known to influence HRQoL in the MLR analysis (Table 2.4), subjects 
with HBV diseases (except AS) and hypertension generally reported significant lower 
scores for all SF-36 summary scales and EQ-5D dimensions when compared with normal 
controls.  However, there was no significant difference between normal controls, AS, 
CHB, CC HBV patients and hypertensive in PCS scale in SF-36.   
 
PCS=55.03 (p=1.000); CHB: mean MCS=44.00 (p= 0.025), mean PCS=54.29 (p=1.000); 
CC: mean MCS= 46.70 (p=1.000), mean PCS= 53.05 (p=1.000); DC: mean MCS= 42.28 
(p= 0.203), mean PCS= 45.90 (p<0.001);  HCC: mean MCS= 40.55 (p= 0.030), mean 
PCS= 44.96 (p<0.001); PLT: mean MCS=45.80 (p=1.000), mean PCS=46.01 (p<0.001)].  
DM claimed the highest percentage of having extremely anxiety/depression (4.7%).  
However, there were more HCC patients (50%) in the sample reported having 
anxiety/depression compared to DM (46.9%).  On the contrary, self care was the 
dimension that most subjects reported no problem with, except among DM patients 
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Table 2.3: Percentage (%) of respondents to each EQ-5D dimensions and descriptive data for each group of participants 
HBV disease stages 


















Self-classifier, %          
Mobility         
         
          
         
          
         
          
         
          
 
    No problems 94.7 97.1 98.4 91.3 81.8 86.4 94.5 79.1 98.1 
    Some problems 5.3 2.9 1.6 8.7 13.6 13.6 5.5 20.9 1.9 
    Extreme problems 
 
0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.0 0.0 
Self-care
    No problems 98.7 99.3 100.0 100.0 95.5 100.0 100.0 97.3 100.0 
    Some problems 1.3 0.7 0.0 0.0 4.5 0.0 0.0 2.7 0.0 
    Extreme problems 
 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Usual activities
    No problems 95.4 96.4 96.9 82.6 81.8 81.8 93.4 73.0 100.0 
    Some problems 4.6 3.6 3.1 17.4 13.6 18.2 6.6 26.4 0.0 
    Extreme problems 
 
0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.7 0.0 
Pain/discomfort
    No pain/discomfort 86.8 86.4 85.9 56.5 59.1 68.2 69.2 62.2 87.9 
    Moderate pain/discomfort 12.5 13.6 14.1 43.5 36.4 31.8 29.7 35.8 12.1 
    Extreme pain/discomfort 
 
0.7 0.0 0.0 0.0 4.5 0.0 1.1 2.0 0.0 
Anxiety/depression
    No anxiety/depression 84.2 72.1 78.1 69.6 50.0 63.6 72.5 52.0 87.9 
    Moderate anxiety/depression 15.8 26.4 20.3 30.4 50.0 31.8 26.4 42.2 12.1 
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Table 2.3 (Continued): Percentage (%) of respondents to each EQ-5D dimensions and descriptive data for each group of 
participants 
 
HBV disease stages 




































Median          
 
         
         
          
         
1.0 1.0 1.0 0.85 0.83 0.85 1.0 0.85 1.0
Range
 
0.26-1.0 0.26-1.0 0.29-1.0 0.62-1.0 -0.17-1.0 0.31-1.0 -0.08-1.0 -0.01-1.0 0.66-1.0
Visual analogue scale (VAS) 




















82.5 75.0 79.0 70.0 70.0 90.0 75.0 66.5 80.0
Range 40-100 30-100 30-100 50-100 9-100 38-99 35-100 10-100 30-100
 
*P < 0.05 compared with normal healthy control. 
 
Footnote:AS      - Asymptomatic carrier  
          CHB   - Chronic hepatitis B  
          CC   - Compensated cirrhosis 
               DC      - Decompensated cirrhosis 




HCC  - Hepatocellular carcinoma 
PLT  - Post-liver transplants  
Hpt  - Hypertensive 
DM  - Diabetes Mellitus 
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Table 2.4: Adjusted differences in mean scores for HBV infection and comparison groups with normal controls as the reference 
group on SF-36 summary scales and EQ-5D dimensions (adjusted for the influence of age, gender, ethnicity and education level) 
using multiple linear regression analysis. 
 
HBV disease stages  
 
 
Normal healthy Control 
(No chronic medical disease) ^





SF-36 PCS 54.19 (5.31) 1.39     0.10 -0.312 -6.90*** -7.55*** -6.91*** -0.82 NA
SF-36 MCS 48.25 (8.82) -1.68        
        
        
-5.55*** -3.77* -8.79*** -10.85*** -5.39* -4.24* NA
EQ-5D utility  0.94 (0.12) -0.02 -0.05* -0.03 -0.10** -0.17*** -0.11** -0.063** -0.12***
EQ-5D VAS 80.77 (15.54) -1.33 -8.64*** -6.97* -12.67** -14.79*** -4.68 -7.62** -17.67***
^Mean (SD) scores 
*p<0.05, ** p<0.01, *** p<0.001 compared with normal healthy control. 
 
Footnote:          
                    AS           - Asymptomatic carrier  
CHB - Chronic hepatitis B  
CC - Compensated cirrhosis 
DC - Decompensated cirrhosis 
HCC - Hepatocellular carcinoma 
PLT - Post-liver transplants  
Hpt - Hypertensive  
DM - Diabetes Mellitus 
                   Control - Normal controls   
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 Figure 2.4: EQ-5D visual analogue scale score for different disease groups of patients 
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2.4 DISCUSSION 
Our study shows that the HRQoL of HBV patients in their early stages generally did not 
differ significantly with the normal healthy control group, especially in their physical 
health component.  This is consistent with the finding of a study in UK where overall 
HRQoL was similar in HBV-infected, noncirrhotic patients and the healthy control 
population, even though the sample size of 30 HBV patients for that study was relative 
small, and the study recruited only early stage of HBV patients (Foster et al., 1998).  
Similar to our study, they also found that HBV infected patients in early stages of the 
disease do not have any significant impairment in their physical functions and the 
significant reduction in HRQoL were only found in general health scale in SF-36.  
What is more surprising from our study is that patients with CC do not have any 
impairment in their HRQoL and physical functioning, and significant deterioration only 
occurs when DC and HCC develop.  In contrast, HCV patients have significantly 
reduced HRQoL even in patients without advanced liver disease (Carithers et al., 1996; 
Foster et al., 1998; Gallegos-Orozco et al., 2003; von Wagner et al., 2006). 
Consequently, findings pertinent to HRQoL in chronic HCV may not be extrapolated to 
those of chronic hepatitis B. 
 
An important implication of this finding is that symptoms of disease in chronic hepatitis 
B cannot be used as an indication of disease activity.  In our study, the presence of 
symptoms were often associated with advanced liver disease, the very endpoint that 
screening and early treatment were seeking to prevent.  This becomes important when it 
impacts patient follow-up. For instance, during a screening program for known hepatitis 
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B carriers, we found that some 67% of hepatitis B carriers were not on regular follow-up 
(Wai, 2002). The reasons for this behaviour are far from clear, but one reason could 
certainly be due to misconceptions regarding development of symptoms and health status 
in chronic hepatitis B.  In a follow-up study, the results showed that only 32% of 
patients interviewed realized that early liver cancer was not symptomatic (Wai et al, 
2005). The current study thus confirms that the vast majority of patients with chronic 
hepatitis B did not show symptoms.  In the effort to manage chronic hepatitis B better 
and prevent end-stage liver disease through regular screening, expedient and appropriate 
therapy, patient’s HRQoL, and relation of disease to symptoms are central to their beliefs 
on illness (Wai et al, 2005). 
 
Not surprisingly, our study found that post liver-transplants patients generally reported 
better HRQoL than patients with DC and HCC patients.   This finding is reassuring that 
liver transplantation does improve HRQoL and is congruent with other reports that most 
liver transplant recipients reported improvement in various measures of quality of life 
after the operation (Nunes et al., 2000).  
 
The other findings from our study also show that all stages of HBV patients reported 
better PCS scale scores than their MCS scale scores when measured by SF36.  
Similarly, there were more patients who reported problems in the anxiety/depression 
dimension in EQ-5D self-classifier compared with the other dimensions such as mobility, 
self-care, usual activities and pain/ discomfort.  These indicated that mental health 
component for HBV patients were affected more than their physical health component.  
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This implies that simply being known as "a hepatitis B carrier" can directly affect 
patients’ HRQoL.  In fact, this effect has been shown in hepatitis C patients where 
stigmatization is emotionally burdensome, and may adversely affect the self-esteem and 
quality of life of the affected individuals (Zickmund et al., 2003; Crocker et al., 2000; 
Miller et al., 2000). Similarly, this phenomenon was also observed in epileptic patients 
where being labeled as an epileptic causes greater concern and distress than the type or 
frequency of seizures (Scambler, 1990).   
 
Our study is unique in providing comparative data on HRQoL of patients with different 
stages of HBV infected patients with patients with hypertension, DM patients and normal 
healthy subjects.  To the best of our knowledge, this is the first study conducted to 
compare the HRQoL of different stages of HBV patients with other chronic diseases.  
However, our study has some limitations.  Firstly, all subjects were recruited from 
tertiary healthcare centers, and one would expect that such patients have generally more 
advanced or complicated liver disease. The finding that a large proportion of these 
patients were largely asymptomatic and similar to normal healthy controls indicated that 
the patients recruited from a tertiary referral centre had little influence on the study.  
Another potential limitation of the present study is that it only aims to evaluate the impact 
of HBV infection on HRQoL comparing with the other chronic diseases, while factors 
such as duration of disease, abnormality in laboratory tests or medication are not being 
studied.  Finally, a major limitation of the study is that we have adopted the convenience 
sampling method for recruiting HBV patients and other comparison groups without group 
matching the patients according to their age, gender, ethnicity etc.  However, multiple 
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linear regression analysis performed to adjust for those possible confounders in our study 
found that these factors do not affect the HRQoL scores significantly for most of the 
scales.  Hence, the results of this study might still provide some fairly significant insights 
and be a good source of data; at the very least it will serve as a foundation for future 
studies.    
 
 
2.5 CONCLUSIONS  
We have shown that the HRQoL status among HBV patients with early disease including 
those with CC have scores comparable with those of healthy controls and hypertensive 
patients, and deteriorate with disease progression.  Furthermore, in HBV patients, the 
impact of the disease affects the mental domain more adversely than the physical domain.  
These findings confirm clinical impressions that chronic hepatitis B is largely 
asymptomatic and impact on HRQoL would not be significant until the disease becomes 
advanced.  Consequently, the impetus for patients to return for follow-up rests largely on 
patient education; that the disease can lead to complications, that the complications are 
serious, and that treatment can reduce such complications, all these being key aspects of 
the health belief model. 
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Hepatitis B, an inflammatory condition of the liver, is caused by the hepatitis B virus 
(HBV) infection (Roger et al., 2002).  It is a highly infectious disease transmitted by 
direct contact with the blood and body secretions of hepatitis B surface antigen (HBsAg)-
positive individuals (Fontana et al., 2001).  The initial symptoms are typically mild and 
nonspecific, which include intermittent fatigue and less frequently, nausea, right upper 
quadrant discomfort, and muscle aches and pains (Di Bisceglie et al., 2000).   
Nevertheless, a significant proportion of the patients will eventually develop cirrhosis and 
hepatocarcinoma.  As HBV infected subjects progress from asymptomatic to 
symptomatic disease and then to compensated and decompensated cirrhosis, their 
symptoms get progressively more serious.  However, little is known about the 
relationship between the development of symptoms and its impact on patients’ well being 
and quality of life.  Due to the chronic nature of HBV infection, this is an area that 
warrants more investigation. 
Besides its ability to capture how patients perceive their own health status, health-related 
quality of life (HRQoL) can serve as outcomes measure of patients’ preference for the 
outcomes of various treatments in clinical studies.  Therefore, measuring HRQoL in 
patients with chronic diseases is becoming increasingly important in clinical medicine 
where a comprehensive disease management approach, which tracks a population of 
patients across the entire continuum of a condition, from wellness through disease and 
disability is more meaningful than the traditional “biomedical model” based on basic 
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sciences (molecular biology, genetics, physiology, biochemistry, etc.) (Testa et al., 1996; 
Wilson et al., 1995; Solz et al., 2001). 
Many interventions in patients with chronic liver disease are geared primarily to make 
patients feel better and hence improve their HRQoL.  While investigators may choose 
from a variety of validated generic HRQoL instruments such as SF-36 and EQ-5D, these 
questionnaires may fail to detect small but important improvements in HRQoL in 
hepatitis B patients.  Disease-specific instruments generally measure the same domains, 
but the items are tailored to particular disease characteristics and may also include items 
dealing with side effects of therapy.  Hence, a disease-specific instrument is likely to be 
more responsive or sensitive to changes in HRQoL that, while small, are nevertheless 
important (Guyatt et al., 1986; Kongpatanakul et al., 1992; Fowlie et al., 1987; Guyatt et 
al., 1987a, 1987b; Bruin et al., 1992; Bergnen et al., 1981; Ware et al., 1992).   
 
Unfortunately, there is no HRQoL instrument that covers the entire spectrum of hepatitis 
B and liver disease presently.  In contrast, HRQoL has been well studied in patients with 
chronic hepatitis C (HCV) with more than a few questionnaires validated for use in this 
group of patients (Davis et al., 1994; Carithers et al., 1996; Hunt., et al., 1997; Bayliss et 
al., 1998; Bonkovsky et al., 1999; Ware et al 1999; Rodger et al., 1999; Hussain et al., 
2001; Fontana et al., 2001; McHutchison et al., 2001; Schwarzinger et al., 2004).  
Particularly, there are some similarities between hepatitis B and hepatitis C virus 
infection.  Each virus can be transmitted by blood borne routes, such as transfusion or 
injection drug use.  Chronic infection with either  virus may cause minimal symptoms for 
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decades, but ultimately progress to cirrhosis and hepatocellular carcinoma.  However, 
there are distinctive differences between hepatitis B and hepatitis C.  For example, the 
risk of developing hepatitis B is closely correlated with the patient’s age at the time of 
infection.  Most children and infants exposed to hepatitis B develop chronic infection, but 
adults typically have self-limited infection.  By contrast, the risk of developing chronic 
hepatitis C is high, irrespective of the age at which initial infection occurs.  There are also 
marked differences in the risk of sexual and maternal-fetal transmission of the two 
viruses. Highly effective methods are available for preventing infection with hepatitis B.  
By contrast, no effective means of active or passive prevention of HCV infection are 
currently available (Carithers, 2001).    
 
In order to provide a more holistic approach in managing patients with hepatitis B, one of 
the major challenges is to find a valid and reliable HRQoL instrument for this group of 
patients.  The main objective of this study, therefore, was to culturally adapt an overseas 
developed HRQoL instrument, namely, the Hepatitis Quality of Life Questionnaire 
(HQLQ) and assess its suitability for use in English-speaking hepatitis B patients in 
Singapore.  This is because HRQoL instruments developed in one country  may not 
necessarily be applicable cross-culturally (Hunt, 1998). It is clear that cultural factors 
play an important role in HRQoL assessment.  Two cultures (the original and the target 
cultures) might not share the same concepts of HRQoL (Herdman et al., 1998).  
Measurement properties (reliability, validity and responsiveness) should be retained 
across different cultures for the adapted instruments (Herdman et al., 1998).  Therefore, 
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culturally adapted HRQoL instruments need to be validated before formal use, and this is 




A cross-sectional study design was adopted and the study protocol was approved by the 
Institutional Review Board of the National University Hospital (NUH), Singapore.  The 
study consisted of several phases detailed as follows. 
Selection of HRQoL instrument 
A disease-targeted, multi-item scales HRQoL questionnaire, Hepatitis Quality of Life 
Questionnaire (HQLQ), which covers hepatitis specifically, and containing the SF-36 
questionnaire as the generic core was chosen as the main instrument in our study (Ware et 
al., 1999).  The SF-36 health survey questionnaire is one of the most widely used HRQoL 
instrument and has been tested in numerous patients and medical conditions (Ware et al., 
1992, 1993, 1994).  HQLQ consists of (1) the standard SF-36 generic core comprising 8 
scales; (2) five generic items consisting of two questions for social functioning scale and 
one question for role physical, role emotional and vitality scales each to augment existing 
SF-36 scales; (3) two generic scales measuring health distress and positive well-being; 
and (4) two subscales specific for hepatitis (hepatitis-specific limitations and hepatitis-
specific health distress) (Ware et al., 1998).   The scale scores range from 0 to 100, with 
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higher scores representing better health status and vice versa.  In addition, there are two 
summary scales, the Physical Component Summary (PCS) and Mental Component 
Summary (MCS) scales.  The formula for calculation of PCS and MCS scale scores for 
Singapore used in this study were obtained from a local study (Thumboo et al., 2003) 
using the method recommended by the developers of the SF-36 (Ware et al., 1994).  
HQLQ is a self-administered profile-based instrument and has been tested for its validity 
and reliability overseas (Bayliss et al., 1998).  It was originally developed in the United 
States and has been mainly tested in hepatitis C patients in clinical trials in the same 
country (Perrillo et al., 2004; Bayliss et al., 1998; Ware et al., 1999).  It is important to 
note, however, that similar studies carried out on HBV infected patients are far and few. 
Even though common symptoms may be manifested in both chronic viral hepatitis 
diseases, distinctive differences as aforementioned continue to warrant the need for a 
study specifically designed for HBV infected patients using HQLQ as the main 
instrument.       
Cultural Adaptation of Instruments 
 
Two patient focus groups were conducted to assist the research team comprising experts 
in health outcomes research, gastroenterologist, research nurses and moderators in 
culturally adapting the English version of the HQLQ instruments.  Each focus group 
session consisted 6 or 7 patients.   This was in line with the number as suggested by the 
literature where a number of 4 to 12 was considered most appropriate (Tang et al., 1995).  
The sessions were conducted in English and informed consent was obtained from each 
participant.  The subjects for the focus groups were HBV infected patients who have 
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regular clinic follow-ups in NUH and represented as wide a spectrum as possible 
consisting of both genders, ethnic groups and a broad range of ages.  They were randomly 
approached by the research nurses to participate in the study.  Prior to the focus group 
meeting, the subjects were given a short briefing regarding the purpose of the study by a 
practicing gastroenterologist in NUH.  To determine content validity, subjects were asked 
to identify any items, words or phrases that they found difficult, irrelevant or ambiguous 
during the discussion session after attempting the questionnaire.  During the discussion 
session, patients were encouraged to discuss their points of view freely, ask questions, 
raise any ambiguity they had encountered while attempting the questionnaire, and give 
suggestions if any, for every single question.  The researchers also raised various 
questions in order to further verify the subjects’ understanding of the questionnaire.  Data 
collection for the focus group sessions was performed by audio-taping,  with two research 
nurses as well as two researchers  jotting down the main points discussed in the sessions.  
Audio tapes and notes from focus groups were then transcribed and reviewed.  
Pilot testing  
Before formal validation studies were performed, the newly-designed instrument was 
administered to a small group of targeted respondents for the purpose of examining the 
coverage, relevance and understandability of the new instrument.   A convenience sample 
of 10 subjects representing a wide spectrum of ages and socio-cultural backgrounds and 
from both genders was recruited from HBV patients seen in Gastroenterology clinics in 
NUH to pilot test the culturally adapted instrument.  Informed consent was obtained from 
all participants.  After completing the questionnaire, the respondents were interviewed to 
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assess the clarity, understandability and adequacy of the phrasing of the cultural adapted 
version of HQLQ to determine content validity of the questionnaire.  
Patient recruitment for the cross-sectional validation study 
After incorporating all the suggested modifications from the focus groups, the HQLQ was 
tested in a sample of HBV infected patients attending the Gastroenterology Clinic at 
NUH.  The sampling methods for HBV infected patients have been detailed in Chapter 2 
of this thesis.  Briefly, these patients were identified from the database kept by the 
Department of Gastroenterology and Hepatology, NUH.  Other inclusion criteria were 
age above 16, and ability to self-complete the questionnaires in English (the 
administrative language and the language of instruction at all educational institutions in 
Singapore).  After obtaining informed consent, the participants filled in the questionnaire 
prior to or after their clinic appointment with the gastroenterologist.  Patients were 
stratified by disease severity, namely asymptomatic HBV carrier (AS), chronic hepatitis 
B (CHB), compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocellular 
carcinoma (HCC) and up to six years post-liver transplantation patients (PLT).  The 
exclusion criteria for HBV patients were those illiterate (unless family members or care-
givers offered to read the questions out to patients and obtained the answers directly from 
them).  The questionnaires were self-administered whenever possible.  Other data 
collected included sociodemographic information, such as gender, age, ethnicity, 
education level, income etc.      
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As a comparator group, healthy volunteers with no significant disease were approached 
to participate in this study using the same set of questionnaire, but with disease specific 
items such as HQLQ hepatitis-specific domains excluded.  A detailed description of the 
recruitment methods, inclusion and exclusion criteria for normal controls were presented 
previously (see Chapter 2, METHODS section in this thesis).   
Psychometric analysis 
HRQoL instrument should possess some psychometric properties, for example, reliability, 
validity and responsiveness to be clinically useful (Fayers et al., 2000).  Reliability refers 
to the degree to which an instrument yields reproducible or consistent scores each time it 
is administered (Hays et al., 1998).  Reliability of the instruments was assessed by 
Cronbach’s alpha coefficients (for internal consistency) and intraclass correlation 
coefficients (for test-retest reliability) (Fayer et al., 2000; Nunnally et al., 1994; Crocker 
et al., 1986).  For the purpose of interpretation, Cronbach’s alpha coefficients above 0.7 
are generally regarded as acceptable for conducting group comparisons and alpha 
coefficients above 0.9 are acceptable for assessing individual subjects (Nunnally et al., 
1994).  For test-retest reliability, each participant was given a second set of the 
questionnaire and a self-addressed stamped envelope.  Participants were asked to 
complete the questionnaire in at least 3 days’ time from their first test and return the 
questionnaire by mail.   
 
Scoring assumptions of the HQLQ were investigated at item level by examining item-
scale convergent validity (also referred to as item internal consistency (Ware and Gandek, 
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1998)). Item internal consistency refers to the assumption that an item should be 
substantially related to the underlying scale. Item-to-scale correlation (corrected for 
overlap) was assessed using Spearman’s rank correlations (ρ) between scale scores and 
their constituent items with ρ≥0.4 is considered acceptable (Fayers et al., 2000).  The 
scale score distributions were evaluated by computing the percentage of respondents 
achieving either the highest possible score (ceiling) or the lowest possible score (floor).  
A scale would be limited in detecting change over time if a high proportion of patients 
scored at either end of the distribution (Bayliss et al., 1998). 
 
Validity refers to the degree to which an instrument measures what it is supposed to 
measure.  Construct validity, as one of the most important characteristics of a 
measurement instrument, refers to the degree to which an instrument measures the 
construct it is designed to measure.  Particularly, components assessed in construct 
validity included convergent validity, divergent validity, known-groups validity and 
criterion validity.   
 
Convergent validity tests the hypothesis that a HRQoL scale should substantially 
correlate with other measures that measure similar or related constructs. In contrast, 
divergent validity tests the hypothesis that a HRQoL scale should not correlate with other 
measures that measure constructs other than the construct being assessed.  The 
correlations were assessed using Spearman’s rank correlation coefficients (ρ). As 
recommended in the literature, a rho value larger than 0.5 as strong correlation, 0.35 to 
0.5 as moderate correlation and 0.2 to 0.34 as weak correlation was adopted for the 
 54
Chapter 3. Cultural Adaptation and Validation of the                 Siew Chin, Ong 
Hepatitis Quality of Life Questionnaire     
  
  
current study (Juniper et al., 1996).  Therefore, construct validity of the HQLQ at scale 
level was investigated by examining the correlations between HQLQ and EQ-5D 
domains.  As SF-36 has been validated previously in Singapore (Thumboo et al., 1997, 
1999, 2001), only those additional scales measuring health distress, positive well-being 
and subscales specific for hepatitis (hepatitis-specific limitations and hepatitis-specific 
health distress) from HQLQ were tested.  Thus, 10 a priori hypotheses based on the 
clinical experience were generated for convergent construct validity where moderate to 
strong correlations (i.e., correlation coefficient ≥0.35) were expected between domains 
measuring similar constructs, namely (1) HQLQ health distress, positive well-being and 
hepatitis-specific health distress with EQ-5D anxiety/ depression; (2) HQLQ hepatitis-
specific limitations with EQ-5D mobility, usual activities and pain/discomfort; and (3) 
HQLQ health distress, positive well-being, hepatitis-specific health distress and hepatitis-
specific limitations with EQ-5D visual analog scale (VAS).  Another 14 a priori 
hypotheses were generated for divergent construct validity where weak correlations were 
expected between domains measuring dissimilar constructs, namely (1) HQLQ health 
distress, positive well-being and hepatitis-specific health distress with EQ-5D mobility, 
self-care, usual activities and pain/discomfort; and (2) HQLQ hepatitis-specific 
limitations with EQ-5D anxiety/ depression and self-care.  
 
Likewise, a valid scale should show differences in the predicted direction, between 
specific groups of patients (Fayers et al., 2000).  The ability of scale scores to 
discriminate amongst groups, which is known to differ in their HRQoL, is being 
evaluated through statistical test comparing mean scores across the groups.  For known-
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group validity, we hypothesized that individuals with advanced stage of HBV disease 
such as DC and HCC will have worse HRQoL mean scores in most HQLQ scales than 
those in their early stage of disease such as AS and CHB, and the scores for early stage of 
HBV patients will be similar to those from the control group of healthy volunteers.  In the 
physical and mental component summary scales scores, we hypothesized that the similar 
trend will be observed also especially in the physical component summary scale.  Due to 
the non-completion of the HQLQ hepatitis-specific questions for normal controls as the 
questions were not relevant to them, AS was set as the comparator group as they were 
HBV patients hypothesized closest to normal controls.   
 
One-way analysis of variance (ANOVA) was employed to test for the statistically 
significant difference in all scale scores among different categories of hepatitis B patients.  
We have grouped the DC, HCC and PLT patients into one group and named “severe 
HBV” in the analysis in order to make the analysis more meaningful with increased 
sample size for advanced stages of HBV infection.  All statistical analyses were 
performed using SPSS for Windows version 13.0 (SPSS Inc., Chicago, Illinois).  
Statistical significance for all tests was set at 5%.  As detailed in Chapter 2 of this thesis, 
multiple linear regression analysis (MLR) has been used to adjust the possible 
confounder factors eg. age, gender and educational level.    
 
The responses from HQLQ scales were scored according to the Hepatitis Quality of Life 
Questionnaire (HQLQ) Scoring Documentation manual (Ware, 1998).    
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Cultural adaptation of instrument  
A total of 13 patients with hepatitis B (6 and 7 patients for each session comprising of 11 
men, 2 women, mean age 31.4 year, range 19-47 year) were interviewed during two focus 
group meetings (held in November 2002 and January 2003).  Several internal meetings 
were held by the research team (comprising of experts in health outcomes research, 
gastroenterologist, research nurses and the researcher) after the focus group meetings to 
discuss the culturally adaptation of the instruments to locally used English.  As SF-36 has 
previously been adapted and validated for use in Singapore (Thumboo et al., 1997, 1999, 
2001), the adapted and validated Singapore English version of the questionnaire was 
incorporated directly. The proposed replacement or modifications and justification for 
these changes are tabulated in Table 3.1.    
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or phrase Proposed revision Justification 
   
Questions 




original phrase with 
“down” or 
depressed 
The original words are seldom used in local 
English. The proposed wordings are more 
colloquial and have been well accepted in 





original phrase with 
exciting 
The original phrase and suggested word have 
the similar meaning, but the original phrase is 
found to be abstract by focus group participants 
as rarely used in Singapore. The proposed word 
is what is generally used in Singapore.   
 
Questions 
(17c) and (17d) 
having 
hepatitis  
Adding the original 
phrase with having 
hepatitis or liver 
disease 
The original phrase was confused by some of 
the focus group participants as having “acute 
hepatitis A”.  The suggested additional 
wordings are more relevant to the chronic 
condition of the hepatitis B infection especially 




Pilot testing of the culturally adapted instrument 
The first consensus English version of the culturally adapted HQLQ were administered to 
10 native English speakers locally (9 men, 1 women, mean age 35.8 year, range 21-48). 
All patients voluntarily agreed to participate in the pilot testing of the HQLQ after a 
verbal introduction and detailed explanation by the researcher.   In a series of one-to-one 
interviews, respondents were briefed on the purpose of the test and the questionnaire was 
completed in the presence of the investigator.  Respondents generally felt that the 
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questionnaire was clear, easy to understand and easy to answer.  There was only one 
respondent who expressed that the questionnaire was a “nuisance” as there are some 
repetitive questions.  However, nothing was done for the above comments as these 
questions are intended to be repetitive using different wordings to capture subjects’ real 
condition.  The completion rate for the culturally adapted questionnaire was good with no 
missing data and found to be suitable for subsequent validation studies by the research 
team.  In view of these, no changes have been done for the culturally adapted instrument 
after pilot testing the questionnaire.      
Sample characteristics for cross-sectional validation of questionnaire  
From August 2003 to November 2006, all patients attending outpatient clinic for HBV 
infection were approached to participate in this study as detailed in Chapter 2.  The 
original pool of potential HBV subjects was reduced as 21 patients refused to participate, 
citing time constraints (they were in a rush to go back to work after the clinic 
appointment) and privacy  issues (as it was mentioned in the informed consent that the 
patients’ medical records will be made accessible by the researchers).  Additionally, there 
were 32 patients who initially agreed to participate, but did not return a completed 
questionnaire. Another 26 patients claimed they had completed and returned the 
questionnaire, but the questionnaires were not received by us.  In total, 298 completed 
questionnaires from HBV patients and 91 questionnaires from normal control were 
received by us.  Therefore, the percentage of non-respondent rate for HBV infected 
patients was about 20%.  The response rate for normal controls was good (100%) with all 
subjects approached by the researcher having agreed to participate in the study.    
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We have restricted the analysis to Chinese patients as the numbers of other ethnic groups 
were too small: Indian (n=1), Malays (n=13) and others (n=3).  Hence, other ethnic 
groups from the controls were also removed from the analysis.   All in all, a total of 281 
HBV patients and 70 controls of Chinese ethnicity were analyzed in the study. 
 
The mean age of the 281 HBV participants was 44.42 years (SD: 12.53; range of 19-75 
years) with 79% being male.  For control group, the mean age of 70 participants was 
31.23 years (SD: 12.43; range of 16-65).  The employment rate of HBV patients was 
similar to those from normal control group (66.2% for HBV group versus 60.0% for 
normal control group).  Additional socio-demographic information obtained included 
educational level, income, household monthly income and marital status (Table 3.2).  The 
average time taken to complete the questionnaire was 24.1 minutes (range: 5-40 min).  
There were no significant differences in the two groups with regards to age and 
household income.  However, there were significant differences in HBV and control 
groups in gender, race, occupation and marital status tested using Chi- square test.  This 
was an acceptable trend as HBV infection predominantly occurs among male Chinese in 
Singapore. 
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Table 3.2. Sample characteristics (socio-demographic factors) for each group of 
participants 
 HBV         Control 
Gender (male) number (%) 222 (79.0) 21 (30.0) 
Age years, mean (SD) 44.42 (12.53) 31.23 (12.43)  
Race, 
 Chinese 281  70 
Marital status, number (%) 
 Single 69 (24.6) 38 (54.3) 
 Married 199 (70.8) 31 (44.3) 
 Divorced or separated 6 (2.1) 1 (1.1) 
 Widowed 5 (1.8) 0 (0.0) 
 Not specified 2 (0.7) 0 (0.0) 
Disease stage, number (%) 
 Asymptomatic carrier (Asymp) 103 (36.7) N.A 
 Chronic hepatitis B (CHB) 102 (36.3) N.A 
 Compensated cirrhosis (CC) 40 (14.2) N.A 
 Decompensated cirrhosis (DC) 14 (5.0) N.A 
 Hepatocellular carcinoma (HCC) 12 (4.3) N.A 
 Liver transplants (PLT) 10 (3.6) N.A 
Education level, number (%)   
 No qualification 2 (0.7)  0 (0.0) 
 Primary 11 (3.9) 2 (2.9) 
 Secondary 91 (32.4) 29 (41.4) 
 Polytechnic or diploma 65 (23.1) 21 (30.0) 
 University or postgraduate degree 105 (37.4) 16 (22.9) 
 Other 5 (1.8) 1 (1.4) 
 Not specified 2 (0.7) 1 (1.4) 
Employment status, n (%)   
 Working 198 (66.2) 42 (60.0) 
 Unemployed 10 (3.6) 0 (0.0) 
 Retired 35 (12.5) 3 (4.2) 
 Full time student 10 (3.6) 18 (25.7) 
 Homemaker or housewife 16 (5.7) 3 (4.2) 
 National service personnel 9 (3.2) 4 (5.7) 
 Not specified 3 (1.1) 0 (0.0) 
Total monthly household income, n (%)   
 Below SGD 2999 (USD1817)* 154 (54.8) 61 (87.1) 
 SGD 3000- SGD 5999 (USD1818-USD3635) 72 (25.6) 8 (11.4) 
 SGD 6000- SGD 8999 (USD3636-USD5453) 24 (8.5) 0 (0.0) 
 SGD 9000 and above (USD5454) 15 (5.3) 0 (0.0) 
 Not specified 16 (5.7) 1 (1.4) 
Notes: n=number; SD= standard deviation; N.A= Not applicable; * USD1 equivalent to 
SGD 1.65 as of 13 May 05. 
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Table 3.3 summarized the sociodemographic characteristics of the different clinical 
subgroups of HBV patients.  As expected, those with advanced stages of HBV infection 
such as DC, HCC and PLT were older in age as compared to patients with early stages of 
HBV infection.  Generally, there were more male than female for each group of patients.  
The rest of sociodemographic factors were quite similar for each group of HBV patients.       
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Table 3.3. Socio-demographic characteristics of HBV patients of different disease stages. 
 













Gender (male) number (%) 62 (60.2) 87 (85.3) 27 (67.5) 13 (92.9) 10 (83.3) 10 (100.0) 
Age years, mean (SD) 45.06 (11.72) 38.02 (11.32) 49.13 (10.07) 54.21 (9.95) 58.33 (11.80) 54.00 (8.01) 
Marital status, number (%)       
      
Single 21 (20.4) 39 (38.2) 7 (17.5) 1 (7.1) 0 (0.0) 1 (10.0) 
Married 76 (73.8) 59 (57.8) 32 (80.0) 11 (78.6) 12 (100.0) 9 (90.0) 
Divorced or separated 3 (2.9) 1 (1.0) 1 (2.5) 1 (7.1) 0 (0.0) 0 (0.0) 
Widowed 2 (1.9) 2 (2.0) 0 (0.0) 1 (7.1) 0 (0.0) 0 (0.0) 
Not specified 1 (1.0) 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
Education level, number 
(%) 
No qualification 0 (0.0) 0 (0.0) 0 (0.0) 2 (18.2) 0 (0.0) 0 (0.0) 
Primary 2 (1.9) 3 (2.9) 3 (7.5) 0 (0.0) 0 (0.0) 0 (0.0) 
Secondary 25 (24.3) 18 (17.6) 9 (22.5) 2 (18.2) 2 (40.0) 3 (37.5) 
Polytechnic or diploma 9 (8.7) 6 (5.9) 8 (20.0) 2 (18.2) 2 (40.0) 2 (25.0) 
University or postgraduate 
degree 25 (24.3) 
33 (32.4) 7 (17.5) 2 (18.2) 0 (0.0) 1 (12.5) 
Other 41 (39.8) 41 (40.2) 13 (32.5) 3 (27.3) 1 (20.0) 2 (25.0) 
Not specified 1 (1.0) 1 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
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Descriptive statistics, reliability and validity of the instrument 
The descriptive statistics and reliability coefficient (Cronbach’s alpha) of the scales were 
detailed as per Table 3.4.  Missing data for each scale were low (less than 1%) except for 
physical functioning scale (3.9%).  Ceiling effect was observed for all scales in the 
analysis with role physical and role emotional scales showed the highest percentage of 
ceiling effect, 79.4% and 78.3% respectively.  The other notable ceiling effects were 
observed in the bodily pain and hepatitis-specific limitations scales (52.3% and 57.3% 
respectively).  Although flooring effects were also observed in 8 scales, the percentage of 
respondents scoring the floor in these scales was generally less than 2% of the sample.  
The internal consistency reliability coefficients, alpha values were excellent with α> 0.7 
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4 0.0 0.0 100.0 1.1 79.4 0.866 
Bodily pain 
 




5 0.4 10.0 100.0 0.0 1.4 0.838 
Vitality 
 








4 0.0 0.0 100.0 1.1 78.3 0.776 
Mental 
health 
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Table 3.5 shows the results of the test-retest reliability analysis using single measure 
intraclass correlation coefficient (ICC).  A total of 54 subjects participated in the test-
retest analysis.  Subjects completed the second set of questionnaire in the range of 3 to 23 
days after completing the first set of questionnaire.  With the exception of  role physical 
and role emotional scales, 10 of the 12 scales showed acceptable correlation coefficients 
(i.e., α > 0.7) (Aday, 1989).  Among the 10 scales, 8 showed a value greater than 0.8.  




Table 3.5. Test-retest reliability of scales (n=54) 
  Single measure ICC* 95% CI** 
SF-36 Scales   
Physical functioning 0.90 0.84 – 0.94 
Role physical 0.48 0.24 – 0.66 
Bodily pain 0.86 0.77 – 0.92 
General health 0.86 0.77 – 0.92 
Vitality 0.82 0.71 – 0.89 
Social functioning 0.78 0.65 – 0.87 
Role emotional 0.67 0.49 – 0.80 




Health distress 0.82 0.70 – 0.89 
Positive well-being 0.79 0.67 – 0.87 
Hepatitis-specific limitations 0.80 0.68 – 0.88 
Hepatitis-specific health distress 0.89 0.82 – 0.94 
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Range of convergent item-to-scale correlations and their medians are displayed in Table 
3.6.  Item-to-scale correlations were good with all items highly correlated with their 
hypothesized scales, with only one item each from role physical and role emotional scales 
(0.27 and 0.28 respectively) below the cutoff value (ρ≥0.4) recommended for scale 
construction.  These two items came from the augmented item to the existing SF-36 role 
physical and role emotional scales.    
  
Table 3.6. Item-to-scales correlation (n=281) 
 






SF-36 Scales   
Physical functioning (PF) 0.45-0.85 0.70 
Role physical (RP) 0.27-0.90 0.88 
Bodily pain (BP) 0.94-0.98 0.96 
General health (GH) 0.64-0.88 0.82 
Vitality (VT) 0.75-0.86 0.82 
Social functioning (SF) 0.64-0.84 0.73 
Role emotional (RE) 0.28-0.90 0.80 




Health distress (HD) 0.90-0.93 0.91 
Positive well-being (PWB) 0.89-0.93 0.90 
Hepatitis-specific limitations (HSL) 0.94-0.95 0.95 
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Correlations between the HQLQ and EQ-5D are displayed in Table 3.7.  For convergent 
construct validity, as hypothesized, strong correlations were presented for one hypothesis 
(ρ= 0.60) and moderate correlations for 7 other hypotheses (ρ between 0.39 and 0.47) of 
10 a priori hypotheses.  However, the hepatitis-specific limitations scale correlated only 
weakly with EQ-5D mobility and usual activities domains.  On the other hand, divergent 
construct validity was supported by all a priori hypotheses with all scales from HQLQ 



















EQ-5D     
Mobility -0.19 -0.14 -0.18 -0.29 
Self-care -0.12 -0.10 -0.13 -0.15
Usual activities -0.24 -0.22 -0.24 -0.33 
Pain/discomfort -0.27 -0.24 -0.22 -0.43 
Anxiety/ depression -0.44 -0.40 -0.43 -0.31
Visual analog scale 0.60 0.39 0.47 0.41 
 
*Hypotheses which are supported for convergent construct validity are bold; and 
divergent construct validity are bold and underlined.   
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Table 3.8 details the mean scale scores and standard deviation in various scales in a 
possible score of 0 – 100 for HBV patients and controls.  Higher score indicated better 
level of perceived HRQoL for the scales.  For known-group validities, as hypothesized, a 
comparison of mean scores at different stages of the disease showed significantly lower 
HRQoL in the case of more advanced stages of HBV disease, named as “severe HBV” 
(consisted of patients with DC, HCC and PLT), in most SF-36 scales.  There is no 
significant difference among controls, AS, CHB and CC patients in all scales too, except 
in the general health scale where normal control group showed significantly better self-
perceived HRQoL than all groups of patients.   For the physical component summary 
(PCS) scale, as hypothesized, the HRQoL for more advanced stages of HBV infected 
patients was significant lower than the normal group, with HCC group demonstrating the 
largest deterioration compared with the other stages of HBV patients.  Meanwhile, the 
mental component summary (MCS) scale scores did not show significant differences 
among different groups of HBV infected patients and normal controls, although their 
HRQoL scores were lower than that of normal controls. When compared with AS, similar 
results were also found in the two hepatitis-specific scales from HQLQ where DC and 
HCC patients generally showed significant lower scale scores and no significant 
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Table 3.8.  Mean scales scores (standard deviation) in different scales for each group 
of patients and control 
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Table 3.8 (Continued).  Mean scales scores (standard deviation) in different scales 
for each group of patients and control 













HQLQ-specific scales      



















































*P<0.05 compared with normal healthy control 
^ P<0.05 compared with AS 
 
Footnote: 
AS  - Asymptomatic HBV carrier  
CHB   - Chronic hepatitis B  
CC  - Compensated cirrhosis 
DC  - Decompensated cirrhosis 
HCC  - Hepatocellular carcinoma 
PLT  - Post-liver transplants  
Control - Normal healthy controls 
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After adjusting for sociodemographic factors (including age, gender and educational level) 
known to influence HRQoL in the MLR analysis (Table 3.9), the results remained 
unchanged.  For example, severe HBV group consisted of DC, HCC and PLT patients 
consistently reported significant lower scores for all SF-36 summary scales and HQLQ-
specific scales when compared to normal controls or AS patients.  There is also no 
significant difference among controls and early stages of HBV infection such as AS and 
CHB in most of the scales, except in the Health Distress Scale where normal controls 
showed significant better self-perceived HRQoL than all groups of patients.  Notably, 
mental component summary scales and those scales measuring the mental component of 
participants such as Health Distress and Hepatitis-specific Health Distress scales for all 
groups of HBV patients (except AS)  were significantly lower than that of normal 
controls.   
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Table 3.9: Adjusted differences in mean scores for HBV infection with normal controls 
as the reference group on SF-36 summary scales and HQLQ-specific scales (adjusted 
for the influence of age, gender and education level) using multiple linear regression 
analysis. 
 












SF-36 Scales     


















HQLQ-specific scales     
































*p<0.05, ** p<0.01, *** p<0.001 compared with normal healthy control. 
^p<0.05, ^^ p<0.01, ^^^ p<0.001 compared with asymptomatic carrier. 
 
Footnote:          
                    AS                        - Asymptomatic carrier  
CHB              - Chronic hepatitis B  
CC              - Compensated cirrhosis 
                    Severe HBV         - Consisted of DC, HCC and PLT patient   
                    NA                       - Not applicable 
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3.4 DISCUSIONS 
 
In this study, we performed cultural adaptation and investigated the validity and 
reliability of the English version of the HQLQ.  The HQLQ was originally developed in 
the United States, and as such could not be used directly on English-speaking HBV 
patients in Singapore due to the subtle differences in English usage between the two 
countries as well as existing cultural differences.  To the best of our knowledge, this is 
the first disease-specific HRQoL instrument adapted and validated for HBV patients in 
Singapore.  From a Medline search for all years, there were only 4 studies using HQLQ 
in chronic hepatitis C patients (Perrillo et al., 2004; Bayliss et al., 1998; Ware et al., 1999; 
Nearly et al., 1999).  In fact, most HRQoL studies for chronic liver diseases were mainly 
performed in hepatitis C patients, or did not have coverage of a wide range of HBV 
patients from asymptomatic carrier to liver transplant patients (Carithers et al.,1996; 
Hunt., et al., 1997; Foster et al., 1998; Rodger et al., 1999; Younossi et al., 2001; Hussain 
et al., 2001; Fontana et al., 2001; McHutchison et al.,  2001; Cordoba et al., 2003; Pojoga 
et al., 2004; Schwarzinger et al., 2004).  Hence, the relationship between HRQoL and 
severity of the disease has not been explored nor the impact of treatment and 
interventions on HRQoL been well documented in hepatitis B patients.  Therefore, the 
validation of an instrument that ideally measures HRQoL in individuals with HBV 
infection is timely and contributive to hepatitis B management. 
 
In the current study, we found the internal consistency reliability coefficients, Cronbach’s 
alpha, of the multi-item scales to be excellent with 2 of 12 scales achieving values > 0.7 
and 10 of 12 scales achieving values > 0.8.  Test-retest reliability was supported with 10 
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of the 12 scales showing acceptable correlation coefficients (i.e., α > 0.7). Of these, 8 
scales showed a value greater than 0.8.  Role physical and role emotional were the only 
scales that showed unsatisfactory correlation coefficient, 0.48 and 0.67 respectively.  
These might be due to the newly added items correlating weakly to the existing SF-36 
role physical and role emotional scales as observed in the present study in the evaluation 
of the items-to-scale correlation, where the rho values given by these two items were 
below the cutoff value (ρ≥0.4) recommended for scale construction.  This was consistent 
with previous validation study done by Bayliss et al in hepatitis C patients, where these 
two items were also shown to have a relatively low correlation with their parent scales, 
probably due to their low rates of endorsement as suggested by the author (Bayliss et al., 
1998).   
 
The significant ceiling effect observed in the present study, especially in role physical 
and role emotional scales was also reported by Bayliss et al in their validation study 
(Bayliss et al., 1998).  This effect might be overcome by substituting the current 
dichotomous response choices of “Yes” or “No”  with  five level response options of  
“All of the time”, “Most of the time”, “Some of the time”, “A little of the time” and 
“None of the time” as used in SF-36 Version 2.  The increase in the number of response 
choices for these two scales has been shown to significantly decrease the ceiling and floor 
effects observed in SF-36 Version 2 by Ware et al (Ware et al, 2000). 
 
The convergent and divergent construct validities are supported by the expected 
correlations between the HQLQ scales and the EQ-5D domains measuring similar or 
dissimilar constructs.  In the present study, 8 of 10 hypotheses for convergent construct 
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validity and all hypotheses for divergent construct validity were fulfilled demonstrated 
good construct validity for Singapore HQLQ.   
 
In the evaluation of known-group validity of the questionnaire, we hypothesized a priori 
that individuals with advanced stages of HBV disease will have worse HRQoL mean 
scores than those in their early stages of disease.  As hypothesized, the instrument 
demonstrated good construct validity as most scales demonstrated better HRQoL for 
controls and asymptomatic carriers and worse HRQoL for more severe cases of HBV 
patients such as DC and HCC. There was no significant difference among controls, AS, 
CHB carriers and CC patients in all scales too.  This observation is congruent with the 
fact that hepatitis B has a long clinically symptoms-free phase until liver function 
deteriorates.  Nevertheless, there is one exceptional scale, mental health, which showed a 
relatively better HRQoL for PLT comparable to value obtained for the normal controls.  
However, it failed to show statistically significance compared to the other groups of 
patients.  Thus, it is hard to give a definite conclusive reason for this scale. Further 
investigation is therefore needed to verify the reliability of the scale. 
 
As hypothesized, the sum scores of the SF-36 component of HQLQ, which summarize 
the eight domains of the SF-36 in PCS and MCS scales, showed deterioration with the 
severity of the liver disease, and this was especially significant with the PCS scale.  CC 
and “severe HBV” (consisted of DC, HCC and PLT patients) showed a significant 
decrease in the PCS scale scores compared to AS, CHB and normal control group.  This 
finding obviously implies that symptom severity would directly impact HRQoL of HBV 
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patients.  This is supported by the observation that the results of MLR analysis was 
consistent with the findings in the univariate anlaysis.  In addition, the results of the 
Mental Component Summary scale and the mentally related scales were consistent with 
the results in Chapter 2 of this thesis, where all groups of HBV patients (except AS) 
scored significantly lower than that of normal controls.  These findings confirmed that 
mental health component for HBV patients were affected more than their physical health 
component.    
 
Finally, we recognize several limitations of the present study.  The first major limitation 
was that the sample size for DC, HCC and PLT patients was relative small, comprising 
between 3-5% of the total study subjects.  During the study, effort was taken to increase 
the number of these patients by encouraging their participation through phone calls.  
Unfortunately, we did not receive satisfactory responses as most of these patients were 
generally quite ill with some unconscious and non-ambulatory in the hospital during our 
phone call period.  However, this was the first HRQoL study carried out locally for HBV 
patients; at the very least it will serve as a foundation for future studies.  Secondly, the 
current study was conducted using a cross-sectional study design, we were therefore 
unable to evaluate the instrument’s responsiveness, which is its ability to detect change in 
HRQoL over time.  Thirdly, background information of non-respondents was not 
collected in this study. Therefore, we were unable to compare the characteristics between 
respondents and non-respondents. Such a comparison would provide useful information 
on the representativeness of the study sample.  Nevertheless, given that the non-response 
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rate of this study was quite low (20%); it seemed that our sample would be a reasonably 
good representation of the target population in many socio-demographics.  
 
3.5 CONCLUSION 
We have found the evidence to support HQLQ as culturally appropriate, valid and 
reliable in a sample of English-speaking Singaporean with HBV infection at a tertiary 
healthcare institution.  Therefore, clinicians or investigators who are interested to capture 
how HBV patients perceive their own health status and outcomes of treatments, or 
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chronic hepatitis B: Hong Kong and Singapore  
4.1 INTRODUCTION 
In Hong Kong, it is estimated that about 10% of the population are chronic hepatitis B 
(CHB) infected (Lok et al., 1987).  Almost 700,000 Chinese subjects are CHB infected, 
of which about 72% are male patients (Sung et al., 2000; Tang et al., 1997).  As 
elsewhere in the world, HBV infection in Hong Kong is responsible for substantial 
morbidity and mortality resulting from the liver disease sequelae of chronic infection: 
liver cirrhosis and hepatocellular carcinoma. 
 
Similarly, in Singapore, CHB infection is the most common cause of chronic viral liver 
disease.  It is also the most common cause of primary liver cancer, which is one of the 
most frequent cancers among males in Singapore (Chia et al., 2002; State of Health 
Editorial Committee, 2002).  With the introduction of compulsory vaccination of babies 
born to carrier mothers, the number of newborn carriers has reduced in the last decade.  
Cases of acute HBV have fallen by 60% in Singapore over the past 15 years, with 140 
new cases reported in 1999 and only 64 new cases reported in 2003.  However, about 
60% of the population has no immunity, and this is especially true in the younger age 
groups where only 28% of those aged 18–29 years have immunity (James et al., 2001).  
Although the incidence of HBV infection is decreasing, between 160,000 and 230,000 
Singaporeans remain chronically infected as of 2001 (Lo et al., 1998).  The chronic 
infection rate is highest among ethnic Chinese, who constitute more than 75% of the 
population of Singapore (Goh, 1997). 
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Although CHB carriers can remain asymptomatic, a substantial percentage will 
eventually develop acute liver failure, liver cirrhosis or hepatocellular carcinoma 
(Melnick, 1980), with a risk of death from hepatocellular carcinoma and/or cirrhosis of 
40–50% for men and about 15% for women (Beasley, 1988).  Because of the large 
number of chronically infected people and the high prevalence of liver cirrhosis and 
hepatocellular carcinoma among middle-aged Asians, CHB infection represents a serious 
health threat in the Asia Pacific region.  Although the management cost of CHB is 
understood to be a burden on the healthcare budget, there have been few studies initiated 
to quantify its impact.  The study by Yang et al (Yang et al., 2001) presented data on the 
economic burden of the disease in South Korea.  However, for most Asian countries, in 
particular those countries with larger population of ethnic Chinese, the economic impact 
arising from management has never been assessed. 
 
The present study aims to estimate, from the perspective of a public health organization, 
the direct medical cost for the management of both HBV infection and its complications, 
such as the different stages of liver cirrhosis and hepatocellular carcinoma, in Hong Kong 
and Singapore. There are several reasons for performing a cost comparison of the 
management of HBV infection and its complications between Hong Kong and Singapore. 
Considering the two countries, there are many similarities that would make such a cost 
comparison extremely valuable for healthcare providers and administrators (Table 4.1).  
Firstly, both are modern urban cities with a high standard of healthcare that is on par with 
the developed world.  Secondly, both cities have experienced an economic downturn in 
recent years resulting in mounting pressure on the healthcare budget.  Thirdly, both Hong 
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Kong and Singapore were former British colonies and hence share many practices in 
healthcare delivery despite the healthcare reforms that have been ongoing in both places 
over the years. Fourthly, the majority of residents in both locations are ethnic Chinese, 
with a significant proportion of each population infected with the HBV.  Lastly, the 
healthcare systems of the two places are very similar, though the system in Singapore 
may more closely resemble that of United States.  In Hong Kong, the government 
assumes the role both as the user as well as the supplier of healthcare services because 
more than 95% of the healthcare expenditures are subsidized.  On the other hand, less 
than 5% of the population is covered by insurance schemes, and reimbursement is 
therefore not a significant issue.  In Singapore, healthcare funding is through a 
combination of taxation, compulsory saving, insurance and out-of-pocket payments.  The 
mode of funding is therefore more diversified and shares some similarities with United 
States.  The healthcare burden caused by this virus and its associated complications are 
substantial for both regions.  Therefore, a comparison of the cost of management of CHB 
and its sequelae in these two cities would provide valuable information for healthcare 
planners and providers.  Such information may lead to an improvement in the 
management of CHB and related complications, resulting in healthcare savings.  
 
Hence, the objective of this project is to estimate and compare the direct medical cost in 
providing medical care and treatment of patients with CHB infections and the associated 
complications, including cirrhosis, hepatocellular carcinoma and liver transplant in Hong 
Kong and Singapore.  
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Table 4.1: Comparison between Hong Kong and Singapore 
 Hong Kong Singapore 
Population 6,708,389 (as of 2001)a 3,263,209 (30.1% below 15 
years old) 
Estimated per-capita 
gross domestic product 
as of 2002 (US$) 
26,064 29,297 







Estimated number of 
chronic hepatitis B 
carriers 
~700,000 (10%) 0–5.3% (vaccinated group)#
4.6–27.1% (unvaccinated 
group)#
Number of new hepatitis 
cases per year 
2.15 cases per 100,000 
population Bb
2.4 cases per 100,000 
population##
Date when hepatitis B 
vaccination program 
started 
15 November 1988 (for all 
newborns) 
July 1992 (one-off 
vaccination for all children 
born between 1986 and 
1988) 
1 October 1985 (for babies from 
carrier mothers) 
1 September 1987 (for all 
newborns) 
February 2001 (for all 
secondary and tertiary students) 
Year when first liver 
transplant performed   
1991 1995* 
Total number of liver 
transplants performed  
270 74** 
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Footnotes: 
 
a Hong Kong Population Census 2001 
b Department of Health, Hong Kong, Public Health & Epidemiology Bulletin, Vol 8, No. 
2, May 1999 
# Based on hepatitis B surface antigen and hepatitis B core antigen antibody prevalence 
rates from 1998/1999 National Seroepidemiological Survey 
# # 2001 data 
* First case performed in 1990 with a total of four cases performed between 1990 and 
1992; program restarted in 1995 ** From 1996 to 2001 (inclusive of live donor and 
cadaveric liver transplants) 




4.1 METHODS   
Study Design 
The study was retrospective in nature, with all data collection from medical records of 
patients identified as infected with HBV.  There was no direct contact between the 
investigator and the patients.  Ethics approval was obtained from the hospitals to be 
chosen as study sites prior to the commencement of the study. 
 
Study Sites 
After approval from the Institutional Review Board, data collection in Singapore was 
conducted at the National University Hospital, a 935-bed, acute-care, tertiary hospital, 
which serves as the liver transplant center in Singapore.  In Hong Kong, the study sites 
were at two major public hospitals: the Prince of Wales Hospital and the United Christian 
Hospital.  They were chosen for two main reasons.  Firstly, they are the largest general 
hospitals in the north-eastern area of Hong Kong, where population density is high; and 
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secondly, both are teaching hospitals of the Chinese University of Hong Kong and hence 
data collected should reliably reflect the standard of care in the territory.  
 
Subject Recruitment 
In Singapore, adult patients with HBV were identified from the database maintained by 
the Department of Gastroenterology at the National University Hospital.  In Hong Kong, 
patients who had been receiving medical treatment from either the Prince of Wales 
Hospital or the United Christian Hospital over the past 5 years since first CHB diagnosis 
were the targets of our study.  The case notes of the identified patients were then 
retrieved from the Medical Records Office at the study hospitals.  A target of 200 and 
500 subjects were planned for the study sites from Singapore and Hong Kong 
respectively.  All the subjects were confirmed to have CHB infection only; those with 
mixed infections were excluded from the study. 
 
Patient Classification 
Patients were categorized into five groups.  CHB patients were defined as those without 
cirrhosis, which was confirmed mainly by laboratory testing.  Stable or compensated 
cirrhosis patients were defined as those with no complications such as variceal bleeding, 
ascites, bacterial peritonitis or hepatic encephalopathy.  These patients were identified 
through clinical signs such as jaundice, spider angiomas or gynecomastia. 
Decompensated cirrhotic patients had one or more complications such as variceal 
bleeding, ascites, bacterial peritonitis or hepatic encephalopathy.  Liver transplant 
patients were defined as those HBV infected who required a liver transplant because of 
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liver disease complications of CHB.  Hepatocellular carcinoma patients were defined as 
HBV infected people whose disease had progressed to liver cancer. 
 
Each patient was assigned to one of the five categories based on the clinical conditions as 
recorded in the case notes, which contained all the information on patients’ laboratory, 
ultrasound and radiographic results, as well as their medical histories as recorded by the 
attending physicians.  The time frame of data collection and evaluation for each patient in 
the abovementioned disease states started at first diagnosis and was followed up at the 
clinic at study hospitals for a period of up to 5 years (or as practical a time period as the 
situation permitted).  To avoid extensive adjustments of cost estimates necessitated by the 
revision of the rate of charges from time to time and potential changes in management 




Relevant data were collected from medical and financial records of HBV-infected 
patients.  For each study subject, the window of investigation started on the first day that 
the patient tested positive for CHB and ran through a period of 5 years (or as practical a 
time period as the situation permitted). 
 
The clinical data being collected included clinical diagnosis, laboratory investigations, 
ultrasound, computer tomography and liver biopsy results.  In addition, the direct medical 
resource utilization information was collected, as detailed in the next section.  
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Costs Considered 
The major cost items identified and considered were the direct medical costs related to 
the treatment of CHB and its associated complications.  The total direct medical cost 
comprised three components, namely clinic-visit cost, investigation cost and treatment 
cost.  Clinic-visit cost included outpatient visits and hospital admissions.  Investigation 
cost included laboratory tests and procedures.  Treatment cost included the use of 
antiviral agents and other CHB-related medications.  The treatment costs due to CHB and 
its related complications were specifically differentiated from the medical costs due to 
other medical conditions to allow more precise estimation of the treatment cost in 
patients with CHB infection.  Drug acquisition costs were obtained from the pharmacy 
departments of the study hospitals.  
 
In Singapore, the costs for other resource utilization, such as procedures and laboratory 
tests were obtained from the relevant departments.  Any information that could not be 
obtained by this method was retrieved through direct accessing of patients’ financial 
statements from the hospital finance department. In Hong Kong, the costs of these were 
estimated using the Hong Kong government published rate of charges for healthcare 
services (Hong Kong SAR, 2003), as our study sites were public hospitals  that had to 
adopt standardized fees and charges set by the governments.  All costs were analyzed 
with respect to the different disease states: CHB, compensated cirrhosis, decompensated 
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Analysis of Data and Cost Estimation of Resource Consumption 
Treatment costs were calculated as total annual treatment costs for each category of 
patients.  The costs were expressed as the mean values calculated according to the 
number of years of follow-up.  Costs were annualized based on the years of follow-up.  In 
the estimation of every resource used, the cost was calculated by multiplying annual 
frequency and cost per item.  The total annual direct cost for each patient was obtained by 
summing up all the defined items.  
 
The costs incurred for patients undergoing liver transplant were separated into the costs 
during the transplant procedure itself and the costs incurred during the first and second 
year post-transplant, when available.  The reasons for segregating the costs were as 
follows.  Firstly, the transplant procedure is a very costly process that needs special 
attention until patient is discharged.  Secondly, since most organ rejection occurs during 
the first year post-transplantation, the costs of management are recognized to be 
substantial.  However, since not all transplant patients survive the first year following 
transplant, the average cost calculation based on adding the treatment costs during the 
first year to the costs incurred during the transplant procedure would underestimate the 
actual costs.  Therefore, segregating the costs into two parts more realistically captures 
the true costs incurred for liver transplant.  Thirdly, the cost of management in the second 
year post-transplantation more accurately reflects the cost of management of patients 
following liver transplant because the surgical procedure could be considered successful 
once patients have survived any graft rejection during the first year. 
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Data were expressed as means with standard deviation, where appropriate.  In Hong 
Kong, all costs were calculated and reported in the value term of year 2000 in Hong 
Kong dollars (HKD), while in Singapore, the costs were reported in the value term of 
year 2003 in Singapore dollars (SGD).  For comparison, data were also presented in U.S. 
dollars.  The time difference in costing was due to a difference in the starting time of the 
study between the two cities.  Nonetheless, this difference is not expected to cause any 
major discrepancy in our final results, because both places had suffered from an 
economic downturn over the period and costs of healthcare services within each system 
have remained relatively stable. 
 
4.3 RESULTS  
 
Study Subjects 
Data were collected and analyzed from the medical or financial records of 660 adult 
patients aged between 16 and 65 years.  Of these, 488 patients were recruited from the 
study sites in Hong Kong from the period starting from September 2001 until December 
2002 and 172 patients were recruited from the study site in Singapore from the period 
starting from October 2002 until May 2003.  A breakdown of the patients recruited from 
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Table 4.2: Patient recruitment 
Number of study subjects Disease category 
Hong Kong Singapore 
Chronic hepatitis 232 116 
Compensated cirrhosis 112 17 
Decompensated cirrhosis 55 9 
Hepatocellular carcinoma 89 10 
Liver transplants – 20* 
* One patient had two transplants in 1 year 
 
Of the 20 patients who underwent the liver transplant procedure in Singapore, four were 
non-residents (i.e. foreigners who came to Singapore for surgery).  After surgery, these 
patients were discharged to their home countries for aftercare and therefore did not 
contribute any data to the cost analysis of management in the first year post-liver 
transplant.  In addition, four patients who died within a few days of liver transplant and 
were not included in this cost analysis.  Of the remaining patients, data for the 
management costs were available for eight. 
 
In Hong Kong there were no patients scheduled for the procedure during the period of the 
study, so the cost of liver transplant was estimated based on medical experts’ opinions 
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Overall Cost Analysis of Hepatitis B and its Associated Complications 
In Hong Kong, the estimated average annual treatment costs of the different categories of 
patients were: CHB, HKD 6,318 (US$810) (range: HKD 5,686 to HKD 6,950); stable or 
compensated cirrhosis, HKD 10,304 (US$1,321) (range: HKD 8,758 to HKD 11,850); 
decompensated cirrhosis, HKD 58,428 (US$7,490) (range: HKD 35,056 to HKD 
81,799); hepatocellular carcinoma, HKD 121,822(US$15,618) (range: HKD 91,366 to 
HKD 152,277) as summarized in Table 4.4.  Each liver transplant case was estimated to 
cost HKD 514,498 (US$65,961).  All conversions into US$ were based on a conversion 
rate of US$1 = SGD 1.75 and US$1 = HKD 7.80. 
 
In Singapore, the estimated average annual treatment costs of the different categories of 
patients were: CHB, SGD 718.15 (US$410.37) (range: SGD 80.11 to SGD 4,690.05); 
stable or compensated cirrhosis, SGD 1,175.34 (US$671.62) (range: SGD 316.60 to SGD 
2,203.60); decompensated cirrhosis, SGD 15,389.84 (US$8794.19) (range: SGD 7065.40 
to SGD 25,638.80); and hepatocellular carcinoma, SGD 12314.04 (US$7036.59) (range: 
SGD 4580.41 to SGD 8819.91) as detailed in Table 4.5. 
 
Resource Utilization Patterns 
Detailed breakdowns of the resource utilization for the various disease stages in Hong 




(n = 488) 
Singapore 
(n = 172)  
Annual cost per 
patient, HKD (USD)) % 
Annual cost per 
patient, SGD (USD) % 
Outpatient medical 
consultations 2,839.60 (364.05) 7.54 153.53 (87.73) 1.24 
Laboratory tests 3,135.20 (410.95) 8.32 2,060.28 (1,177.30) 16.66
Procedures 5,233.50 (670.96) 13.89 6,609.74 (3,776.99) 53.46
Medications  490.00 (62.82) 1.30 1,620.34 (925.91) 13.10
Antivirals 482.40 (61.85) 1.28 105.61 (60.35) 0.85 
Hospitalization 25,496.20 (3,268.74) 67.67 1,816.25 (1,037.86) 14.69
Total 37,676.90 (4,830.37) 100 12,365.76 (7,066.15) 100 
Footnote: Data from Singapore were the weighted average values 
(imaging/computer tomography costs were incorporated into procedure costs to be 
comparable with Hong Kong data) 
HKD = Hong Kong dollars; SGD = Singapore dollars 
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Table 4.3: Comparison of costs of chronic hepatitis B virus management between 





Chapter 4: Cost comparison of management of             Siew Chin, Ong 
chronic hepatitis B: Hong Kong and Singapore       
 
      Table 4.4: Estimated annual costs, HKD(USD) per patient by five chronic hepatitis B disease states in Hong Kong 
Chronic hepatitis 
B             
(n = 232) 
Compensated 
cirrhosis          
(n = 112) 
Decompensated 
cirrhosis           
(n = 55) 
Hepatocellular 
carcinoma        
(n = 89) 
Liver transplant 
 































Medications  44.40 (5.69) 0.70 
71.10  






































Chapter 4: Cost comparison of management 
chronic hepatitis B: Hong Kong and Singapore 
 
of             Siew Chin, Ong 
      
94




Decompensated cirrhosis    
(n=9) 




Cost        % Cost % Cost % Cost %
Outpatient 
consultation 
125.28        
(71.59)         
17.40 180.87    
(103.35)         
15.39 412.42    
(235.67)         





–     
     
   
      
– – – 7,880.89
(4,503.37)       
51.21  3,574.88 
(2,042.79) 
29.03  
Antivirals 39.08           
(22.33)         
5.40 55.89        
(31.94)          
4.76  1,141.02 
(652.01)         
7.41  241.28   
(137.87) 
1.96  
Medications  – – 2.29            
(1.31)           
0.19 799.18   
(456.67)         
5.19  124.98     
(71.42) 
1.01  
Laboratory tests 334.68  
(191.25)      
46.60 474.04       
(270.88) 
40.33 3,025.13





(112.26)        




7.36  2,468.97 
(1,410.84) 
20.05  
Procedures 22.66          
(12.95)         
3.20 65.47        
(37.41) 
5.57  998.76   
(570.72) 
6.49   4149.67 
(2,371.24) 
33.70  









Table 4.5: Estimated annual costs, SGD (USD) per patient by five chronic hepatitis B disease states in Singapore 
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As mentioned above, the estimated costs for liver transplant management in Singapore 
were divided into two categories: treatment costs during hospitalization for the surgical 
transplant procedure, and treatment costs in the first and second years following 
transplant.  The estimated average cost during the hospitalization for the surgical 
procedure alone was SGD 86,369.28 (US $49,353.87) (range: SGD 47,435.48 to SGD 
186,708.56).  The average length of stay for 20 patients during the liver transplant 
process was 30.15 days (SD = 18.78 days; median = 28.5 days; range = 4–94 days). 
During the hospitalization period, the average length of stay in the intensive care unit was 
7.95 days (SD = 5.75 days; median = 6 days, range = 3–25 days).  Details of the total 
costs incurred for the 20 patients during hospitalization for liver transplant are 
summarized in Table 4.6. 
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Table 4.6: Resource utilization (Singapore dollars) for patients during hospitalization 
for liver transplant procedures (n = 20) 





4,852.75 4,143.00 3,611.07 145.00–16,560.00 
Intensive care unit 
 
3,463.60 2,550.00 2,416.39 1,275.00–10,625.00 
Imaging/X-ray 
 
3,020.00 2,576.00 1,445.47 1,303.00–7,171.00 
Drugs 
 




13,390.35 12,548.50 6,754.85 7,640.00–39,393.00 
Daily treatment fee 
 
1,969.60 1,631.50 1,320.29 200.00–6,674.00 
Procedure 
 
2,504.10 1,882.50 3,341.85 57.00–15,330.00 
Theater fees 
 
25,785.19 13,890.00 27,075.65 8,811.00–85,436.37 
Professional fees 
 




2,540.40 1,640.00 1,848.88 887.00–6,862.00 
Miscellaneous fees 
 
620.01 394.35 554.77 70.00–1,909.00 
Dialysis 
 
983.00 0 2,778.04 0–0,400.00 
Total average 
annual cost 
86,369.28 67,731.68 38,914.29 47,435.48–186,708.56 
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The data from Singapore also included the management costs during the first and second 
years post-liver transplant. Similar data were not available for Hong Kong.  The 
treatment costs for liver transplant patients in the first year following transplant were 
SGD 20,220.09 (range: SGD 15,665.58 to SGD 37,912.04), and during the second year 
following transplant were SGD 11,841.15 (range: SGD 7,874.28 to SGD 24,171.91). 
Details of treatment costs during the first and second years following liver transplant are 
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Table 4.7: Treatment costs (Singapore dollars) during the first and second years following liver 
transplant 





Treatment costs during the first year following liver transplant (n = 12) 
Outpatient visits 1,116.27 1,060.80 302.51 665.60–1,622.40 5.52 
Inpatient admissions 2,452.61 161.20 6,642.97 0–23,305.68 12.13 
Antivirals 2,620.70 2,620.70 – – 12.96 
Immunosuppressants 7,916.67 7,000.00 288.68 7,000–8,000 39.15 
Medications 688.22 108.16 1,365.21 0–3,973.54 3.40 
Laboratory tests 4,516.46 4,304.56 847.40 3,572.40–6,419.92 22.34 
Imaging/ X-ray 836.39 403.52 1,154.98 0–3,490.00 4.14 
Procedures 72.79 2.50 156.33 0–540.80 0.36 
Total average annual 
cost 
20,220.09 17,321.84 6,243.22 15,665.58–37,912.04 100 
 
Treatment costs during the second year following liver transplant (n = 8) 
Outpatient visits 332.80 270.40 224.57 166.40–873.60 2.81 
Inpatient admissions 967.20 483.60 1,378.64 0–4,191.20 8.17 
Antivirals 2,282.16 2,401.70 523.82 1,003.75–2,620.70 19.27 
Immunosuppressants 4,361.08 4,486.00 867.06 0–3,714.35 36.83 
Medications 581.87 92.46 1,276.32 3,241.20–5,737.80 4.91 
Laboratory tests 2,509.65 1,813.76 1,934.56 925.60–6,857.76 21.19 
Imaging/ X-ray 592.54 698.36 503.76 0–1,406.08 5.00 
Procedures 213.85 57.20 428.64 0–1,260.48 1.81 
Total average annual 
cost 
11,841.15 10,661.32 5,142.05 7,874.28–24,171.91 100 
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Treatment Patterns 
The overall patterns of resource utilization in the management of the various stages of 
HBV infection in Hong Kong and Singapore generally followed a similar trend, showing 
progressively increasing resource consumption as the disease stage progressed from CHB 
to liver transplant.  However, a detailed comparison of the resource utilization patterns of 
the different disease states revealed both similarities and differences between Hong Kong 
and Singapore.  For example, lamivudine and interferon-alpha are the two most common 
antiviral agents used in most Southeast Asian countries including Hong Kong (Guan et al., 
2001).  However, in Singapore, lamivudine was the antiviral agent most commonly used 
during this study, and interferon-alpha was seldom used. 
 
In general, all the CHB patients studied in Hong Kong had undergone extensive 
laboratory tests.  In particular, alanine aminotransferase, alfa-fetoprotein and hemoglobin 
marker assays, as well as ultrasonography, were performed in over 90% of the patients.  
For HBV-related medications, although a diversity of agents was used, none had been 
used in more than 5% of the patients.  Thus, drug costs in this group of patients were 
minimal. Similar patterns were observed in Singapore, where confirmative laboratory 
tests were performed in 100% of the CHB patients and practically no prescription 
medications were used in the group. 
 
For patients with decompensated cirrhosis, laboratory tests were performed more 
extensively than in the CHB and compensated cirrhosis groups, possibly owing to the 
increase in the severity of disease.  In addition, decompensated cirrhosis patients had to 
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undergo various diagnostic/therapeutic procedures, including abdominal ultrasonography, 
liver biopsy, computer tomography scanning, magnetic resonance imaging, hepatic 
angiogram and blood transfusion.  Consequently, hospital admissions and outpatient 
clinic visits were more frequent for these patients.  This trend was demonstrated by the 
hospitalization costs that constituted approximately 65% and 51% of the total annual 
management for decompensated cirrhosis patients in Hong Kong and Singapore, 
respectively.  These figures were reflected in the four- to five-fold increase in dollars 
spent both in Hong Kong and Singapore on procedures (and imaging) by decompensated 
compared with compensated cirrhosis patients.  In Hong Kong, a similar picture was 
observed for the usage of medications, as more patients with decompensated cirrhosis 
received drug treatment than in the patients with compensated cirrhosis.  Vitamin K, 
spironolactone, famotidine, frusemide, lactulose, multivitamin and propranolol were used 
in around 50% of the decompensated cirrhosis patients.  A parallel trend was also 
observed in Singapore with the exception that medication used was minimal for both the 
CHB and compensated cirrhosis patient groups when compared with the data from Hong 
Kong.  
 
As the disease progresses to hepatocellular carcinoma, procedures such as chemotherapy, 
radiotherapy, sclerotherapy and transarterial chemo-embolization are often indicated.  
Hospital admissions and outpatient/specialist clinic visits are therefore also frequent in 
this group. For the hepatocellular carcinoma group in Hong Kong, although the disease 
had progressed further, laboratory test utilization rates were lower than those of the 
decompensated cirrhosis group, and only alanine aminotransferase and complete blood 
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count were performed in over 90% of the patients.  In terms of medications, there was an 
obvious increase in the variety, but not the rate, of drugs used by this group.  In 
Singapore, however, although hospitalization and procedures were major cost drives 
constituting 58% and 33% of the total management costs respectively, the trend towards 
lower laboratory utilization rates was not observed.  A further resource utilization pattern 
that was captured in Singapore was that immunosuppressants and antivirals became the 
major cost items during the first and second years following liver transplant.  These two 
items together with laboratory tests constituted more than 70% of the total post-transplant 
management costs.  This highlights that even where there are sufficient healthcare 
resources to perform very expensive liver transplant operations, the long-term financial 
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4.4 DISCUSSION  
While many studies on similar topics had been performed using central claims data from 
health management organizations or insurance companies (Metcalf et al., 1999), the data 
for this study were collected from patients’ medical records from two regional hospitals 
in Hong Kong and one hospital in Singapore.  There are two reasons for choosing the 
present method of study.  Firstly, neither Hong Kong nor Singapore has a large health 
maintenance organization or insurer where claims data can be easily obtained.  Secondly, 
it was the opinion of the researchers that direct collection of data from patients’ medical 
records would yield data that reflects the resource utilization in the management of HBV 
infection and its associated complications more accurately.  Although information from 
the claims data may have the advantage of being able to capture a larger patient 
population, and hence the theoretical advantage of providing a more global estimate of 
the management cost of a specified disease or disorders, the information may be limited 
to the numbers and items that can be claimed within a financial year.  Furthermore, this 
method excludes resource items that cannot be claimed from health maintenance 
organizations or insurance companies, whether public or private. 
 
A limitation of the present study lies in the fact that some of the cost data incorporated 
hospital charges to patients.  Since these charges may not truly reflect actual costs, 
inaccuracies may have been introduced into the cost estimation.  However, since all 
public hospitals in Hong Kong and Singapore are non-profit-making institutions, the 
charges used may be considered to be a reasonably accurate estimate of the actual costs, 
in lieu of actual cost data. 
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chronic hepatitis B: Hong Kong and Singapore  
 
Only an estimate of the cost of liver transplant in Hong Kong was possible.  However, 
this estimation closely approaches the actual figures released by the government 
authorities (HKD 514,000 estimated in this study versus HKD 540,000 released by the 
government), suggesting that our estimate is accurate.  Nevertheless, the lack of data for 
first and second year post-liver transplant from Hong Kong prevents a complete 
comparison of the management costs for this CHB-related disease state between the two 
countries.  The comparison of cost data from the year 2000 in Hong Kong but from the 
year 2003 in Singapore represents a further possible limitation to this study.  However, in 
order to alleviate public hardship caused by the Asian financial crisis, healthcare charges 
at public hospitals in Singapore have been kept relatively stable by the government over 
the past few years.  Likewise, the same situation happened in Hong Kong as evident from 
the published rates of various healthcare services by the Hong Kong Government 
Gazettes over the years.  Thus, even though the two data sets were valued at different 
time points, they would be expected to be reasonably comparable. 
 
In summary, data was obtained for the study of the cost of management of HBV and its 
complications in Hong Kong and Singapore.  This is the first set of such data ever 
obtained from Hong Kong and the most comprehensive set of data for Singapore.  The 
cost data presented here agreed with those of a previous, smaller study of 79 HBV 
patients, which used a slightly different method to measure costs (Yeoh et al., 2000).  The 
same costs were captured despite the differences in methodology, suggesting that the data 
reported here is an accurate reflection of disease cost trends.  In the present study, an 
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chronic hepatitis B: Hong Kong and Singapore  
increase in the direct medical costs involved in the management of HBV and its 
complications was observed as the disease progresses.  This trend is congruent with 
observed pathophysiological changes caused by disease progression.   
 
4.5 CONCLUSIONS  
The data obtained confirmed that CHB infection and its associated complications 
imposed a significant financial burden on the healthcare systems of Singapore and Hong 
Kong.  This burden could be relieved by minimizing disease progression for those 
already infected and by preventing infection through vaccination.  These data provide 
valuable information for healthcare planners and providers in the management of HBV 
infection, particularly in the area of resource allocation. 
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5.1 INTRODUCTION 
In Singapore, HBV infection is endemic and the most common cause of chronic viral 
liver diseases (Guan, 1996; James et al., 2001). Hepatitis B viral infections are being 
treated mainly in 5 of the 7 public restructured hospitals in Singapore, namely, the 
National University Hospital (NUH), Changi Hospital, Tan Tock Seng Hospital, 
Singapore General Hospital (SGH) and Alexander Hospital, with NUH and SGH being 
tertiary referral centres.  Besides these, some of the primary healthcare institutions such 
as outpatient polyclinics and private general practitioners do provide some primary 
healthcare services for HBV patients.   
A hepatitis B seroprevalence survey conducted in 1999 showed that the overall 
prevalence of chronic hepatitis B virus infection in Singapore was 4.1% among residents 
aged between 18 to 69 years (James et al., 2001).  This figure was similar to the 
prevalence rate of hepatitis B in the general population of 5-6% reported by other studies 
(Goh, 1987; Merican et al., 2000).  Of the long-term complications of cirrhosis and HCC, 
cirrhosis was seen in about 20% of HBV carriers locally (Guan, 1996), while HCC was 
the third commonest cancer for males and constituted 8.1% of cancers diagnosed in 1998-
2002 with about 75-90 % of HCC patients presented with HBV infection (Seow et al., 
2004; Lemon et al., 2000; Pokorski et al., 2001; Guan et al., 1989; Oon et al., 1987; Chan 
et al., 1984).   It has been estimated that male Chinese carriers of the HBV carry a lifetime 
risk of almost 50% of developing hepatocellular carcinoma (HCC), one of the most 
rapidly growing tumors with most untreated patients dying within 12 months from the 
onset of symptoms (Johnson, 2000).  In fact, excluding deaths due to HCC, chronic liver 
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disease and cirrhosis accounted for 0.7% of total annual death, or the 10th most common 
principal cause of death in Singapore in the year 2002 (State of Health Editorial 
Committee, 2002).                                                                                   
Financially, HBV imposes a significant personal and social burden on those infected, as 
well as to the healthcare system.  For example, in South Korea the estimated total annual 
cost (direct plus indirect) associated with HBV-related diseases in 1997 was 936.1 billion 
Won (or US$833.1 million).  Of which, the direct costs amounted to 782.2 billion Won 
(or US$696.2 million) and was equivalent to 3.2% of the national healthcare expenditure 
for 1997 (Yang et al., 2001).  It can be inferred from this data that the actual and potential 
costs of HBV infection treatment and care to Singapore would also be substantial.   
In particular, cost-of-illness (COI) analysis measures the economic burden of disease and 
illness on society.  This method, often referred to as burden of illness, identifies and 
estimates the overall cost associated with a specific disease or illness in a defined 
population (Bungay et al., 2003).  The measurement of this economic burden 
incorporates direct medical and non-medical costs incurred in treating and caring for 
those afflicted with the disease in question, as well as indirect costs associated with 
productivity losses due to disease morbidity and mortality, and psychosocial or intangible 
costs associated with changes in the quality of a patient’s life due to the disease.  
However, assigning a cost to the intangible aspects of disease is difficult and, thus, rarely 
included in COI analysis (Cox, 2003).  On the other hand, COI analysis can determine 
within each disease category the distribution of resources across cost categories (direct, 
indirect and intangible) and be used to assess how and where healthcare resources are 
 107
Chapter 5:  A Cost-of-illness Study of Hepatitis B Infection in Singapore Siew Chin, Ong 
being allocated.  Thus, COI analysis can assist policy-makers in establishing priorities for 
research funding or to target disease categories for health prevention campaigns.   
Nevertheless, very little data exist on the financial burden of HBV infection to the 
Singaporean society as a whole.  In view of this, there is a rationale for quantifying the 
COI caused by HBV infection to provide decision-makers with an important guide and 
resource for policy development, priority setting, and management of public health.  The 
aim of the present study is therefore to assess the COI (direct and indirect cost) of HBV 
infection to Singapore, which is an extension of the cost analysis study as discussed in 
Chapter 4 of this thesis.   
5.2 METHODS  
There are two general approaches used to measure COI: the incidence-based and the 
prevalence-based approach.  Incidence is a measure of the number of new events or cases 
of disease that develop in a population of individuals at risk over a specified time 
interval, typically 1 year.  Incidence-based analysis measures the costs over the lifetime 
of the individual with the condition or disease - from diagnosis to cure or death.  It 
provides a more accurate baseline for estimating the benefit of a new treatment or 
preventive programs whose benefits may accrue over many years.  However, this 
approach is more difficult and used less frequently compared to prevalence-based 
approach due to the information requirements needed to calculate lifetime costs.  It 
requires knowledge of disease progression, survival probabilities, current and future 
projections of incidence rates, and current and future treatment patterns (Cox, 2003).   
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Currently, most COI analyses are conducted using a prevalence-based approach.  
Prevalence measures the proportion of individuals in a population who have a disease in a 
specified time period, usually one year.  Prevalence-based COI studies estimate the cost 
of disease within a specified time period for all individuals diagnosed with the disease 
regardless of the time since diagnosis (Cox, 2003).  Due to the unavailability of 
information on incidence rate, we had adopted the more commonly used prevalence-
based approach in this study, which allowed also the calculation costs for newly 
diagnosed HBV infected patients as well as patients in later stages of their disease.  
The study consisted of two parts.  The first part of the study attempted to quantify the 
direct cost of HBV infection, which was the extension of the cost analysis performed 
previously as detailed in Chapter 4 in this thesis, while the second part attempted to 
quantify the indirect cost.  The study protocol was approved by the Institutional Review 
Board of the National University Hospital (NUH).  
5.2.1 Measurement of Direct Medical Cost 
A detailed description of the study design, study sites, patient recruitment, data 
collection, cost considered and analysis of data, was presented previously (see Chapter 4, 
Section 4.2 in this thesis).   
Calculation of Direct Medical Cost 
The total annual direct cost per patient from each category of HBV infection was 
calculated by adding up all the defined items from different resource categories which 
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have been established from the cost analysis study as presented previously (Chapter 4, 
Section 4.2 in this thesis).   
These data were then multiplied by the estimated prevalence of the various stages of 
HBV infections in Singapore for the calculation of estimated direct cost component for 
the cost-of-illness study.  Cost data were expressed in Singapore dollar (SGD) [$US1= 
SGD 1.75)]  
Estimation of Prevalence  
In order to extrapolate the sample cost estimates to the population level, the values 
obtained from the cost analysis study needed to be multiplied by the overall Singapore 
prevalence of HBV sufferers in the various categories (as presented in Chapter 4).  
 
Based on the estimations from several recent studies, it was assumed that the prevalence 
of HBV carriers in Singapore to be between 4-6% of the population (James et al., 2001; 
Goh, 1987; Merican et al.  2000).  With a population of 4,185,200 people in Singapore in 
year 2003 (Ministry of Health, 2005a), the total number of the HBV carriers was 
estimated to be between 167, 408 to 251, 112 people.  In order to simplify the calculation 
of base-case estimation for direct and indirect costs, we assumed the prevalence rate for 
HBV carriers in Singapore to be 5% of the population, which equates to 209,260 (average 
of 4-6% of the population)    
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Of these, 20% were cirrhosis patients (Guan, 1996), with the ratio of patients with 
compensated to decompensated liver cirrhosis estimated to be around 8.25: 1, according 
to the HBV patient database kept by Department of Gastroenterology at National 
University Hospital.  Therefore, the numbers of patients with compensated cirrhosis (CC) 
and decompensated cirrhosis (DC) were estimated to be 36,779 and 5073 respectively.  
No prevalence data were available for patients suffering from HCC in Singapore. This 
had to be estimated from the incident rate, which is readily available by using the 
following equation: 
Average Prevalence (P) = Incidence (I) x Average Duration of illness (D). 
 
Therefore, if the average duration for HCC is assumed to be 2 years, then P = 2 I. 
However, HCC is highly fatal and patients do not survive long after diagnosis. The 
average survival for HCC patients is about 1 year according to unpublished data from the 
Singapore Cancer Registry (personal communication from Professor Lee HP, Department 
of Community and Family Medicine, Yong Loo Lin School of Medicine, National 
University of Singapore).  Under such circumstances, the prevalence rate would be equal 
to the incidence rate.   
Based on the population size of Singapore, the incidence of HCC would be around 774 
cases per year using the age-standardized incidence rate for HCC of 18.5 per 100,000 
population per year in 1998-2002 (Seow et al., 2004).   Of these, about 75-90% of HCC 
patients were HBV infected locally (Seow et al., 2004; Chia et al., 2002; Lemon et al., 
2000; Pokorski et al., 2001; Guan et al., 1989; Oon et al., 1987; Chan et al., 1984), which 
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would then translate to give the prevalence of HBV-infected HCC patients in Singapore 
as around 581 to 697 people in year 2002 (hence, an average number of 639 people was 
used  for base-case estimation).  
On average, there are 7.7 cases of liver transplantation performed yearly for adults in 
Singapore.  This value was calculated from total number of transplants, 46 cases, 
performed from December 1996 to December 2002, divided by a total of 6 years.  As 
46.8% of these patients were HBV-infected (unpublished data from Liver Transplants 
Unit, NUH), we estimated that there would be around 4 HBV-infected patients 
undergoing liver transplantation yearly. 
Sensitivity Analysis 
The sensitivity analysis was first performed using two one-way sensitivity analyses.  The 
first one-way sensitivity analysis tested the lower and upper limits of the cost components 
(the ranges tested were obtained from the cost analysis study conducted previously as 
reported in Chapter 4 Table 4.5 and summarized in Table 5.1) while keeping the number 
of patients unchanged.    
The second one-way sensitivity analysis performed would keep the cost components 
unchanged but varying the number of patients in each category of HBV patients.  The 
number of patients tested in each disease category were based on the assumptions made 
as detailed in the next paragraph.   
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We tested the prevalence of HBV infected patients in a range of 4-6% of the Singapore 
population.  However, not everyone with HBV infection will seek healthcare services 
every year.  In view of this, the likelihood is that patients with HBV infection who may 
not seek medical health services will serve as the lower bounds of the number of patients 
being tested in each disease category of HBV patients.  Based on a local study conducted 
recently, 64 % of participants who were known hepatitis B carriers had not had screening 
over the last 12 months (Wai et al., 2004), and thus we assumed that they do not incur 
any cost, not being in receipt of public health services.  We assumed this group of 
patients belongs to the group of early stage of HBV carriers, known as the chronic 
hepatitis B infected (CHB) patients in our study.  Therefore the proportion of people who 
are in receipt of healthcare services for this group of patient may be as low as 36%.  The 
other assumption we made was that the likelihood of patients seeking healthcare 
treatment will depend on the severity of disease.  Thus, we estimated that 80% of patients 
in receipt of health services were those with compensated cirrhosis and all patients with 
more advanced stages of HBV infection including DC, HCC and post-liver transplants 
(PLT) would be in receipt of health services.   
The range of the HCC patients tested in the sensitivity analysis was based on the fact that 
about 75-90% of HCC patients were HBV infected locally, i.e. 581 to 697 patients, given 
that all of them sought healthcare services.  On the other hand, we allowed the range of 
PLT tested to vary ± 1 patient due to the relatively small sample size (4 patients).   
In order to test the combination effect of the variation in the number of subjects and 
treatment costs on the outcomes, two-way sensitivity analysis was also performed by 
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allowing both the cost components and number of patients in each disease stage of HBV 
infection to vary simultaneously.  In the two way sensitivity analysis, only the best and 
worst case scenarios were evaluated. 
5.2.2   Measurement of Indirect Medical Cost  
Study design 
The second part of the study in the estimation of indirect cost of HBV infections was a 
financial burden survey. This was a snap-shot study conducted to capture from the 
patients’ perspective the financial burden and/or loss of productivity caused by HBV 
infection. The information on the estimation of indirect cost attributable to HBV 
infection was calculated by the human capital approach (Black & Pole, 1975). The 
human capital approach to measure the productivity based on market earnings and an 
imputed value for housekeeping services is commonly used in economic evaluation 
(Rice, 2000). 
Patient recruitment 
All hepatitis B patients attending the Gastroenterology outpatient clinic from August 
2003 to August 2004 at NUH were approached to participate in our survey. The patients 
were identified from the Unit Digestive Centre, NUH.  Informed consent was obtained 
from each patient recruited in the study.  The study protocol was approved by the 
Institutional Review Board.  The patients were again divided into the 5 categories 
according to clinical diagnosis (see Chapter 4, Section 4.2).  
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Data Collection 
After informed consent, patients were asked to answer a few questions using a simple 
standardized questionnaire.  The survey questionnaire consisted of demographic and 
socioeconomic characteristics, patients’ opinion whether HBV infection is a financial 
burden to them, productivity loss questions associated with HBV infection such as 
medical leave due to outpatient visit or hospitalization, time-off claimed for outpatients 
visit inclusive travelling time to and from clinic follow-up, job loss due to HBV infection, 
any caregiver give up their jobs due to taking care of sick family member and is there 
any caregiver especially employed to take care of them.   
In order to assess the patients’ perceived loss of productivity at work due to HBV 
infection, which would not be captured by the information collected from the questions 
for those non-working population such as retiree, homemaker and unemployed persons, 
the participants were requested to draw an arrow in a visual analogue scale (VAS) 
ranging from 0 to 100% to indicate the percentage of their estimated loss of productivity 
for the past 12 months with an assumption of 100% of productivity before they had been 
diagnosed with HBV infection.  
Calculation of Indirect Cost  
In order to calculate the indirect cost for the working population, time-off claimed for 
outpatients visit and medical leave due to HBV-related diseases were used as an 
indicator of indirect costs and were converted into monetary units.   
 115
Chapter 5:  A Cost-of-illness Study of Hepatitis B Infection in Singapore Siew Chin, Ong 
The calculations were based on the average monthly earnings of SGD 3213 (US$1836) 
in year 2003 (statistics on the average monthly earnings are based on the payroll of 
Central Provident Fund (CPF) contributors) (Labour Market Statistics, 2003).  Based on 
the assumption of 5 working days per week and 20 working days per month, the daily 
wage rate was estimated to be SGD 160.65 (USD 91.8).  Daily earnings were further 
divided by 8 (i.e., the official number of working hours in a day) to give the estimated 
hourly earnings which would work out to be SGD20.08 per hour.   
The annual cost of time-off claimed from employer due to outpatient’s clinic follow-up 
was calculated by multiplying the total time claimed and the hourly earnings.  Total days 
claimed for medical leave were multiplied by daily wage rate to estimate the annual cost 
of medical leave.   
For those non-working population such as retiree, homemaker and unemployed persons, 
reported loss of productivity at work was used as indicator for indirect cost calculation.  
Their monthly wage rate was assumed to be the current market price of housekeeping 
activities (around SGD280 per month) (Employing Foreign House Help, 2006).  Annual 
cost of reduced productivity at work attributable to HBV infection was determined by the 
following formula: 
Annual cost of reduced productivity at work 
=Reported loss of productivity at work × monthly wage rate × 12 
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In order to estimate the indirect cost to the national level, we extrapolated the calculated 
indirect cost per patient (by adding up all the above mentioned indicators) to the 
population level according to the estimated prevalence rate for each group of HBV 
infected patients  
Data Analysis 
The Kolmogorov-Smirnov test demonstrated that the distribution of indirect costs was 
skewed.  Therefore, we used median rather than mean as the base-case estimation of 
indirect cost for HBV infected patients.  The influence of various socio-demographic 
factors e.g. gender, ethnicity, monthly income, cash in hand after monthly expenses, 
marital status, education level, employment status, severity of HBV disease etc. which 
might affect the patients’ opinion whether HBV infection is a financial burden to them 
were evaluated by using multiple linear regression (MLR) analysis.   
All statistical analyses were performed with Statistical Package for the Social Sciences 
(SPSS Inc., Chicago, Illinois) 13.0 for Windows.  Statistical significance for all tests was 
set at 5%.   
Sensitivity Analysis 
Two one-way sensitivity analyses were performed first followed by a two-way 
sensitivity analysis.  The first one-way sensitivity analysis tested the 25th and 75th 
percentile of the indirect cost and the number of patients in each category of HBV 
patients remains unchanged.  The second one-way sensitivity analysis varied the number 
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of HBV patient (the ranges used were same as mentioned in the sensitivity analysis 
section in the estimation of direct cost) and the indirect costs components remain 
unchanged.   
In order to test the combination effect of the variation in the number of subjects and 
treatment costs on the outcomes, two-way sensitivity analysis was also performed by 
allowing both the cost components and number of patients in each disease stage of HBV 
infection to vary simultaneously.  In the two-way sensitivity analysis, only the best and 
worst case scenarios were being evaluated. 
The total indirect cost was then calculated based on the various combinations of 
assumptions for the base-case estimation as well as the best and worst case scenario we 
made in our sensitivity analysis.    
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5.3 RESULTS 
5.3.1 Direct Medical Cost 
A total of 172 patients were recruited for this part of the study (see Chapter 4, Section 
4.3).    The mean age of the patients was 46.2 years (range of 22-75 years) with 62% 
being male and 38% being female.  The majority of the subjects were Chinese with only 
3% of them being non-Chinese.  These patients could be classified into 5 categories, 
namely: chronic hepatitis B infection (CHB) (N=116), compensated cirrhosis (CC) 
(N=17), decompensated cirrhosis (DC) (N=9), hepatocellular carcinoma (HCC) (N=10) 
and post-liver transplants (PLT) (N=20). 
 
Detailed breakdown of the resource utilization for the various disease states for this 
cohort has been reported in Chapter 4 in this thesis.  Summary of the resources used in 
different disease states of HBV infection in Singapore is shown in Figure 5.1.  As 
expected, direct cost of management for HBV infection increased sharply with the 
severity of disease, for PLT patients being the main cost driver among all the other 
disease states of HBV infection.   
Based on the estimated prevalence for different disease stage of HBV infection as 
mentioned in our method section, and their mean cost calculated as detailed in Chapter 4, 
the base-case direct cost of management for different disease stages of HBV infection are 
shown in Table 5.1.  Base-case total direct cost of managing HBV infection in Singapore 
was estimated to be approximately SGD 249 million annually or approximately US $ 142 
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million annually (Table 5.1).  In our one-way sensitivity analyses, the effect of varying 
the cost components and fixing the number of patients was more prominent than varying 
the number of patients and fixing the cost components (Tables 5.2 and 5.3).  The 
estimation of direct cost by varying the cost components for HBV patients in the first 
sensitivity analysis was approximately SGD 76 million to SGD 720 million, compared to 
varying the number of patient in each disease stage of HBV patient in the second 
sensitivity analysis, ranged from SGD 131 million to 297 million.  The two-way 
sensitivity analysis as summarized in Table 5.4, allowing both the cost components and 
number of patients in each disease stage of HBV infection to vary simultaneously, 
indicated that the total annual direct cost ranged from SGD 33 million to SGD 859 
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Table 5.1: Base-case estimated number of patients in different disease stages and their base-case cost of management. 
Disease category Base-case estimated number of patients  
Base-case  annual cost per 
patient (mean cost) (SGD) 
Estimated cost per annum 
(SGD) 
Chronic hepatitis B      166,769 718.15 119,765,157.40 
Compensated cirrhosis 36,779 1, 175.34 43,227,829.86 
Decompensated cirrhosis 5,073 15, 389.84 78,072,658.32 
Hepatocellular carcinoma 639 12, 314.04 7,868,671.56 
Liver-transplants    
    
4 106,589.37 426,357.48
Total 209,260 136,186.74 249,360,674.60
 
 
Table 5.2: One-way sensitivity analysis by varying the cost of management and fix the estimated number of patients in different 





Disease category Base-case estimated number of patients  
Range of cost tested in 
sensitivity analysis (SGD) Estimated cost per annum (SGD) 
Chronic hepatitis B       66,769 316.60–2,203.60 52,799,065.40-367,492,168.00 
Compensated cirrhosis 36,779 295.80–3,098.51 10879228.20-113960099.00 
Decompensated cirrhosis 5,073 2,263.16–41,415.06 11481010.68-210098599.00 
Hepatocellular carcinoma 639 2,277.20–43,699.76 1455130.80-27924146.60 
 Liver-transplants  
  
4 63,101.06-224,620.60 252404.24-898482.40 
Total 209,260 68,253.82-315,037.53 76,866,839.32-720,373,496.00
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Table 5.3: One- way sensitivity analysis by varying the estimated number of patients in different disease stages and fix the cost of 
management.    
Disease category Range of estimated number of patients tested in sensitivity analysis* 
Annual cost per 
patient (SGD) 
Estimated cost per annum 
(SGD) 
Chronic hepatitis B 48,002**-200,189 718.15 34,472,636.30-143,765,730.40 
Compensated cirrhosis 23,571*** - 44,196 1, 175.34 27,703,939.14-51,945,326.64 
Decompensated cirrhosis 4,018 – 6,027 15, 389.84 61,836,377.12-92,754,565.68 
Hepatocellular carcinoma 581-697  12, 314.04 7,154,457.24-8,582,885.88 
Liver-transplants   
   
3-5 106,589.37 426,357.48-426,357.48
Total 167,408-251,112 - 131,593,767.30-297,474,866
 
*Based on the prevalence rate of 4-6% of population were HBV infected. 
**Assumed there was only 36% of HBV carrier who seek medical treatment. 
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Table 5.4: Two-way sensitivity analysis by varying the estimated number of patients in different disease stages and varying the cost 
of management in each disease stage in the best and worst case scenario.    
Disease category 
Range of estimated number 
of patients tested in 
sensitivity analysis* 
Range of cost tested 
in sensitivity analysis 
(SGD) 
Best case scenario for 
estimated cost per 
annum (SGD) 
Worst case scenario 
for estimated cost per 
annum (SGD) 
Chronic hepatitis B 48,002**-200,189 316.60–2,203.60 15,197,433.20 441,136,480.40 
Compensated cirrhosis 23,571*** - 44,196 295.80–3,098.51 6,972,301.80 136,941,748.00 
Decompensated cirrhosis 4,018 – 6,027 2,263.16–41,415.06 9,093,376.88 249,608,566.60 
Hepatocellular carcinoma 581-697  2,277.20–43,699.76 1,323,053.20 30,458,732.72 
Liver-transplants     
  
4 63,101.06-224,620.60 252,404.24 898,482.40
Total 167,408-251,112 68,253.82-315,037.53 32,838,569.32 859,044,010.10
 
*Based on the prevalence rate of 4-6% of population were HBV infected. 
**Assumed there was only 36% of HBV carrier who seek medical treatment. 
***Assumed there was only 80% of the compensated cirrhosis patients who seek medical treatment 
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5.3.2 Financial Burden of Illness Survey 
Patient’s response whether HBV infection is a financial burden to them  
A total of 406 hepatitis B patients participated in the study.  The mean age of the patients 
was 45.4 years (range of 19-80 years), and 70.4 % of the sample was male, reflecting the 
fact that more men are infected than women in Singapore.  Other sample characteristics 
are shown in Table 5.5.   
Of the participants, 65% considered HBV infection as a financial burden.  Among these 
patients, 54% of them chose the option “definitely agree” with the statement, “Do you 
think hepatitis B is a financial burden to you?”  As a general trend, the percentage of 
patients choosing “definitely agree” to the survey question were found to be increasing in 
line with their severity of disease as shown in Table 5.6.  This is in line with the fact that 
the costs of care increases sharply in the advanced stages of the disease as indicated by 
the results of the cost analysis study (see Chapter 4).  
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 Table 5.5: Sample characteristics 
Gender (male) n (%) 286 (70.4) 
Age years, mean (SD) 45.4 (12.6) 
 
Race, n (%) 
Chinese 389 (95.8) 
Malay  13 (3.2) 
Indian 1 (0.2) 
Other 3 (0.6) 
 
Marital status, number (%) 
Single 81 (20.0) 
Married 306 (75.4) 
Divorced or separated 7 (1.7) 
Widowed  8 (2.0) 
Missing data 4 (0.9) 
 
Disease stage, n (%) 
Chronic hepatitis B 298 (73.4) 
Compensated cirrhosis 66 (16.3) 
Decompensated cirrhosis 18 (4.4) 
Hepatocellular carcinoma 9 (2.2) 
Liver transplants 15 (3.7) 
 
Education level, number (%) 
No schooling 7 (1.7) 
Primary 37 (9.1) 
Secondary 148 (36.4) 
Polytechnic or diploma 82 (20.4) 
University or postgraduate degree 123 (31.1) 
Other 0 (0.0) 
Missing data 4 (0.9) 
 
Employment status, n (%) 
Working 297 (73.1) 
Unemployed 18 (4.4) 
Retired 51 (12.6) 
Homemaker or housewife 34 (8.3) 
Missing data 6 (1.4) 
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Table 5.5 (Continued): Sample characteristics 
 
Total household income, n (%) 
Below SGD 2999 147 (36.2) 
SGD 3000- SGD 5999 112 (27.6) 
SGD 6000- SGD 8999 54 (13.3) 
SGD 9000 and above 47 (11.6) 
Missing data 46 (11.3) 
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Table 5.6: The percentage of patients in answering the question “Do you think hepatitis B is a financial burden to you?” 
 
Options of  the survey question 
Definitely 









N %        
             
N % N % N % N % N %
Chronic hepatitis B 91 30.43 87 29.10 62 20.74 33 11.04 11 3.68 15 5.02
Compensated cirrhosis             
             
             
            
            
24 36.92 26 40.00 5 7.69 4 6.15 4 6.15 2 3.08
Decompensated cirrhosis 10 50.00 5 25.00 2 10.00 1 5.00 0 0.00 2 10.00
Hepatocellular carcinoma
 
5 71.43 0 0.00 1 14.29 0 0.00 1 14.29 0 0.00
Liver transplants
 
11 73.33 3 20.00 0 0.00 1 9.09 0 0.00 0 0.00
Total 141 34.74 121 29.80 70 17.24 39 9.61 16 3.94 19 4.68
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Factors Affecting Patients’ Selection  
In the multiple linear regression analysis, factors that significantly influenced the 
patients’ selection whether HBV is a financial burden to them were the employment 
status and HBV disease severity.  Their magnitudes of influence are summarized in Table 
5.7. 
The non-working population such as retiree, homemaker, full time students and 
unemployed persons was associated with patients’ positive choices (i.e., disagreeing with 
HBV infection being a financial burden).  On the other hand, more advanced stages of 
HBV disease were more influential toward the patients’ negative selection, that is, they 
were more agreeable to HBV infection being a financial burden.  Level of education, 
ethnicity, gender and income were not found to significantly affect patients’ selection.    
 
Table 5.7: Factors that significantly affected the patients’ selection in answering the 
question “do you think hepatitis B is a financial burden to you?” in multiple linear 
regression analysis 
 
Factors Beta (standardised regression coefficients) P value 
Employment status 0.154 0.032 
HBV disease severity -0.170  0.003 
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Indirect Cost Components of Care- givers and Loss of Job  
No participants in the present financial survey study reported that they need to specially 
employ any care giver to take care of them.  Likewise, none of the participants’ family 
members has given up their job to take care of them due to their HBV condition.  In 
addition, less than 1% of the participants in the study claimed that they have lost their job 
due to HBV infection.  Therefore, based on the study results, these three components 
would have no impact on our estimation of indirect costs for HBV infected patients in 
Singapore. 
Indirect Cost of Loss of Productivity, Medical Leave and Time-off Claimed 
In this analysis, median rather than mean values were used in the report of indirect cost as 
the distribution was found to be skewed.  Based on the respondents’ report, medical leave 
based upon the numbers of days taken off work was the main cost driver for the 
estimation of indirect cost for HBV infected patients in Singapore.  When estimated using 
the average monthly salary of the working population, this component amounted to be 
SGD 7069 per annum (or USD 4039 per annum).  It was followed by reduced 
productivity reported by the non-working population (such as retirees, homemakers and 
unemployed persons), with an estimated value of approximately SGD 6972 per annum 
(or USD 3984 per annum).   
As expected, indirect cost components as calculated by summing up all the indirect cost 
components including reduced productivity, medical leave days and time-off hours 
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The base-case estimation for total annual indirect cost for HBV infection in Singapore is 
approximated to be SGD 180 million or USD 103 million (Table 5.9).  The results of the 
one-way sensitivity analyses performed were summarised in Tables 5.10 and 5.11.  
Again, the range tested for varying the cost component gave a broader range of total 
indirect cost (SGD 51 million - SGD 486 million) compared to varying the number of 
patients in each disease category of HBV infection (SGD 74 million- 216 million).  The 
two-way sensitivity analysis that varied the indirect cost and number of patients 
simultaneously showed that the total annual cost could range from SGD 20 million to 
SGD 583 million (Table 5.12).       
claimed was highest among patients with DC as compared with the other HBV disease 
state.  Patients suffering from DC claimed the highest indirect cost of medical leave days 
(SGD 4016.25) and time-off hours (SGD200.80) (Table 5.8).  The total annual indirect 
cost for DC patient was estimated to be SGD 5783.40, followed by SGD 2650.73 for PLT 
patient and SGD1673.07 for HCC patient.  In contrast, the indirect costs were estimated 
to be only SGD773.12 for CHB patients and SGD572.28 for patients with CC.  
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Table 5.8: Indirect cost of HBV infection by each disease state in terms of reduced productivity, medical leave and, time-of 
claimed.  All values reported are in median (25th-75th percentiles).  
Indirect cost (SGD) 
Disease State 
Medical Leave Time-off Reduced Productivity Annual Indirect Cost 
Chronic hepatitis B   80.33 (0-1124.55) 160.64 (0-481.92) 1176.00 (252.00-2058.00) 773.12  (240.96-2058.27) 
Compensated cirrhosis 0 (0-843.41) 100.40 (0-401.60) 672.00 (0-1008.00) 572.28 (160.65-1938.83) 
Decompensated cirrhosis 4016.25 (2249.10-19278.00) 200.80 (0-5481.84) 1008.00 (0-1680.00) 5783.40 (1008.00-13895.61) 
Hepatocellular carcinoma 1606.50 (0-1927.80) 30.12 (0-5511.96) 1680.00 (1680.00-1680.00) 1673.37 (416.69-1865.85) 
Liver transplants 1365.53 (0-4337.55) 0 (0-421.68) 2436.00 (1638.00-2016.00) 2650.73 (909.29-4779.25) 
Total 7068.61 (2249.10-27511.31) 491.96 (0-7379.40) 6972 (3570-8442) 11452.90 (2735.59-24537.81) 
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Disease State Base-case Estimated  indirect cost (SGD) 
Base-case estimated number 
of patients Annual total indirect cost (SGD) 
Chronic hepatitis B        773.12       166,769 128,932,449.30 
Compensated cirrhosis 572.28 36,779 21,047,886.12 
Decompensated cirrhosis 5,783.40 5,073 29,339,188.20 
Hepatocellular carcinoma 1,673.37 639 1,069,283.43 
Liver transplants 2,650.73 4 10,602.92 




Table 5.10:  One-way sensitivity analysis by varying the indirect cost (25th-75th percentile) for each HBV disease state and fix the 
estimated number of patients.  
 
Disease category Range in sensitivity analysis for Indirect Cost (SGD) 
Base-case estimated 
number of patients  Estimated cost per annum (SGD) 
Chronic hepatitis B  240.96-2058.27       166,769 40,184,658-343,255,629.60 
Compensated cirrhosis  160.65-1938.83 36,779 5,908,546-71,308,228.57 
Decompensated cirrhosis 1008.00-13895.61 5,073 5,113,584-70,492,429.53 
Hepatocellular carcinoma  416.69-1865.85 639 266,265-1,192,278.15 
Liver-transplants  909.29-4779.25  4 3,637-19,117 
Total    2735.59-24537.81 209,260 51,476,691-486,267,683
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Table 5.11:  One-way sensitivity analysis by varying the estimated number of patients and fix the indirect cost for each HBV 
disease state and fix.  
 
Disease category Base-case Estimated Indirect Cost (SGD) 
Range of Estimated number of 
patients tested  in sensitivity analysis* 
Estimated cost per annum 
(SGD) 
Chronic hepatitis B        773.12 48,002**-200,189 37,111,306.24-154,770,119.70 
Compensated cirrhosis 572.28 23,571***-44,196 13,489,211.88-25,292,486.88 
Decompensated cirrhosis 5,783.40 4,018 – 6,027 23,237,701.20-34,856,551.8 
Hepatocellular carcinoma 1,673.37 581-697 972,227.97-1,166,338.89 
Liver-transplants    
    
2,650.73 3-5 7,952.19-13,253.65
Total 360,798,819.90 167,408-251,112 74,818,399.48-216,098,750.9
 
Table 5.12: Two-way sensitivity analysis by varying both the estimated number of patients and the indirect cost of HBV infection in 
each disease stage in the best and worst case scenario.    
Disease category Range in sensitivity 
analysis 
for Indirect Cost 
Range of estimated 
number of patients tested 
in sensitivity analysis 
Best case scenario 
for estimated cost 
per annum (SGD) 
Worst case scenario 
for estimated cost 
per annum (SGD) 
Chronic hepatitis B  240.96-2058.27 48,002**-200,189 11,566,561.92 412,043,013 
Compensated cirrhosis  160.65-1938.83 23,571*** - 44,196 3,786,681.15 85,688,531 
Decompensated cirrhosis 1008.00-13895.61 4,018 – 6,027 4,050,144 83,748,841 
Hepatocellular carcinoma  416.69-1865.85 581-697  242,096.89 1,300,497.50 
Liver-transplants  909.29-4779.25  3-5 2,727.87 23,896.25 
Total   - 167,408-251,112 19,648,211.83 582,804,779
*Based on the prevalence rate of 4-6% of population were HBV infected. 
**Assumed there was only 36% of HBV carrier who seek medical treatment. 
***Assumed there was only 80% of the compensated cirrhosis patients who seek medical treatment 
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Total cost for HBV infection (direct and indirect) 
 
The estimated total cost for HBV infection in Singapore, including of direct and indirect 
cost, calculated according to the proportion of each disease stage of HBV infection was 
approximately SGD 430 million (ranging from SGD 52 million to 1,442 million by 
allowing various assumption to be made as shown by the results of the sensitivity 
analyses).  The ratio of direct to indirect costs based on the base-case estimation 
increased with disease severity, with the highest ratio obtained for the PLT patients 
(40.2:1), followed by HCC (7.4:1) and DC patients (2.7:1).     
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(26,763,995.12-853,179,493.43) 0.93: 1 




(10,758,982.95-222,630,278.68) 2.1: 1 




(13,143,520.88-333,357,408.07) 2.7: 1 




(1,565,150.09-31,759,230.17) 7.4: 1 




(255,132.11-922,378.65) 40.2: 1 
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5.4 DISCUSSION 
The present study depicted that HBV infection and its associated complications is a 
significant cost burden to the Singapore healthcare system and society in general.  The 
estimated total annual cost of HBV infection and its associated complications in 
Singapore was SGD 430 million (ranged from SGD 52 million to 1,442 million) or 
USD246 million (USD 30 million to USD 824 million), with 58% or SGD 249 million 
attributable to direct cost.   Based on the base case estimation, total direct cost alone is 
equivalent to 0.012% of the national health-care expenditure for year 2003 [Singapore 
spent about SGD 2.01 billion or 5% of GDP on healthcare in year 2003 (Health Facts 
Singapore 2005, Government Health Expenditure.)  
Regarding the pattern of resource utilization for the various stages of HBV infection, the 
trend of the resources used in the estimation of direct cost for HBV infection was quite 
similar for CHB and CC cases.  Laboratory tests accounted the highest portion of the 
resources used, followed by imaging and outpatient visits.  There were no medications 
indicated for CHB patients other than antiviral.  Medications prescribed were mainly for 
symptomatic treatment for complication cases such as propanolol for portal hypertension, 
lactulose for prevention of encephalopathy, diuretic and IV albumin for ascites, and 
antibiotics for sepsis.   
Once DC occurs, the prognosis is poor and more innovative treatment options are needed.  
Therefore, inpatient admission accounted the largest proportion of the resources used in 
DC cases.  This was mainly due to some patients having repetitive episodes of variceal 
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bleeding and encephalopathy which led to high frequency of inpatient admission and 
prolonged stay in hospital.  Whereas in HCC cases, the highest portion of the resources 
used were procedures.  This is expected to be high as chemoembolisation and resection 
are the very costly procedures commonly performed for HCC patients.   
Although the average cost for antiviral treatment seems to be relatively low when 
compared to the other resources used, a patient would need to pay up to SGD 10 
thousand for a course of interferon therapy.  Cheaper options of antiviral drugs for HBV 
infected patients, lamivudine and adefovir may also cost a patient around SGD 2500 and 
SGD 3800 respectively per annum.  Many factors have to be taken into account by a 
physician when prescribing an antiviral, and the high cost of antivirals appears to be a 
significant factor to be considered.   
Among the patients with various stages of HBV infection, the total direct cost incurred 
by CHB patients represents the biggest cost component to the Singapore healthcare 
system, even though the cost of treating a PLT patients was around 150 times higher than 
that of managing a CHB patient.  This was mainly due to the higher proportion of CHB 
patients in Singapore.  Nevertheless, DC patients have claimed the position as the second 
highest direct cost contributor despite the proportion of DC patients was only around 
2.4% of the total HBV carrier population in Singapore.   
Overall, the results of our study were consistent with the results reported from other 
countries, where the cost increases in line with the severity of the disease as summarized 
by Kowdley in one of his articles which concluded a multinational project on the direct 
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medical cost of CHB patients (Kowdley, 2004).  Countries which participated in this 
project included Australia, Canada, China, Hong Kong, Europe, South Korea, Taiwan, 
and the United States.  Although the collection of data and analyses were done 
independently by each research team and each team decided on the methodology that 
best suited their locality, all of these countries consistently reported the similar trend of 
the cost incurred by the HBV patients (Kowdley, 2004).  
In total, indirect cost represent 42% of the total cost of HBV infection in Singapore, 
which highlights the substantial economic burden borne by HBV infected patients.  This 
result confirmed that the indirect cost is an important cost component in the estimation of 
total cost incurred by HBV infection, the exclusion of which would underestimate the 
true burden of this infectious disease. 
The results of our multiple regression analysis surprisingly showed that personal or 
household monthly income and cash in hand after expenses did not significantly affect 
the patients’ choice concerning whether HBV infection is a financial burden.  Likewise, 
other socio-demographic factors, e.g., gender, ethnicity, education level were also found 
not to be influential toward patients’ choices.  However, as expected, the more advanced 
the stage HBV infected patients were in, the more likely they are agreeable to the fact that 
HBV infection is a financial burden.  Moreover, this group of patients had shown 
significant correlation with the increased reported reduced productivity.  Surprisingly, 
non-working population such as retirees, homemakers, full time students and unemployed 
persons was disagreeable with HBV infection being a financial burden.  The reason for 
this is far from clear.  One plausible explanation may be that this group of patients was 
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able to obtain financial assistance from many sources, eg. Medifund through hospital 
social workers, hospital endowment fund or any charity organization set-up mainly to 
support medical expenses for those in need.  
To the best of our knowledge, this is the first study in Singapore that attempts to quantify 
the direct costs at the national level and indirect cost in terms of missed workdays 
(absenteeism) and reduced productivity at work attributable to HBV infection and its 
associated complications.  The cost estimates in this study could be considered as a lower 
end of the true cost of disease because several costs items were not addressed.  Omitted 
direct costs included that paid by the patients to seek other healthcare resources other 
than our study site, such as seeking help from polyclinics or other healthcare centres.   
One recent study conducted locally found that there was evidence of doctor hopping 
among the HBV carriers in seeking the follow-up of their disease (Tan et al, 2005).  
However, a sample size of 39 patients which included only asymptomatic HBV patient 
from that study was insufficient to conclude on the extent of HBV patients practicing 
such an inappropriate health-seeking behaviour.  Alternative medicines, dietary 
supplement to improve the health condition and transportation costs to visit the 
physicians were also omitted from our estimation of costs.  The other limitation of the 
present study was the omission of the estimation of prevention cost for HBV infection 
such as compulsory vaccination for the newborns and students.  Although the vaccination 
program for the whole population could be higher than the annual treatment cost of all 
HBV infected individuals, the impact on quality of life and productivity needs to be 
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considered.  This may be one of the directions for future study to evaluate the cost-
effectiveness for HBV prevention and treatment cost.    
On the other hand, the indirect costs were estimated to be higher than the value we have 
calculated as we did not estimate the cost for premature mortality.  We have also 
excluded the indirect costs of uncompensated care rendered by patients’ family members 
and volunteers as none of the study participants claimed they need such help.  This lack 
of report of needing personal care might be due to a better health status in the participants 
recruited from the clinic in the current study. . Furthermore, no attempt was made to 
estimate intangible costs such as stress, pain, and suffering as these were deemed difficult 
items to measure.    Thus, the cost of HBV infection estimated in this study might 
generate a conservative cost estimate to the Singapore society. 
A limitation of the present study lies in the fact that our survey method used for 
calculating the indirect cost is subject to respondent recall bias.  In order to minimise the 
effect of such bias, sensitivity analysis was performed to assess each input variable, 
which might affect the aggregate indirect cost estimation.  The other limitations for the 
estimation of direct cost have been discussed in detail in Chapter 4.   
A recent study conducted locally showed an alarming sign that 64% of the participants 
had not had routine screening over the last 12 months for their HBV disease (Wai et al., 
2004). This may pose an important public health threat as such behaviour would result in 
increased morbidity and mortality for the individual and overall higher healthcare costs 
for the nation in the long run. 
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For comparison, total costs of HBV infection are 36 times higher for managing the 
varicella in Singapore (approximately to be US$11.8 million per annum).  Varicella has 
been chosen as a comparison to HBV infection as they share some similarities:  both are 
common types of viral infections in Singapore; both are vaccine-preventable infection; 
and both can cause significant morbidity and mortality if the infections were not managed 
properly.  The financial burden of HBV infection is thus considerable.   
5.5 CONCLUSIONS 
Management of HBV infection imposes more than a medical challenge as it imposes a 
sizeable economic burden both from the payer and societal perspectives.  Besides the 
clinical benefits to the patients and the maintenance of their quality of life, considerable 
savings of economic resources will be guaranteed for each HBV infection successfully 
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6.1 INTRODUCTION 
In Singapore, chronic hepatitis B virus (HBV) infection imposes a considerable health 
and economic burden to patients and society as discussed in the previous few chapters.  
Although vaccination is the most effective tool in preventing the transmission of HBV 
infection, it is ineffective in subjects with pre-existing HBV infection, and treatment with 
antivirals becomes the sole option for combating the liver disease once it has been 
established (Lavanchy, 2004).   
 
The early phase of CHB is characterized by the presence of hepatitis B e antigen 
(HBeAg) and high serum levels of HBV DNA (referred to as HBeAg-positive/ +ve 
CHB).  Following infection, the immune system attempts to clear the HBV by destroying 
infected hepatocytes.  This leads to increasing circulatory blood levels of alanine 
aminotransferase (ALT).  However, the majority of patients will clear HBeAg (and 
produce anti-HBe antibodies) and achieve a state of non-replicative infection, 
characterized by low or undetectable serum levels of HBV DNA and normal ALT levels.  
High HBV DNA and ALT levels may persist in some anti-HBe-positive patients (referred 
to as HBeAg-negative/ -ve CHB) because of the presence of an HBV variant that is 
unable to produce HBeAg (HBeAg –ve variant, also called HBV precore stop codon 
mutant) (Lavanchy , 2004; Carman et al., 1989).  Patients with chronic HBeAg -ve 
hepatitis have a high risk of developing progressive liver disease and cirrhosis, 
particularly if their alanine aminotransferase (ALT) levels and hepatitis B virus HBV-
DNA concentrations are persistently elevated or fluctuating (Funk et al., 2002; 
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antiviral agent, HBeAg +ve patients generally achieved better virological response rate as 
compared to HBeAg –ve patients (Lai et al., 1998; Tassopoulos et al., 1999; Dienstag et 
al., 1999; Chien et al., 1999; Liaw et al., 2000; Song et al., 2000; Lau et al., 2000; Buti et 
al., 2000; Santantonio et al., 2000; Hadziyannis et al., 2000; Leung et al., 2001; 
Santantonio et al., 2002; Schiff et al., 2003; Lai et al., 2003; Dienstag et al., 2003; Lee et 
al., 2003; Chien et al., 2003; van Nunen et al., 2003; Papatheodoridis et al., 2003; 
Marcellin et al., 2003; Hadziyannis et al., 2003; Di Marco et al., 2004; Fung et al., 2004; 
Marcellin et al., 2004; Chan et al., 2005).     
 
Antiviral agents which are currently approved for use in Singapore for the treatment of 
HBV infection are interferon-α2b (interferon), lamivudine and adefovir dipivoxil 
(adefovir).  A full course of interferon therapy  requires  approximately SGD 10 thousand 
annually, whereas annual drug cost for lamivudine 100 mg and adefovir 10mg daily were 
estimated to be around SGD 2500 and SGD 3800 respectively.  
 
Interferon is administered subcutaneously three times weekly for four to six months, and 
is effective only in a minority of patients with frequent side effects that limit its 
tolerability (Hoofnagle et al., 1997; Wong et al., 1993).  Interferon is therefore less 
favourable an option as compared to lamivudine and adefovir which can be orally 
administered and bear excellent safety profiles.  In fact, in Singapore, the usage of 
interferon is rather low among hepatitis B patients as evident from the resource utilization 
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patients being studied.  Therefore, interferon has been excluded in this cost-effectiveness 
and utility study.   
 
Lamivudine, (–)-ß-L-2’, 3’-dideoxy-3’-thiocytidine is a cytosine analog with potent 
inhibitory effect on the RNA-dependent DNA polymerase of HBV and HIV.  Its antiviral 
effects against HBV have been established both in vitro and in vivo (Lai et al., 1997; Ben 
et al., 1997).   Lamivudine is triphosphorylated intracellularly to an active intermediate, 
which is incorporated into growing DNA chains and acts as a chain terminator (Ben et al, 
1997; Johnson et al., 1999).  Lamivudine may also reverse the T-cell hyporesponsiveness 
to hepatitis B viral antigens observed in patients who have chronic HBV infection (Boni 
et al., 1998).   
Adefovir dipivoxil (Hepsera, Gilead Sciences) is an oral prodrug of adefovir, an acyclic 
monophosphate adenine analog (Gilson et al., 1998; Tsiang et al., 1999).  The active 
metabolite of adefovir inhibits HBV DNA polymerase (reverse transcriptase) by 
competing with the natural substrate, deoxyadenosine triphosphate, and by causing DNA 
chain termination after its incorporation into viral DNA.  Adefovir has potent activity 
against HBeAg +ve, HBeAg –ve/ anti-HBe +ve/ HBV DNA +ve (presumed precore 
mutant) and lamivudine-resistant HBV (Bureau of Pharmaceutical Services, 2002) 
 
Response to lamivudine is high, but long term treatment is associated with high rate of 
viral resistance, approximately 23% per year (Lai et al. 1998, 2003; Tassopoulos et al., 
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al., 2000; Lau et al., 2000; Buti et al., 2001; Buti et al., 2001; Papatheodoridis et al., 
2002; Lee et al., 2003; Schiff et al., 2003; Chien et al., 2003; van Nunen et al., 2003; 
Benvegnù et al., 2004; Di Marco et al., 2004; Fung et al., 2004).  In comparison, adefovir 
has the advantage of a much lower rate of viral resistance, 1.3% per year, which permits a 
higher sustained virological response while on therapy (Qi et al., 2004). However, the use 
of adefovir has been limited by its relatively higher cost compared with lamivudine.  
Both adefovir and lamivudine have particular drawbacks and benefits over one another, 
which of these drugs to be initiated for the treatment of HBV infection is therefore 
uncertain. Furthermore, the cost of treatment for HBV infection with antiviral agents is 
high, so optimal and appropriate use of this class of drug is of utmost important in 
resource allocation.  In this aspect, the application of pharmacoeconomic principles can 
assist clinicians in decision-making for the most cost-effective management of HBV 
infection using antiviral agents.   
 
 
Although Buti et al (Buti et al., 2006) have evaluated the cost-effectiveness of lamivudine 
and adefovir over 4-year duration in HBeAg –ve CHB patients, virological response for 
both drugs at year 4 of continuous therapy was their only therapeutic end point, without 
taking into account the health-related quality of life aspect in these patients.  
Furthermore, the perspective of the Spanish Public Health System was used in the study 
and this might not reflect the situation under the healthcare system in Singapore.  Another 
comprehensive cost-effectiveness analysis performed by Kanwal et al (Kanwal et al., 
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HBeAg –ve and +ve CHB patients over a lifetime horizon were assessed through a series 
of Markov cycles.  However, the findings suggested by this study have shown some 
discrepancies with the findings from Buti et al, most probably due to the different 
outcome measures used in the two studies.  Moreover, the utilities used in the study were 
adopted from hepatitis C viral infection, which might not truly reflect the actual utility 
values in CHB patients.   
 
Therefore it would be timely to perform a study locally to provide information to 
decision-makers to assess the cost-effectiveness of using anti-viral agents in the 
management of hepatitis B viral infection.   In the current pharmacoeconomic evaluation 
study, modeling was used instead of a piggy-backed clinical trial.   The main reason was 
based on resource and logistic considerations.  Within these constraints, a modeled 
approach would be more feasible as a relatively inexpensive and effective way of 
synthesizing existing data and available evidence on the outcomes of alternative 
interventions.   
 
The ultimate goal of therapy for chronic hepatitis is to heal hepatic inflammation and 
necrosis, thereby halting progression to cirrhosis and hepatocellular carcinoma (Mailliard 
et al., 2003).  In particular, HBeAg seroconversion has been endorsed as the most reliable 
marker of long-term and sustained virologic response in HBeAg +ve patients, whereas 
the treatment goal for HBeAg –ve patients is persistent HBV DNA suppression with 
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2000; Hadziyannis et al., 2003; Marcellin et al., 2004).  Therefore, we adopted all these 
treatment goals as our primary outcome measures in the modeled analyses.   
 
Quality-adjusted life-year (QALY), which is a useful and the most commonly used 
indicator of outcome for cost-effectiveness or cost-utility analysis in recent years (Cramer 
et al., 1998; Blomqvist, 2002) has been used as one of our outcomes in the current study. 
A QALY is defined as one year of perfect health, taking into consideration both 
differences in quality of life and life expectancy.  In the USA, as a decision rule, it has 
been suggested that interventions costing less than US$20,000 per QALY gained are 
cost–effective, whereas interventions that cost more than US$100,000 per QALY gained 
are deemed to be non-cost–effective (Laupacis et al., 1992). 
 
 
The aim of this study is therefore to evaluate the cost-effectiveness of treatment 
alternatives comparing adefovir and lamivudine, as well as no antiviral treatment in the 
management of patients with chronic hepatitis B (CHB) infection with treatment 
initiation in Singapore.  The study would adopt the response rate to anti-viral treatment 
(i.e., seroconverted to anti-HBe for HBeAg+ve CHB patients, or achieved persistent 
HBV DNA suppression and normalization of aminotransferase levels for HBeAg–ve 
CHB patients), total QALY gained, and percentage of non-progression to cirrhosis cases 
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6.2 METHODS 
Model structure and model assumptions 
A decision analytical model was developed for two oral antiviral treatment alternatives of 
CHB, lamivudine and adefovir, and a no antiviral treatment arm for a hypothetical cohort 
of 1000 CHB patients who were either hepatitis B‘e’ antigen-negative or positive 
(HBeAg -ve and +ve).  The proportion of patients with HBeAg-ve and HBeAg+ve would 
be detailed in later section. 
 
Patients with CHB entered into the hypothetical model received either lamivudine 100 
mg daily, adefovir 10 mg daily or no antiviral treatment.  The assumptions for the 
patients in each cohort were that their baseline characteristics were similar and that they 
were eligible candidates for the antiviral treatment with persistent elevated 
aminotransferase levels (three or more readings) above twice the upper limit of normal 
within a period of 6 months (MOH, Singapore, 2003).  We assumed that patients had not 
received previous antiviral treatment for CHB infection (i.e. antiviral naïve) and had not 
yet progressed to cirrhosis.  The time horizon of 3 years was adopted in this study and the 
model was performed from the perspective of the healthcare institute (in this case, a 
major hospital). 
 
Based on clinical experience, at the end of each annual cycle and after 3 years of no 
antiviral treatment or receiving oral antiviral daily, the assumption in the model was that 
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(1) Asymptomatic carrier (AS) who achieved a clinical response (i.e., 
seroconverted to anti-HBe for HBeAg+ve CHB patients, or achieved persistent 
HBV DNA suppression and normalization of aminotransferase levels for HBeAg 
–ve CHB patients); 
(2) Compensated cirrhosis (CC) with patient’s disease progressing from the initial 
CHB state; or  
(3) CHB with patients remains at their original state without achieving virologic 
response or progress to compensated cirrhosis.   
The transition process to these three health states was assumed to have happened in the 
middle of each annual cycle in our modeled analysis.   
 
The decision analytical model was analyzed by DATA 3.5 (TreeAge Inc., Williamstown, 





Chapter 6. Cost-effectiveness and cost-utility analysis  Siew Chin, Ong 
 





























































































Chapter 6. Cost-effectiveness and cost-utility analysis  Siew Chin, Ong 
 
Inputs for the Model 
The base-case estimated probabilities and their respective ranges for each health state and 
the responses towards different treatments were obtained from literature review and are 
summarized in Table 6.1.  Weighted means were used in the base-case probability 
estimates by combining the data from the various randomized, controlled studies and the 
ranges tested in sensitivity analyses were also representing the data reported from the 
clinical studies (Kanwal et al., 2005).   
 
The proportions of HBeAg –ve and +ve CHB patients in Singapore were obtained from 
two local studies (Yap et al., 1991; Goh et al., 1997) and the range tested in sensitivity 
analysis were based on the reports from two studies which suggested that 80% of CHB 
patients in Asia are HBeAg-ve (Hadziyannis, 1995; Lindh et al., 1996).  There was no 
data reporting the durable response rate for HBeAg –ve patients receiving adefovir, the 
response rate was therefore assumed the same between lamivudine and adefovir as 
suggested by Kanwal et al (Kanwal et al., 2005)      
 
The “no antiviral treatment” arm served as the reference group in the modeled analysis.  
The assumption in the model for this control group was that these CHB patients were 
eligible candidates for antiviral treatment but were not given any antiviral therapy for a 
period of 3 years even though they were attending clinical follow up as usual. 
 
In the model, patients in the lamivudine treatment arm received lamivudine 100 mg orally 
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Patients would switch the antiviral therapy to adefovir once resistance occurred.  Based 
on data reported by Buti et al, the virological response rate for adefovir following 
crossover from lamivudine was assumed to be similar to those who do not receive 
lamivudine before (Buti et al., 2004; Kanwal et al., 2005).  Patients who did not respond 
to therapy and develop resistance to lamivudine would continue to receive lamivudine 
until virological response achieved or until end of year 3.  Adefovir therapy was 
discontinued 6 months after a virologic response. 
 
 
In adefovir treatment arm, patients received adefovir 10 mg orally once daily and the 
antiviral therapy was discontinued 6 months after a virologic response.  Antiviral therapy 
would be discontinued once resistance occurred and the patients would subsequently be 
managed as described in no antiviral treatment arm.  Patients who showed no response to 
therapy and not resistant to adefovir would continue to receive adefovir until virological 
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Table 6.1.  Probability estimates from literature review 
Base-Case Estimate 
(Range tested 
in sensitivity analysis), % 
 







Percentage of patient 39 (0.2 - 0.44) 61 (0.56 - 0.8) Yap et al., 1991; 
Hadziyannis, 1995; Lindh et 
al., 1996; Goh, 1997 
 
Annual rate of 
progression to 
compensated cirrhosis 
3 (0.5-11) 4.6 (0.5-15) Viola et al., 1981; Kosaka et 
al., 1981; Norkrans et al., 
1982; Aldershvile et al., 
1982; Su et al., 1986; 
Fattovich et al., 1986 and 
1988; Yang et al., 1987; 
Liaw et al., 1988; Brunetto 
et al., 2002; Krogsgaard et 
al., 1998. Hsu et al., 2002; 











1.6 (0-11) Liaw et al., 1988; 
Hadziyannis et al., 1990 and 
2003;  Fattovich et al., 1992; 
Niederau et al., 1996;  
Lampertico et al., 1997; Di 
Marco et al., 1999; Furusyo 
et al., 1999; Dienstag et al., 
1999; Tassopoulos et al., 
1999; Perrillo et al., 2002; 
Lai et al., 2003; Schiff et al., 
2003; Kao et al., 2004; 
Yuen et al., 2004; Marcellin 
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Table 6.1 (continued): Probability estimates from literature review 
*No data available, assumptions was made based on lamivudine treatment 
Base-Case Estimate 
(Range tested 
















10 (0-15) Lai et al., 1998;  Dienstag et al., 
1999; Chien et al., 1999; Dienstag 
et al., 1999; Tassopoulos et al., 
1999; Liaw et al., 2000; Song et 
al., 2000; Lau et al., 2000;  
Hadziyannis et al., 2000; Buti et 
al., 2000; Santantonio et al., 2000;  
Leung et al., 2001;   Santantonio et 
al., 2002; Dienstag et al., 2003; 
Lee et al., 2003;  Schiff et al., 
2003; Lai et al., 2003; Chien et al., 
2003; van Nunen et al., 2003; 
Papatheodoridis et al., 2003; Fung 
et al., 2004; Marcellin et al., 2004;  






23 (15-32) 23 (15-32) Lai et al. 1998, 2003; Tassopoulos 
et al., 1999; Santantonio et al., 
2000; Hadziyannis et al. 2000; Lau 
et al., 2000; Buti et al., 2001; 
Papatheodoridis et al., 2002; Schiff 
et al., 2003; Lee et al., 2003; Chien 
et al., 2003;  van Nunen et al., 
2003; Di Marco et al., 2004; Fung 
et al., 2004;  Benvegnù et al., 2004. 
 




response  rate 
12 (10–20) 10 (0.5 -15)* Marcellin et al., 2003; Hadziyannis 














The cost analyses were taken from a societal perspective and are presented in SGD for 
the year 2003.  The methods used in generating the direct cost for each disease state for 
CHB patients have been discussed in details in Chapter 4 and is summarized in Table 6.2.   
 
The model assumed that the patients assigned lamivudine treatment received 100mg 
tablet once daily, adefovir treatment arm received 10 mg daily and no antiviral treatment 
arm will not receive any antiviral but will still have normal clinic follow-up and 
laboratory tests carried out as usual.  The cost for patients who achieved response (AS) 
was assumed to be similar to those remained at their initial CHB stage as they will still be 
managed closely, except no antiviral drug was given to them again in the antiviral 
treatment arms.      
 
The other assumption was the adverse events profile for lamivudine and adefovir were 
minimal and similar, which was based on the clinical trials indicating that the safety 
profiles of the two drugs were similar to that of a placebo (Zuckerman, 1997; Lai et al., 
1998; Dienstag et al., 1999; Marcellin et al., 2003; Hadziyannis et al., 2003) and therefore 
their possible treatment costs of adverse drug reactions (assuming to be equal in the three 
arms) would not be considered in this study. 
 
As previously mentioned, based on the institution’s perspective, all indirect cost to 
society and individuals (e.g., loss of productivity, traveling costs, loss of work days) and 
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Table 6.2: Cost estimates for antiviral treatment and each disease state  
 
Cost items Base case estimate (Range tested in 
sensitivity analysis), SGD 
Annual cost for drug   
Lamivudine 100 mg 2427.25 (1825 - 3785.05) 
Adefovir 10 mg 3785.05 (2427.65 – 5000) 
  
Annual cost for each disease state  
Chronic hepatitis B 718.15(316.60 - 2,203.60) 




Utilities for each disease state were obtained from the results of our previous study as 
presented in detail in Chapter 2.  The utility values were based on the EuroQol EQ-5D 
visual analogue scale (VAS) score and self-classifier.  We had standardized the utility 
score from both scales to a range of 0 (worst health state) to 1 (best health state), by 
dividing the VAS score with 100.  Base-case utilities in the model were generated by 
averaging the scores from both scales in each disease state.  Utility for those responses to 
treatment was assumed to be similar with asymptomatic HBV carrier who did not show 
the sign and symptoms of CHB patients before (candidate who is eligible for antiviral 
treatment as mentioned above).  Utilities for each disease state from both EQ5D scales 
and the range tested in sensitivity analysis were detailed in Table 6.3. 
 
Besides, the percentage of patients who had shown spontaneous response for no 
treatment arm or antiviral treatment-related response, remain in original state with CHB 




Chapter 6. Cost-effectiveness and cost-utility analysis  Siew Chin, Ong 
 








Average/ base-case estimate 
(range tested in sensitivity 
analysis) 
Asymptomatic HBV carrier  0.94 0.81 0.873 (0.81 - 0.94) 
Chronic hepatitis B  0.93 0.73 0.830 (0.73 - 0.93) 
Compensated cirrhosis 0.93 0.75 0.842 (0.75 - 0.93) 
 
Calculation of Cost-effectiveness Ratio (CER), Incremental Cost-effectiveness Ratio 
(ICER) or Incremental Cost-utility Ratio (ICUR) 
The cost-effectiveness of each strategy was evaluated in terms of cost-effectiveness ratio 
(CER), such as cost per response rate, cost per non-progression to cirrhosis case and cost 
per QALY gained.  Incremental cost-effectiveness ratio (ICER) or incremental cost-
utility ratio (ICUR) was also calculated to compare between each treatment strategy.  The 
ICER or ICUR is defined as the additional cost incurred to achieve an extra unit of 
effectiveness or QALY gained and was calculated as followed:  
ICER A vs. B = (Cost A – Cost B)/ (Effectiveness A – Effectiveness B) 




One-way sensitivity analyses were performed to test the robustness of the base case 
analysis results for three of our outcomes measures by varying some of the relevant 
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a) Annual response rate for lamivudine and adefovir treatment arms. 
b) Annual resistance rate for lamivudine and adefovir. 
c) Annual probability of progression to cirrhosis. 
d) Annual cost for CHB and cirrhosis cases.  
e) Annual cost for 100 mg lamivudine tablet and 10 mg adefovir tablet. 
f) Proportion of HBeAg +ve and –ve CHB patients. 
g) Utilities for AS, CHB and cirrhosis cases when the total QALY gained as the 
health outcome. 
 
Threshold analyses were performed for those variables which might change the choice of 
optimal strategy. Lastly, extreme scenario analyses (best and worst case scenarios) for 
both lamivudine and adefovir treatment arms were performed by varying two key 
variables at the same time.  Two key variables found to be most influential (given the 
widest ranges in the cost-effectiveness ratio) to lamivudine and adefovir treatment arms 
in the one-way sensitivity analyses would be chosen in these two-way sensitivity 




Percentage of non-progression to cirrhosis cases as the health outcome 
Both lamivudine and adefovir showed significantly higher percentage of non-progression 
to cirrhosis cases than no antiviral treatment for both HBeAg +ve and –ve CHB patients 
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develop in as much as 13% of CHB patient who were HBeAg -ve who did not receive 
antiviral treatment at the end of year 3.  In the same group of patients, cirrhosis developed 
only in 2% and 0.3% of the patients who received lamivudine and adefovir treatment 
respectively at the end of the same time period (Table 6.4).  From the results obtained, in 
comparison to the option of no antiviral treatment, the incremental cost of non- 
progression to cirrhosis case for CHB patients who were HBeAg-ve was relatively lower 
than CHB patients who were HBeAg +ve, regardless of whether the patients were treated 
with lamivudine or adefovir (incremental cost for lamivudine treatment arm: for 
HBeAg+ve CHB patients = SGD 104,652.55, HBeAg–ve CHB patients= SGD70,631.27; 
incremental cost for adefovir treatment arm: HBeAg+ve CHB patients = SGD127,169.91, 
HBeAg –ve CHB patients = SGD77,386.52).  However, the cost-effectiveness ratios for 
HBeAg-ve CHB patients were generally higher than the HBeAg+ve CHB patients in both 
lamivudine and adefovir treatment arms.    
 
A summary of the model analysis for a combination of both HBeAg –ve and +ve CHB 
patients according to their estimated percentage in Singapore was presented in Table 6.5.  
Based on the modeled results, for CHB patients starting on antiviral treatment, adefovir 
was the most effective option given the highest percentage of cirrhosis cases prevented 
after 3 years of treatment for HBeAg +ve and –ve CHB patients.  However, compared 
with no treatment arm, incremental cost per non-progression to cirrhosis case for adefovir 
was more than lamivudine, SGD80,105.30 per non-progression to cirrhosis case and 
SGD90,976.21 per non-progression to cirrhosis case were obtained for lamivudine and 
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term of non-progression to cirrhosis cases.  Compared with lamivudine, adefovir 
treatment cost an incremental of SGD157,681.71 per non-progression to cirrhosis case.  
  
The cost of SGD9,625.66 and SGD11,821.02 per non-progression to cirrhosis case for 
lamivudine and adefovir respectively would be considered relatively cheap, as compared 
to the higher cost incurred if the patients who developed cirrhosis subsequently progress 
to more advanced stage of CHB disease such as decompensated cirrhosis or 




Figure 6.2. Percentage of non-progression to cirrhosis cases by each treatment 








































HBeAg +ve HBeAg -ve
 
Footnote: Results for HBeAg –ve CHB patients in adefovir treatment arm need to be 
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Response rate as the health outcome 
Figure 6.3 depicts the results of the base-case analysis for response rate achieved by each 
treatment alternatives, namely no antiviral treatment, lamivudine treatment and adefovir 
treatment, stratified by the HBeAg status.  Three years of oral antiviral treatment with 
lamivudine has shown the best result among the other treatment alternatives with the 
highest response rate achieved, followed by adefovir and no antiviral treatment in both 
HBeAg +ve and –ve CHB patients.   
 
No antiviral treatment was the least expensive yet least effective strategy compared with 
lamivudine or adefovir treatment.  Compared with no antiviral treatment, lamivudine 
treatment cost an incremental SGD30,190.33 per response rate, whereas adefovir 
treatment cost an incremental SGD51,268.63 per response rate.  The most cost-effective 
treatment options in term of response rate achieved was by lamivudine treatment which is 
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HBeAg +ve HBeAg -ve
 
 
Total QALY gained as the health outcome 
The effectiveness expressed in terms of total QALY gained by each treatment options, 
stratified by HBeAg status are depicted in Figure 6.3.  From the modeling, HBeAg +ve 
CHB patients in lamivudine treatment arm would have gained the highest QALY, while 
HBeAg-ve CHB patients on no antiviral treatment with the least QALY.  Considering 
cost incurred, treating either HBeAg +ve or –ve CHB patients with adefovir would incur 
the highest cost per QALY obtained, and no antiviral treatment option  as expected the 
least cost per QALY obtained (Tables 6.4 and 6.5).  Lamivudine treatment cost an 
incremental SGD 463,410.26 to gain one additional QALY whereas adefovir treatment 








treatment.  Adefovir treatment arm apparently was a less favourable option resulting in 
higher cost and lower total QALY gained, and therefore dominated by lamivudine.    
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Cost at year 3 per patient, SGD 
 
2,208.88      2244.44 8,979.90 9,766.67 11,632.17 11,894.54
Non progression to cirrhosis, % 92.41      
    
    
      
      
  
87.24 98.88 97.89 99.82 99.71




9,081.82 9,976.86 11,652.67 11,928.77 
Incremental cost-effectiveness ratio vs. no antiviral 
treatment 
NA NA 104,652.55 70,631.27 127,169.91 77,386.52
Incremental cost-effectiveness ratio for adefovir vs. 
lamivudine treatment 
 
NA NA NA NA 282156.38 116,915.93
Response rate, % 18.76 4.51 45.24 26.83 31.69 26.82
Mean cost per response rate, SGD 11,775.42 49,744.55 19,847.66 36,397.28 36,708.80 44,342.49 















Total QALY gained 2.5041 2.4954 2.5234 2.5086 2.5117 2.5082
Mean cost per QALY gained, SGD 882.11 899.45 3,558.67 3,893.22 4631.24 4,742.19 
Incremental cost-effectiveness ratio vs. no antiviral 
treatment 








Table 6.4. Summary results of base-case analysis for HBeAg +ve and –ve CHB patients at 3 years.
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Table 6.5.  Summary results of base-case analysis for a combination of HBeAg +ve 
and–ve CHB patients at 3 years. 
 






Cost per patient, SGD 
 
2,230.60 9,459.80 11,792.20 
Non cirrhosis case, % 89.25 98.28 99.76 
Mean cost per non cirrhosis case, SGD 2,499.17 9,625.66 11,821.02 
Incremental cost-effectiveness ratio vs. 
no antiviral treatment 
NA 80,105.30 90,976.21 
Incremental cost-effectiveness ratio for 
adefovir vs. lamivudine treatment 
 
NA NA 157,681.71 
Response rate, % 10.07 34.01 28.72 
Mean cost per response rate, SGD 22,154.96 27,811.86 41,057.83 
Incremental cost-effectiveness ratio vs. 





Total QALY gained 2.4988 2.5144 2.5096 
Mean cost per QALY gained, SGD 892.67 3762.28 4698.89 
Incremental cost-effectiveness ratio vs. 
no antiviral treatment 
 
NA 463,410.26 885,333.33 
 
 
Sensitivity analysis   
Percentage of cirrhosis cases prevented as the health outcome 
The results of the sensitivity analyses are summarized in Table 6.6, which have 
demonstrated the robustness of the results obtained with the base-case analyses.  In most 
cases, changing the values of the variables in one-way sensitivity analyses across the 
ranges described in Table 6.6 did not have any significant effect on the favourable CER 
results obtained by lamivudine compared with adefovir.  However, only the drug cost for 
lamivudine and adefovir significantly affected the optimal strategy results of lamivudine 
within the ranges tested.  Threshold analyses depicted that lamivudine cost needs to be 
more than SGD3565.73, or 48% more than the current price in order for adefovir to be 
 167
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more cost-effective than lamivudine, provided the drug cost for adefovir remains 
unchanged.  The other circumstance for adefovir to be more cost-effective than 
lamivudine was when the drug cost for adefovir is less than SGD2584.42.  In other 
words, cost for adefovir needs to fall from the current price, SGD10.37 per tablet to 
SGD7.08 per tablet (32% reduction from the current price) in order for adefovir to be the 
optimal choice. 
 
In the extreme scenario analysis, CER for best and worst-case scenario analysis for 
lamivudine (varied the lower and upper limit of drug cost and annual resistance rate for 
lamivudine at the same time) was also more favourable in comparison with adefovir 
(varied the upper and lower limit of drug cost and annual response rate for adefovir at the 
same time), ranged from SGD7,963.08 to SGD12,310.94 per non-progression to cirrhosis 
case for lamivudine compared to SGD 8,103.09 to SGD16,538.64 per non-progression to 
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Table 6.6. Sensitivity analysis (Percentage of non-progression to cirrhosis cases as the health outcome) 
Cost-effectiveness ratio (CER) Variable, (range tested) 
No Treatment Lamivudine 
Treatment 
Adefovir Treatment 
ICER for adefovir vs. 
lamivudine 
Or Threshold analysis 
(TA) 
Baseline analysis 2,499.17    9,625.66 11,821.02 157,681.71
Annual response rate, %      
    
 
    
 
    
  
    
     
Lamivudine treatment 
HBeAg +ve CHB, (15–25) 2,499.17 9,476.95-9,779.67 11,821.02 143,170.27-172,463.91 









HBeAg +ve CHB, (10–20) 2,499.17 9,604.86-9,630.86 11,433.46-11,923.67 132,213.05-164,498.05 








Annual resistance rate, % 
Lamivudine, (15-32) 2,499.17 9,256.89-10,002.14 11,821.02 273,496.93- 102,818.36 




Annual probability of 
progression to cirrhosis 
HBeAg +ve CHB, (0.5-11) 2,413.01- 2,779.61 9,586.04- 9,754.14 11,813.95- 11,842.16 93,822.25-199,410.74 
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Table 6.6 (Continued). Sensitivity analysis (Percentage of non-progression to cirrhosis cases as the health outcome) 
Cost-effectiveness ratio (CER) Variable, (range tested) 
No Treatment Lamivudine Treatment Adefovir Treatment 
ICER for adefovir vs. 
lamivudine 
Or Threshold analysis 
(TA) 
Annual cost, SGD      
Chronic hepatitis B,  
(316.60-2,203.60)  
 
2,428.47- 2,760.71 9,397.35- 10,470.26 11,638.09- 12,497.73 160,514.24- 147,203.37 
Compensated cirrhosis,  
(295.80 - 3,098.51) 
 
2,335.09- 2,857.94 9,598.83- 9,684.32 11,818.39- 11,826.76 154,171.64 -159,287.00 
100 mg lamivudine,  
(1825 - 3785.05) 
2,499.17 8,464.33- 12,243.94  11,821.02 TA: Adefovir will be the 




10 mg adefovir, (2427.65 – 5000) 2,499.17 8,643.41- 10,794.28 8,356.76- 15,942.58 TA: Adefovir will be the 
optimal choice if 
adefovir cost 
<SGD2584.42 
     
Proportion of HBeAg -ve CHB, 
(0.56 - 0.8)  
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Cost-effectiveness ratio (CER) Variable, (range tested) 
No Treatment Lamivudine Treatment Adefovir Treatment 




Extreme scenario analysis     
Best case scenario for lamivudine: (Annual 
cost for lamivudine= SGD1825 and annual 
resistance rate for lamivudine=15%) 
 
2,499.17    
    
    
    
7,963.08 11,821.02 -
Worst case scenario for lamivudine: 
(Annual cost for lamivudine= SGD3785.05 
and annual resistance rate for 
lamivudine=32%) 
 
2,499.17 12,310.94 11,821.02 -
Best case scenario for adefovir: (Annual 
cost for adefovir= SGD2427.65 and annual 
response rate for HBeAg-ve CHB in 
adefovir treatment arm =15%) 
 
2,499.17 8,628.91 8,103.09 -
Worst case scenario for adefovir: (Annual 
cost for adefovir= SGD5000 and annual 
response rate for HBeAg-ve CHB in 
adefovir treatment arm =0.5%) 
2,499.17 10,826.37 16,538.64 -
Table 6.6 (Continued). Sensitivity analysis (Percentage of non-progression to cirrhosis cases as the health outcome) 
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Response rate as the health outcome 
The results of the sensitivity analyses are summarized in Table 6.7.  Adefovir is 
consistently being dominated by lamivudine (less effective yet more costly than 
lamivudine with response rate as the health outcome) for most of the ranges tested in one-
way sensitivity analyses.  The exceptional cases for adefovir not to be dominated were 
when the response rate for adefovir treatment arm is 15% (base-case analysis= 10%), 
drug cost for lamivudine is as high as SGD 3785.05 (base-case analysis= SGD2427.25) 
and drug cost for adefovir is as low as SGD 2427.65 (base-case analysis= SGD3785.05).  
Even when the extreme scenarios for some assumptions were applied for lamivudine and 
adefovir as described in Table 6.7, lamivudine still appears the favourable choice 
compared to adefovir (CER for best and worst case scenario for lamivudine was ranged 
from SGD20,470.61 to SGD59,652.86 per response rate in comparison with adefovir 
ranged from SGD22,675.59 to SGD78,615.84 per response rate). 
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Table 6.7. Sensitivity analysis (Response rate as the health outcome) 
Cost-effectiveness ratio (CER) Variable, (range tested) 
No Treatment Lamivudine Treatment Adefovir Treatment 
Threshold 
analysis 
Baseline analysis 22,154.96    27,811.86 41,057.83 -
Annual response rate, %      
    
   
    
   
    
   
    
Lamivudine treatment 
HBeAg +ve CHB, (15–25) 22,154.96 25,237.24-31,192.02 41,057.83 - 
HBeAg -ve CHB, (0-15)  22,154.96 23,288.80-46,960.53 41,057.83 - 
  
Adefovir treatment 
HBeAg +ve CHB, (10–20) 22,154.96 26,750.72-28,101.12 32,352.26-44,233.55 - 
HBeAg -ve CHB, (0.5 -15) 22,154.96 26,601.10-29,184.91 31,973.67-58,177.39 - 
  
Annual resistance rate, % 
Lamivudine, (15-32) 22,154.96 26,487.44-29,223.37 41,057.83 - 





Annual probability of progression to 
cirrhosis 
HBeAg +ve CHB, (0.5-11) 21,599.54-23,989.78 27,756.29-27,990.80 41,052.64-41,073.95 - 
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Table 6.7 (Continued). Sensitivity analysis (Response rate as the health outcome) 
Cost-effectiveness ratio (CER) Variable, (range tested) 
No Treatment Lamivudine Treatment Adefovir Treatment 
Threshold 
analysis 
Annual cost, SGD      
Chronic hepatitis B, (316.60-2,203.60)  11,480.70-61,642.17 24,965.26-38,342.25 37,503.04-54,208.02 - 
Compensated cirrhosis, (295.80 - 3,098.51) 20,700.42-25,335.43 27,734.35-27,981.35 41,048.71-41,077.78 - 
100 mg lamivudine, (1825 - 3785.05) 22,154.96 24,456.36-35,376.98 41,057.83 - 








     
    
    
    
Proportion of HBeAg -ve CHB, (0.56 - 
0.8)  
20,674.56- 30,393.45 26,966.40- 31,489.81 40,667.83- 42,602.05 - 
Extreme scenario analysis 
Best case scenario for lamivudine: (Annual 
cost for lamivudine= SGD1825 and annual 
response rate for HBeAg-ve CHB in 
lamivudine treatment arm=15%) 
 
22,154.96 20,470.61 41,057.83 -
Worst case scenario for lamivudine: 
(Annual cost for lamivudine= SGD3785.05 
and annual response rate for HBeAg-ve 
CHB in lamivudine treatment arm =0%) 
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Cost-effectiveness ratio (CER) Variable, (range tested) 
No Treatment Lamivudine Treatment Adefovir Treatment 
Threshold 
analysis 
Extreme scenario analysis 
Best case scenario for adefovir: (Annual 
cost for adefovir= SGD2427.65 and annual 
response rate for HBeAg-ve CHB in 
adefovir treatment arm =15%) 
 
22,154.96    23,902.49 22,675.59 -
Worst case scenario for adefovir: (Annual 
cost for adefovir= SGD5000 and adefovir’s 
annual response rate for HBeAg-ve CHB 
=0.5%) 
22,154.96    32,748.81 78,615.84 -
Table 6.7 (Continued). Sensitivity analysis (Response rate as the health outcome) 
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Total QALY gained as health outcome 
The results of sensitivity analyses when total QALY gained was used as the health 
outcome are presented in Table 6.8.  Most variables consistently demonstrated the 
robustness of favorable impact of lamivudine cost-effectiveness result within the ranges 
tested in our sensitivity analyses.  Adefovir was again dominated by lamivudine (less 
effective yet more costly than lamivudine), with exception when the drug cost for 
lamivudine to be as high as SGD3785.05 (base-case analysis= SGD2427.25) and drug 
cost for adefovir to be as low as SGD2427.65 (base-case analysis= SGD3785.05).  In the 
extreme scenario analyses, CER for best-case scenario for adefovir (in the assumption of 
annual cost for adefovi to be= SGD2427.65 and annual cost for CHB= SGD316.60) was 
slightly less than the best-case scenario for lamivudine (in the assumption of annual cost 
for lamivudine= SGD1825 and annual cost for CHB= SGD316.60), SGD2915.00 per 
QALY gained for compared with SGD2,923.28 per QALY gained for adefovir and 
lamivudine respectively.  However, in the worst-case scenario analyses, CER for adefovir 
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Table 6.8. Sensitivity analysis (Total QALY gained as the health outcome) 
Cost-effectiveness ratio (CER) Variable, (range tested) 






Baseline analysis 892.67    3762.28 4698.89 -
Annual response rate, %      
    
    
    
   
    
     
    
Lamivudine treatment 
HBeAg +ve CHB, (15–25) 892.67 3,701.96-3,824.83 4,698.89 - 




HBeAg +ve CHB, (10–20) 892.67 3,753.42-3,764.50 4,536.26-4,742.07 - 





Annual resistance rate, % 
Lamivudine, (15-32) 892.67 3,636.83-3,890.67 4698.89 - 
Adefovir, (0-3) 892.67 3,752.53-3,769.78 4,609.81-4,768.11 - 
Annual probability of progression to cirrhosis 
HBeAg +ve CHB, (0.5-11) 885.75-913.60 3,760.78-3,767.06 4,698.77-4,699.24 - 








Chapter 6. Cost-effectiveness and cost-utility analysis     Siew Chin, Ong 
 
Table 6.8 (Continued). Sensitivity analysis (Total QALY gained as the health outcome) 
Cost-effectiveness ratio (CER) Variable, (range tested) 






Annual cost, SGD      
Chronic hepatitis B, (316.60-2,203.60)  462.58-2,483.70 3,377.20-5,186.79 4,292.06-6,203.87 - 
Compensated cirrhosis, (295.80 - 3,098.51) 834.07-1,020.82 3,751.79-3,785.21 4,697.84-4,701.17 - 
100 mg lamivudine, (1825 - 3785.05) 892.67 3,308.36-4,785.66 4,698.89 - 
10 mg adefovir, (2427.65 – 5000) 892.67 3,378.36-4,219.05 3,321.83-6,337.22 - 
     
    
  
    








Asymptomatic HBV carrier, (0.81 - 0.94) 896.22-888.93  3,815.70-3,707.08 4,753.11-4,642.56 - 
Chronic hepatitis B, (0.73 - 0.93) 806.31-999.75 3,433.06-4,161.34 4,266.62-5,228.62 - 
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Cost-effectiveness ratio (CER) Variable, (range tested) 






Extreme scenario analysis     
Best case scenario for lamivudine: (Annual cost for 
lamivudine= SGD1825 and annual cost for CHB= 
SGD316.60) 
 
462.58    
    
    
    
2,923.28 4,292.057 -
Worst case scenario for lamivudine: (Annual cost for 
lamivudine= SGD3785.05 and annual cost for CHB= 
SGD2,203.60) 
 
462.58 6,210.17 6,203.867 -
Best case scenario for adefovir: (Annual cost for 
adefovir= SGD2427.65 and annual cost for CHB= 
SGD316.60) 
 
462.58 2993.28 2915.00 -
Worst case scenario for adefovir: (Annual cost for 
adefovir= SGD5000 and annual cost for CHB= 
SGD2,203.60) 
462.58 5643.56 7842.20 -
Table 6.8 (Continued). Sensitivity analysis (Total QALY gained as the health outcome) 
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6.4 DISCUSSION     
Increasing healthcare expenditures have placed an emphasis on performing 
pharmacoeconomics evaluations for treatment alternatives for diseases, especially to 
those costly diseases like CHB infection.  To the best of our knowledge, cost-
effectiveness and cost-utility analyses to evaluate the treatment alternatives in HBeAg 
+ve and –ve CHB patients with lamivudine and adefovir have not been done locally or in 
Asian countries.  Our cost-effectiveness and cost-utility analyses have several significant 
findings.  First, antiviral treatments with lamivudine or adefovir resulted in significant 
higher number of patients who achieved seroconversion or response and consequently 
prevented the disease progression to cirrhosis.  Although the incremental cost per 
cirrhosis case prevented is high for lamivudine and adefovir compared to no antiviral 
treatment, which were SGD 80,105.30 and SGD 90,976.21 respectively at the end of 3 
years of antiviral treatment, treating patient with antiviral drugs would still be more 
favourable than not treating patients with antiviral drugs.  That is because once cirrhosis 
developed, patients are subject to further disease progression to decompensated cirrhosis, 
hepatocellular carcinoma or even death.  The cost savings from those complications and 
mortality found in CHB disease would definitely offset the cost incurred by both antiviral 
drugs.  Delay in the disease progression and prolonged life expectancy in terms of life-
years gained are health outcomes we have not quantified in this analysis and may also 
indicate that treatment with antiviral is highly cost-effective.  In addition, treating patients 
with antiviral drugs would cause the potential for HBV transmission to reduce as a 
consequence of reduction in the pool of infectious individuals, which would translate to 
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adoption of antiviral treatment for eligible CHB patients should not be limited only by the 
economic evaluation in the short term.  Meanwhile, adefovir gave the highest rate of 
cirrhosis cases prevented at the end of 3 years of antiviral treatment and cost an 
incremental SGD157,681.71 per cirrhosis case prevented when compared with 
lamivudine.  However, the CER for lamivudine in both HBeAg+ve and –ve CHB patients 
were consistently lower than adefovir.  The fact was also applicable when we accessed 
the ICER for lamivudine and adefovir in comparison with no antiviral treatment.      
   
Secondly, lamivudine as first-line treatment yields the best results in two of our health 
outcomes, which were in terms of response rate and total QALY gained.  Apparently, 
they are the less expensive yet more effective option.  Our sensitivity analysis revealed 
that changing the value of key drivers or variables did not have significant effect on the 
results, and confirmed the robustness of our study finding.  This finding is also consistent 
with the finding of Kanwal et al, where the up-front use of lamivudine would be highly 
cost-effective across a range of health care budget from the most liberal to the most 
conservative (Kanwal et al, 2005).  Adefovir has consistently incurred the highest cost 
per effectiveness or outcome compared to lamivudine for the management of CHB.  We 
therefore concluded that adefovir is not cost-effective as first-line treatment in CHB 
infection and should be reserved for use when lamivudine treated patients developing 
viral resistance.  
 
Thirdly, incremental cost-utility ratios for lamivudine and adefovir compared with no 
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QALY gained respectively, values that have exceeded commonly accepted medical 
intervention (Chapman et al., 2000; Laupacis et al., 1992).  These results might suggest 
that the use of antivirals did not improve the health-related quality of life of CHB patients 
significantly.  This was in line with our results showed in chapters 2 and 3, that no 
significant differences were found between normal controls, asymptomatic carrier, 
chronic hepatitis B and cirrhosis CHB patient.  This means antiviral treatment resulted in 
higher response rate and lower rate of cirrhosis cases reported in the study did not have 
high impact toward patients’ perceived HRQoL.  However, one must bear in mind the 
benefit of cost saving for both patients and healthcare system for any cirrhosis case 
prevented by antiviral treatments.  This might be more important than just considering the 
improvement of HRQoL an antiviral will bring to the eligible candidate.  
 
One of the strengths of the present analysis is that it has been based on the patients, 
treatment practices and costs of different stages of CHB disease in Singapore, hence to be 
more applicable to the local practice.  Secondly, our models have evaluated the cost-
effectiveness using various health outcomes, namely response rate to treatments, total 
QALY gained and percentage of cirrhosis cases prevented and therefore provide the 
decision makers a more confirmative and comprehensive results.  This is due to the 
different health outcomes adopted in the analysis may yield different results as discussed 
in our introduction section. 
 
We recognized that our analysis has several limitations and the results of this 
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First, our utility and costs data for CHB patients were based in Singapore and therefore 
might not be applicable to other countries.  Different cultures and healthcare setting 
might generate different utility and cost data for CHB patients in other countries.  
However, logical results suggested by our model analysis and consistency with other 
studies’ results are likely to be applicable to many countries.       
 
Secondly, our model represents a simplified view of CHB patients with HBeAg –ve and 
+ve who are eligible for antiviral treatment and have not yet develop to cirrhosis.  
Therefore, the results suggested by this analysis may not generalizable to other disease 
stage of CHB patients such as cirrhosis, decompensated cirrhosis, hepatocellular 
carcinoma and liver transplantation.  
     
6.5 CONCLUSIONS 
Apparently lamivudine therapy is the most cost-effective treatment option available 
currently compared to the other treatment options in term of response rate and total 
QALY gained.  Compared with lamivudine, adefovir costs an extra SGD 157,681.71 per 
cirrhosis case prevented.  Adefovir therapy is suggested to be reserved for lamivudine-
resistant patients.  Evaluating cost-effectiveness of treatment alternatives for CHB using 
different health outcomes may generate different results.  In view of this, cost-
effectiveness study should be most holistic assessing various aspects of effectiveness 
outcomes so that the results yield from the study may be more confirmative and 
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7.1 Major findings 
 
In this thesis, a series of pharmacoeconomic and outcomes studies have been conducted that 
evaluated the health status and financial implications among patients affected by various 
stages of hepatitis B virus (HBV) infection.  
 
The first set of studies carried out among patients with HBV infection evaluated how HBV 
infection affects a patient’s health-related quality of life (HRQoL).  The comparators used 
included diabetes mellitus patients (DM), hypertensive and healthy subjects in adult 
Singaporeans.  From the study, with two commonly used generic HRQoL instruments, 
namely, the Short form 36 Health Survey (SF-36) and the EQ-5D self-report questionnaire 
(EQ-5D), the findings about health status among hepatitis B patients could be summarized as 
follows:   
(1) HRQoL of HBV patients in their early stages generally did not differ significantly with 
the normal healthy control group.  Post-hoc test done in most SF-36 scales scores and EQ-5D 
scores demonstrated that there were no significant difference in HRQoL scores for well 
compensated HBV group such as asymptomatic HBV carriers (AS), chronic hepatitis B 
(CHB) and compensated cirrhosis (CC) in comparison with normal controls.  This was 
consistently observed in the physical component summary (PCS) scale score in SF-36 [mean 
AS score = 55.03 (p= 1.00), mean CHB score = 54.29 (p= 1.00), and mean CC score = 53.05 
(p= 1.00)], mean normal controls = 54.19]   
(2) Post liver-transplants patients generally reported better HRQoL than patients with 
decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC) patients, as well as DM 
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HCC and hence the improvement in observed HRQoL.  This is also congruent with the other 
reports that most liver transplant recipients reported improvement in various measures of 
quality of life after the operation (Nunes et al., 2000).  
(3) Hepatitis B infection as a disease affected the mental health component of the patients 
more adversely than their physical health component.  For example, the mental component 
summary (MCS) scale scores for all groups of HBV patients in our study showed generally 
lower scores compared to PCS scale scores (AS: PCS mean score= 55.03 , MCS mean score= 
48.42; CHB: PCS mean score= 54.29, MCS mean score= 44.00; CC: PCS mean score= 
53.05, MCS mean score= 46.70; DC: PCS mean score= 45.90, MCS mean score= 42.28; 
HCC:  PCS mean score= 44.96, MCS mean score= 40.55; PLT: PCS mean score= 46.01, 
MCS mean score= 45.80) .  This ability to differentiate the impact on mental and physical 
function again demonstrates and supports the importance and potential application of 
HRQoL as an outcome measure in monitoring patient’s clinical responses and disease 
progression.  
(4) HRQoL of all groups of HBV patients including DC and HCC patients were generally 
better than DM patients, except in EQ5D utility scale where HCC patients scored slightly 
worse than DM patients [EQ5D utility score for HCC= 0.79(p<0.001); EQ5D utility score for 
DM= 0.81(p<0.001)].  This observation remained unchanged even after adjusting for those 
possible confounding factors such as age, gender, ethnicity and educational level in the 
multiple linear regression analysis.   
(5) HRQoL of early stage of HBV diseases such as AS, CHB and CC is similar with 
hypertensive. Post-hoc test done in most SF-36 scale scores and EQ-5D scores demonstrated 
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comparison with hypertensive subjects. This was expected as hypertension is one of the 
asymptomatic chronic diseases which resembled the initial phase of HBV infection.   
 
The lack of a specific HRQoL instrument specifically designed for measuring health status in 
hepatitis B patients is always a barrier in performing health outcome research among this 
group of subjects.   This is of particular importance in Asia since hepatitis B is a disease with 
high prevalence among Asian subjects.   Following the measurement of health status with 
two generic instruments, we then carried out a cultural adaptation and validation of Hepatitis 
Quality of Life Questionnaire (HQLQ), which was originally developed in the United States 
in a sample of English-speaking Singaporean with HBV infection.  The HQLQ instruments 
has been used rather extensively among patients suffering from hepatitis C infection, but its 
use among Asian hepatitis B subjects have not been validated.   In the cultural adaptation and 
validation studies, we found evidence to support HQLQ as a culturally appropriate, valid and 
reliable instrument to be used in patients with HBV diseases in Singapore.  For example, the 
internal consistency reliability coefficients, alpha values were excellent with α > 0.7 and > 
0.8 for 2 and 10 out of the 12 scales respectively (α > 0.7 is acceptable for conducting group 
comparisons).  Test-retest reliability was supported with 10 of the 12 scales showed 
acceptable correlation coefficients (i.e., α > 0.7).  Item-to-scale correlations were good with 
all items highly correlated with their hypothesized scales, with only two items below the 
cutoff value (ρ≥0.4) recommended for scale construction.  Construct validity was supported 
with 8 of 10 hypotheses for convergent construct validity and all hypotheses for divergent 
construct validity were fulfilled.  Furthermore, most of the hypotheses for known-group 
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After evaluating the health status and the feasibility of adapting HQLQ for use among Asian 
patients infected by hepatitis B, the next logical step would be to link the outcomes with 
inputs, which is in this case, the health services utilization.  Therefore, besides looking at 
HRQoL issues among adult Singaporeans with CHB infection, a cost analysis and a cost-of-
illness study were subsequently performed.  Our cost analysis found that CHB cost HKD 
6,318 (US$810) in Hong Kong and SGD 718.15 (US$410.37) in Singapore. CC cost HKD 
10,304 (US$1,321) in Hong Kong and SGD 1,175.34 (US$671.62) in Singapore. DC cost 
HKD 58,428 (US$7,490) in Hong Kong and SGD 15,389.84 (US$8794.19) in Singapore. 
HCC cost HKD 121,822 (US$15,618) in Hong Kong and SGD 12314.04 (US$7036.59) in 
Singapore.  Each case of liver transplant was estimated to cost HKD 514,498 (US$65,961) in 
Hong Kong and SGD 86,369.28 (US$49,353.87) in Singapore. The above findings 
confirmed that CHB infection and its associated complications imposed a significant 
financial burden on the healthcare systems of Singapore and Hong Kong.  In addition, we 
found that the cost of management increased in line with the severity of the CHB disease.  In 
our cost-of-illness study, the estimated base-case cost for CHB: SGD119,765,157.40; CC: 
SGD43,227,829.86; DC: SGD78,072,658.32; HCC: SGD7,868,671.56; and PLT: SGD 
426,357.48, according to their estimated prevalence in Singapore.  Therefore, base-case cost 
for total direct cost of managing HBV infection in Singapore was approximately SGD 249 
million annually or approximately US $ 142 million annually.  In addition, the base-case 
estimation for total annual indirect cost for HBV infection in Singapore amounted to 
approximately SGD 180 million or USD 103 million.  Hence, the estimated total cost for 
HBV infection in Singapore, including the direct and indirect cost and calculated according 
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million (with a range between  SGD52 million to 1,442 million by allowing various 
assumption to be made in the sensitivity analyses).  As expected, the ratio of direct to indirect 
costs based on the base-case estimation increased with disease severity, with the highest ratio 
obtained for the PLT patients (40.2:1), followed by HCC (7.4:1) and DC patients (2.7:1). 
 
Finally, we attempted to link the costs and the outcomes together in a modeled evaluation of 
the cost-effectiveness and cost-utility analysis conducted of two commonly used antiviral 
agents, namely adefovir and lamivudine in the treatment of HBeAg negative and positive 
CHB patients.  Although adefovir was the most effective option in terms of achieving the 
highest percentage of cirrhosis cases prevented after 3 years of treatment, incremental cost 
per non-progression to cirrhosis case compared with no treatment arm for adefovir was more 
than lamivudine, with SGD 80,105.30 and SGD90,976.21 per non-progression to cirrhosis 
case for adefovir and lamivudine respectively.  On the other hand, health outcomes measured 
by response rate and total QALY gained found that lamivudine to be dominant over adefovir 
(more effective yet less expensive than adefovir) for the initial phase of HBV management.  
Therefore, we found that lamivudine therapy is the most cost-effective treatment option for 
CHB patients available currently compared to adefovir in term of response rate, total QALY 
gained and percentage of cirrhosis prevented.   
 
7.2 Contributions 
Pharmacoeconomics and outcomes research performed in this thesis has contributed new 
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First, to the best of our knowledge, this is the first study conducted to evaluate the HRQoL of 
different stages of CHB patients with a comparison of the quantum of its impact on health 
status in comparison with several other chronic diseases such as diabetes mellitus and 
hypertension.    This would provide useful information as to the impact of the disease on the 
humanistic outcomes for future pharmacoeconomic evaluation or clinical trails of new 
therapeutic agents. 
 
Second, before a more disease-specific instrument is developed for hepatitis B, our results 
support the use of HQLQ as a feasible and validated instrument for use among Asian subjects 
with hepatitis B infection.  Therefore, our project has contributed to HRQoL research in 
Singapore by providing a validated instrument to be used in future studies to evaluate how 
HBV patient perceive their own health status and outcomes of treatments or their preferred 
outcomes.  
 
Third, as expected, cost data generated from our study demonstrated that the cost of 
management for CHB disease is substantial, which has particularly provided useful and 
valuable information to the healthcare planner or provider in the area of prioritising resource 
allocation.   
 
Fourth, we have demonstrated with evidence for healthcare professionals that the newer 
antivirals might not be the most cost-effective option and should be reserved for lamivudine-
resistant cases and that lamivudine should be set as the first-line treatment in CHB patients at 
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7.3.  Limitations 
The limitations of the studies have been discussed in the individual chapters and shall be 
briefly summarized here.  First, the sample size for DC, HCC and PLT patients in most of 
our studies was relative small compared to the other disease stages of HBV infection despite 
extensive efforts to increase their sample size.  Nevertheless, this is a natural limitation due 
to the relatively small population size in Singapore.  In addition, there could be a potential 
selection bias as patients who were very ill such as those patients lying unconsciously in the 
hospital were not included in the study.  However, this was the first pharmacoeonomic and 
health outcomes studies carried out locally for HBV patients; at the very least it will serve as 
a foundation for future studies.    
Second, our studies have limited the study subjects to person aged 16 and above for a number 
of reasons including the lack of suitable instruments for children and their availability in 
tertiary referral hospital as most of them will be accompanied by parents who were rushing 
off to work after their appointments.  As such, our findings may not be readily generalizable 
to subjects younger than 16 of age.    
Third, all of our data such as HRQoL scores, utilities scores, cost data etc for HBV infected 
patients were based in Singapore and therefore might not be totally applicable to other 
countries without further validation.  Different cultures and healthcare settings might 
generate different outcomes and results as suggested by this thesis.  The quantum of the 
impact could only be verified by local studies.  Therefore, healthcare professionals or 
providers from other countries need to interpret these data with precaution.  Nevertheless, our 
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Fourth, one could argue that there might be selection bias as most of our cases from the 
studies were recruited from the National University Hospital (NUH), one of the tertiary 
referral hospitals in Singapore.  However, a wide range of the patients, from asymptomatic 
HBV carriers to patients with hepatocellular carcinoma or post-liver transplantation have 
been recruited in the study.  Therefore, they should be reasonably representative to the 
different stages of HBV patients being treated in various health institutions in Singapore.  For 
example, asymptomatic HBV carriers or chronic HBV patients would resemble those 
attending primary health care institutions and those with advanced stages of HBV disease, 
e.g. decompensated cirrhosis, hepatocellular carcinoma etc. would resemble those attending 
other tertiary health care institutions in Singapore.   
 
7.4 Recommendation for future studies 
The projects in this thesis have raised some research questions that need to be addressed in 
the future in order to have a more complete picture of the situation.  
 
Some proposed new studies are: 
1. Factors such as duration of disease, abnormality in laboratory tests or medication used 
need to be evaluated for its influence or correlation towards the HRQoL of CHB patients.  
Knowledge about the specific influence of the HBV disease on HRQoL could inform 
healthcare decision making and at the same time increase the healthcare professionals’ 
awareness or understanding of their patients’ suffering or needs, thus enabling them to 
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studies may highlight the potential areas for educational and clinical interventions for HBV 
infected patients. 
2. It will be ideal to develop and validate Singaporean Chinese language for HQLQ so that 
patients who apprehend the Chinese language better can be included in future studies.  
Singaporean Malay and Tamil language versions are suggested to be developed and validated 
as well so that patients who speak these languages can be included in future studies to 
increase the usefulness of these instruments in Singapore.  Followed by the development and 
validation of Singaporean Chinese, Malays and Tamil languages for HQLQ, the 
measurement equivalence of these versions of HQLQ instrument needs to be confirmed.  
Measurement equivalence is a prerequisite for pooling data derived from these language 
versions for data analysis 
3. A more comprehensive cost study for CHB patients can include the cost items for 
alternative medicines used, dietary supplement to improve the health condition and 
transportation costs to visit the physicians.  The indirect cost calculation may consider the 
uncompensated care rendered by patients’ family members and volunteers. 
4. Long term model describing the costs and outcomes for different treatment options for 
CHB infection can be conducted using Markov model in the future. Cost-effectiveness of 
newer class of antiviral can be evaluated as well once it is available in the market compared 
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1. In general, would you say your health is : 
 
      Excellent         Very good             Good    Fair   Poor 
          
   
 
 
2. Compared to one year ago, how would you rate your health in general now?  
             
Much better  
now than  
    one year ago 
Somewhat better 
now than  
one year ago 
About the  
same as  
one year ago 
Somewhat worse 
now than one 
year ago 
Much worse  
now than one 
year ago 




3. The following items are about activities you might do during a typical day.  Does your physical 













a.  Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports such as badminton, soccer etc  
        
b. Moderate activities, such as moving a table, 
bowling, or doing housework etc         
c. Lifting or carrying groceries         
d. Climbing several flights of stairs         
e. Climbing one flight of stairs         
f.  Bending, kneeling, or squatting         
g. Walking more than a mile or 2 km         
h. Walking several HDB Blocks         
i.  Walking one HDB Block          
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4. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health ?      
 
      Yes       No 
a. Cut down on the amount of time you spent on work or other 
activities     
b. Accomplished less than you would like     
c. Were limited in the kind of work or other activities     
d. Had difficulty performing the work or other activities (for example, 
    it took extra time)     
 
5. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional conditions (such as feeling depressed or 
anxious) ? 
 
      Yes       No 
a. Cut down on the amount of time you spent on work or other activities     
b. Accomplished less than you would like     
c. Didn’t do work or other activities as carefully as usual     
 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours, or groups? 
  
  Not at all    Slightly   Moderately Quite a bit  Extremely 




7. How much bodily pain have you had during the past 4 weeks ? 
  
    None     Very mild    Mild    Moderate  Severe    Very severe 
            
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8. During the past 4 weeks, how much did bodily pain interfere with your normal work (including 
both work outside the home and housework) ? 
  
  Not at all A little bit   Moderately Quite a bit  Extremely 
          
 
9. These questions are about how you feel and how things have been with you during the past 4 
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling.   





Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 






 a. did you feel energetic or full of life?           
b. have you been a very nervous     
    person ?           
c. have you felt so depressed that    
    nothing could cheer you up ?            
d. have you felt calm and peaceful ?           
e. did you have a lot of energy ?           
f. have you felt downhearted and   
sad ?            
g. did you feel worn out or  
exhausted ?            
h. have you been a happy person ?           
i. did you feel tired ?            
 
 
   
10. During the past 4 weeks, how much of the time has your physical health or emotional condition 
interfered with your social activities (like visiting friends, relatives, etc)? 
  
     All of the 
    time 
     Most of the  
    time 
     Some of the  
    time          
   A little of the 
   time 
  None of the 
  time 
          

























a. I seem to get sick a little easier than
 other people           
b. I am as healthy as anybody I know           
c. I expect my health to get worse           















      非常好               很好                 好   一般      差 



































育活动如羽毛球、足球等等       
b. 中等强度的活动，比如搬桌子、玩保龄球或做
家务等等       
c. 提起或携带蔬菜，食品或杂货        
d. 上几层楼梯         
e. 上一层楼梯        
f. 弯腰、跪下或蹲下       
g. 步行一英里或二公里以上       
h. 步行几座政府组屋以上                            
i. 步行一座政府组屋       
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4. 在过去四个星期里，您在工作或其它日常活动中，有没有因为身体健康的原因而遇到下列的问题?   
      
 
     有 没有 
a. 减少了工作或其他活动的时间     
b. 实际做完的比想做的要少     
c. 工作或其它活动的种类受到限制     





     有 没有 
a. 减少工作或其他活动的时间     
b. 实际做完的比想做的要少     








毫无影响   有很少影响   有一些影响   有较大影响 有非常大影响 




7.  在过去四个星期里，您的身体有没有疼痛？如果有的话，疼痛到什么程度? 
  
  完全没有     很轻微   轻微     有一些  剧烈   非常剧烈 












  毫无影响     有很少影响     有一些影响    有较大影响   有非常大影响


















有时 偶尔 从来 
没有 
 
a. 您觉得精力充沛或充满活力？          
b. 您觉得精神非常紧张？          
c. 您觉得情绪低落，以至于没有任
何事使您高兴起来？          
d. 您感到心平气和？          
e. 您感到精力充足？          
f. 您觉得心情不好，闷闷不乐？          
g. 您感到精疲力尽？          
h. 您是个快乐的人？          













  偶尔 
  有影响 
完全 
没有影响 





















a. 我好象比别人更容易生病           
b. 我和所有我认识的人一样健康           
c. 我觉得自己的身体状况会变坏           



































1. In general, would you say your health is : 
 
      Excellent         Very good             Good    Fair   Poor 
          
   
 
 
2. Compared to one year ago, how would you rate your health in general now?  
             
Much better  
now than  
    one year ago 
Somewhat better 
now than  
one year ago 
About the  
same as  
one year ago 
Somewhat worse 
now than one 
year ago 
Much worse  
now than one 
year ago 




3. The following items are about activities you might do during a typical day.  Does your physical 













a.  Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports such as badminton, soccer etc  
        
b. Moderate activities, such as moving a table, 
bowling, or doing housework etc         
c. Lifting or carrying groceries         
d. Climbing several flights of stairs         
e. Climbing one flight of stairs         
f.  Bending, kneeling, or squatting         
g. Walking more than a mile or 2 km         
h. Walking several HDB Blocks         
i.  Walking one HDB Block          







Hepatitis Quality of Life Questionnaire (Singapore English version) Page 
2 
 
4. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health ?      
 
      Yes       No 
a. Cut down on the amount of time you spent on work or other activities     
b. Accomplished less than you would like     
c. Were limited in the kind of work or other activities     
d. Had difficulty performing the work or other activities (for example, 
    it took extra time)     
e. Were unable to perform work or other activities at all     
 
6. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional conditions (such as feeling depressed or 
anxious) ? 
 
      Yes       No 
a. Cut down on the amount of time you spent on work or other activities     
b. Accomplished less than you would like     
c. Didn’t do work or other activities as carefully as usual     
d. Were unable to perform work or other activities at all     
 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours, or groups? 
  
  Not at all    Slightly   Moderately Quite a bit  Extremely 




7. How much bodily pain have you had during the past 4 weeks ? 
  
    None     Very mild    Mild    Moderate  Severe    Very severe 
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8. During the past 4 weeks, how much did bodily pain interfere with your normal work (including 
both work outside the home and housework) ? 
  
  Not at all A little bit   Moderately Quite a bit  Extremely 
          
 
 
9. These questions are about how you feel and how things have been with you during the past 4 
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling.   
 How much of the time during the past 4 weeks…. 
 
 All of 
the 
time 
Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 






 a. did you feel energetic or full of 
life ?          
b. have you been a very nervous     
    person ?          
c. have you felt so depressed that    
    nothing could cheer you up ?           
d. have you felt calm and 
peaceful ?          
e. did you have a lot of energy ?          
f. have you felt downhearted and 
sad ?           
g. did you feel worn out or     
exhausted ?           
h. have you been a happy person ?          
i. did you feel tired ?           
j. did you have enough energy to 
do the things you wanted to do?          
 
 
   
10. During the past 4 weeks, how much of the time has your physical health or emotional condition 
interfered with your social activities (like visiting friends, relatives, etc)? 
  
     All of the 
    time 
     Most of the  
    time 
     Some of the  
    time          
   A little of the 
   time 
  None of the 
  time 
          
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a. I seem to get sick a little easier than
 other people           
b. I am as healthy as anybody I know           
c. I expect my health to get worse           




12. Compared to your usual level of social activity, has your social activity changed because of 
your physical  or emotional condition during the past 4 weeks ? 
  
    Much less 
    socially active 
  than before 
   Less   
   socially active 
    than before     
About as  
socially active  
as  before 
  More 
socially active     
than before 
Much more 
socially active   
than before 
          
 
     
 
13. Compared to others your age, were your social activities more or less limited because of your 
physical health or emotional condition during the past 4 weeks ? 
 
    Much more 
    limited 
  than others 
    More 
    limited 
    than others 
About the  
same  
as others 
    Less  
    limited 
    than others 
 Much less       
limited than 
others 
          
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14. How much of the time during the past  4 week …… 
                                                                          
  
 All of 
the 
time 
Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 






a. Were you discouraged by your 
 health problem ?            
b. did you feel “down” or 
depressed due to your health 
problem ? 
           
c. was your health a worry in your 
life?            
d. were you frustrated by your   




15. How much of the time during the past 4 weeks …… 
 
  
 All of 
the 
time 
Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 






a. have you generally enjoyed the 
 things you do ?           
b. has your daily life been full of  
    things that were interesting to    
you ? 
          
c. have you felt cheerful, 
lighthearted ?           
d. has living been exciting for you?             
 






















 All of 
the 
time 
Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 






a. your everyday physical activities 
    such as walking or climbing stairs, 
    carrying groceries or participating 
 in sports ? 
           
b. your daily work, both work 
outside the home and housework?            
c. your normal social activities with  
    family, friends, neighbours or  
    groups ? 
 
           
 
   
17. How much of the time during the past 4 weeks …… 
    
 All of 
the 
time 
Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 






a. were you discouraged because of 
     your hepatitis or liver disease ?            
b. did you feel “down” or depressed
    by your hepatitis or liver disease ?            
c. was having  hepatitis or liver 
disease a worry in  your life ?            
d. were you frustrated  because of 
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1. In general, would you say your health is : 
 
      Excellent         Very good             Good    Fair   Poor 
          
   
 
 
2. Compared to one year ago, how would you rate your health in general now?  
             
Much better  
now than  
    one year ago 
Somewhat better 
now than  
one year ago 
About the  
same as  
one year ago 
Somewhat worse 
now than one 
year ago 
Much worse  
now than one 
year ago 




3. The following items are about activities you might do during a typical day.  Does your physical 













a.  Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports 
such as badminton, soccer etc  
        
b. Moderate activities, such as moving a table, 
bowling, or doing housework etc         
c. Lifting or carrying groceries         
d. Climbing several flights of stairs         
e. Climbing one flight of stairs         
f.  Bending, kneeling, or squatting         
g. Walking more than a mile or 2 km         
h. Walking several HDB Blocks         
i.  Walking one HDB Block          
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4. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health ?      
 
      Yes       No 
a. Cut down on the amount of time you spent on work or other activities     
b. Accomplished less than you would like     
c. Were limited in the kind of work or other activities     
d. Had difficulty performing the work or other activities (for example, 
    it took extra time)     
 
5. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional conditions (such as feeling depressed or 
anxious) ? 
 
      Yes       No 
a. Cut down on the amount of time you spent on work or other activities     
b. Accomplished less than you would like     
c. Didn’t do work or other activities as carefully as usual     
 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered 
with your normal social activities with family, friends, neighbours, or groups? 
  
  Not at all    Slightly   Moderately Quite a bit  Extremely 




7. How much bodily pain have you had during the past 4 weeks ? 
  
    None     Very mild    Mild    Moderate  Severe    Very severe 
            
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8. During the past 4 weeks, how much did bodily pain interfere with your normal work (including 
both work outside the home and housework) ? 
  
  Not at all A little bit   Moderately Quite a bit  Extremely 
          
 
9. These questions are about how you feel and how things have been with you during the past 4 
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling.   
 How much of the time during the past 4 weeks…. 
 
 All of 
the 
time 
Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 





 a. did you feel energetic or full of life ?            
b. have you been a very nervous     
    person ?            
c. have you felt so depressed that    
    nothing could cheer you up ?             
d. have you felt calm and peaceful ?            
e. did you have a lot of energy ?            
f. have you felt downhearted and sad ?            
g. did you feel worn out or exhausted ?            
h. have you been a happy person ?            
i. did you feel tired ?             
 
 
   
10. During the past 4 weeks, how much of the time has your physical health or emotional condition 
interfered with your social activities (like visiting friends, relatives, etc)? 
  
     All of the 
    time 
     Most of the  
    time 
     Some of the  
    time          
   A little of the 
   time 
  None of the 
  time 
          


























a. I seem to get sick a little easier than
 other people           
b. I am as healthy as anybody I know           
c. I expect my health to get worse           















      非常好               很好                 好   一般      差 



































活动如羽毛球、足球等等       
b. 中等强度的活动，比如搬桌子、玩保龄球或做家
务等等       
c. 提起或携带蔬菜，食品或杂货        
d. 上几层楼梯         
e. 上一层楼梯        
f. 弯腰、跪下或蹲下       
g. 步行一英里或二公里以上       
h. 步行几座政府组屋以上                              
i. 步行一座政府组屋       
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4. 在过去四个星期里，您在工作或其它日常活动中，有没有因为身体健康的原因而遇到下列的问题?   
      
 
     有 没有 
a. 减少了工作或其他活动的时间     
b. 实际做完的比想做的要少     
c. 工作或其它活动的种类受到限制     





     有 没有 
a. 减少工作或其他活动的时间     
b. 实际做完的比想做的要少     








毫无影响   有很少影响   有一些影响   有较大影响 有非常大影响 




7.  在过去四个星期里，您的身体有没有疼痛？如果有的话，疼痛到什么程度? 
  
  完全没有     很轻微   轻微     有一些  剧烈   非常剧烈 













  毫无影响     有很少影响     有一些影响    有较大影响   有非常大影响


















有时 偶尔 从来 
没有 
 
a. 您觉得精力充沛或充满活力？           
b. 您觉得精神非常紧张？           
c. 您觉得情绪低落，以至于没有任何
事使您高兴起来？           
d. 您感到心平气和？           
e. 您感到精力充足？           
f. 您觉得心情不好，闷闷不乐？           
g. 您感到精疲力尽？           
h. 您是个快乐的人？           













  偶尔 
  有影响 
完全 
没有影响 






















a. 我好象比别人更容易生病           
b. 我和所有我认识的人一样健康           
c. 我觉得自己的身体状况会变坏           
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1. In general, would you say your health is : 
 
      Excellent         Very good             Good    Fair   Poor 
          
   
 
 
2. Compared to one year ago, how would you rate your health in general now?  
             
Much better  
now than  
    one year ago 
Somewhat better 
now than  
one year ago 
About the  
same as  
one year ago 
Somewhat worse 
now than one 
year ago 
Much worse  
now than one 
year ago 




3. The following items are about activities you might do during a typical day.  Does your physical 













a.  Vigorous activities, such as running, lifting 
heavy  
    objects, participating in strenuous sports such 
as  
    badminton, soccer etc  
        
b. Moderate activities, such as moving a table, 
bowling, 
    or doing housework etc 
        
c. Lifting or carrying groceries         
d. Climbing several flights of stairs         
e. Climbing one flight of stairs         
f.  Bending, kneeling, or squatting         
g. Walking more than a mile or 2 km         
h. Walking several HDB Blocks         
i.  Walking one HDB Block          
j.  Bathing or dressing yourself         
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4. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health ?      
 
      Yes       No 
a. Cut down on the amount of time you spent on work or other activities     
b. Accomplished less than you would like     
c. Were limited in the kind of work or other activities     
d. Had difficulty performing the work or other activities (for example, 
    it took extra time)     
e. Were unable to perform work or other activities at all     
 
6. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional conditions (such as feeling depressed or 
anxious) ? 
 
      Yes       No 
a. Cut down on the amount of time you spent on work or other activities     
b. Accomplished less than you would like     
c. Didn’t do work or other activities as carefully as usual     
d. Were unable to perform work or other activities at all     
 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered 
with your normal social activities with family, friends, neighbours, or groups? 
  
  Not at all    Slightly   Moderately Quite a bit  Extremely 




7. How much bodily pain have you had during the past 4 weeks ? 
  
    None     Very mild    Mild    Moderate  Severe    Very severe 
            
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8. During the past 4 weeks, how much did bodily pain interfere with your normal work (including 
both work outside the home and housework) ? 
  
  Not at all A little bit   Moderately Quite a bit  Extremely 
          
 
 
9. These questions are about how you feel and how things have been with you during the past 4 
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling.   
 How much of the time during the past 4 weeks…. 
 
 All of 
the 
time 
Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 





 a. did you feel energetic or full of life ?            
b. have you been a very nervous     
    person ?            
c. have you felt so depressed that    
    nothing could cheer you up ?             
d. have you felt calm and peaceful ?            
e. did you have a lot of energy ?            
f. have you felt downhearted and sad ?            
g. did you feel worn out or exhausted ?            
h. have you been a happy person ?            
i. did you feel tired ?             
j. did you have enough energy to do   
   the things you wanted to do ?            
 
 
   
10. During the past 4 weeks, how much of the time has your physical health or emotional condition 
interfered with your social activities (like visiting friends, relatives, etc)? 
  
     All of the 
    time 
     Most of the  
    time 
     Some of the  
    time          
   A little of the 
   time 
  None of the 
  time 
          
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a. I seem to get sick a little easier than
 other people           
b. I am as healthy as anybody I know           
c. I expect my health to get worse           




12. Compared to your usual level of social activity, has your social activity changed because of your   
        physical  or emotional condition during the past 4 weeks ? 
  
    Much less 
    socially active 
  than before 
   Less   
   socially active 
    than before     
About as  
socially active  
as  before 
  More 
socially active     
than before 
Much more 
socially active   
than before 
          
 
     
 
13. Compared to others your age, were your social activities more or less limited because of your 
physical health or emotional condition during the past 4 weeks ? 
 
    Much more 
    limited 
  than others 
    More 
    limited 
    than others 
About the  
same  
as others 
    Less  
    limited 
    than others 
  Much less       
limited than 
others 
          
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14. How much of the time during the past  4 week …… 
                                                                          
  
 All of 
the 
time 
Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 





a. Were you discouraged by your 
 health problem ?            
b. did you feel “down” or depressed 
    due to your health problem ?            
c. was your health a worry in your life?            




15. How much of the time during the past 4 weeks …… 
 
  
 All of 
the 
time 
Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 





a. have you generally enjoyed the  
 things you do ?            
b. has your daily life been full of  
    things that were interesting to you ?            
c. have you felt cheerful, lighthearted 
?            
d. has living been exciting for you  ?               
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16. How much of the time during the past  4 weeks has your hepatitis or liver disease limited you in : 
  
  
 All of 
the 
time 
Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 






a. your everyday physical activities  
    such as walking or climbing stairs, 
    carrying groceries or participating 
 in sports ? 
           
b. your daily work, both work outside 
    the home and housework  ?            
c. your normal social activities with   
    family, friends, neighbours or  
    groups ? 
 
           
 
   
17. How much of the time during the past 4 weeks …… 
    
 All of 
the 
time 
Most of the 
time 
(Frequently) 
A good bit 
of the time 
(Often) 
Some of the 
time 
(Sometimes) 






a. were you discouraged because of  
     your hepatitis or liver disease ?            
b. did you feel “down” or depressed 
    by your hepatitis or liver disease ?            
c. was having  hepatitis or liver disease
     a worry in  your life ?            
d. were you frustrated  because of 
    having hepatitis or liver disease ?            
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